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Abstract 
 
Feline immunodeficiency virus (FIV) is a naturally occurring lentivirus of 
domestic cats, which shares many similarities with its human counterpart, 
human immunodeficiency virus (HIV). FIV infects its main target cell, the CD4+ T 
lymphocyte, via interactions with its primary receptor CD134 (an activation 
marker expressed on activated CD4+ T lymphocytes), and, the chemokine 
receptor CXCR4. According to the different ways in which FIV isolates interact 
with CD134, FIV may be categorised into two groups. The first group contains 
strains that tend to dominate during the earlier phase of infection, such as GL8 
and CPG41.  These strains are characterized by their requirement for an 
additional interaction with the second cysteine rich domain (CRD2) of the CD134 
molecule and are classified as “CRD2-dependent” strains. The second group, on 
the other hand, contains either laboratory-adapted isolates or isolates that 
emerge after several years of infection, such as PPR or the GL8 variants that 
emerged in cats 6 years post experimental infection and were studied in this 
thesis. These isolates are designated “CRD2-independent” as they can infect 
target cells without interacting with CRD2 of the CD134 molecule.  
 
This study provides the first evidence that FIV compartmentalisation is 
related to FIV-CD134 usage and the tissue availability of CD134+ target cells. In 
tissue compartments containing high levels of CD134+ cells such as peripheral 
blood and lymph nodes, CRD2-dependent viruses predominated, whereas CRD2-
independent viruses predominated in compartments with fewer CD134+ cells, 
such as the thymus. The dynamics of CD4+CD134+ T lymphocytes at different 
stages of FIV infection were also described. The levels of CD4+CD134+ T 
lymphocytes, which were very high in the early phase, gradually decreased in 
the later phase of infection. The dynamics of CD4+CD134+ T lymphocyte numbers 
appeared to correlate with FIV tropism switching, as more CRD2-independent 
viruses were isolated from cats in the late phase of infection. Moreover, it was 
observed that pseudotypes bearing Envs of CRD2-dependent variants infected 
CD134+ target cells more efficiently than pseudotypes bearing Envs of CRD2-
independent variants, confirming the selective advantage of CRD2-dependent 
variants in environments with high levels of CD134+ target cells.  
 
3 
In conclusion, this study demonstrated that target cell types and 
numbers, as well as their dynamics, play important roles in the selection and 
expansion of FIV variants within the viral quasispecies. Improved understanding 
of the roles of target cells in FIV transmission and pathogenesis will provide 
important information required for the development of an improved, more 
successful protective FIV vaccine and will provide insight into the development 
of effective vaccines against other lentiviral infections such as HIV. 
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PVL proviral load 
qPCR quantitative polymerase chain reaction 
RER rough endoplasmic reticulum 
rev regulator of expression of virion proteins 
RNA ribonucleic acid 
RPLN retropharyngeal lymph node 
RPMI 1640 Roswell Park Memorial Institute medium 1640 
RRE rev-responsive element 
RT reverse transcriptase enzyme 
R10 RPMI1640 supplemented with 10% FBS 
SD standard deviation 
SDF-1 stromal cell-derived factor 1 
sec second 
SFFV spleen focus-forming virus 
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Abbreviation Definition 
SIV simian immunodeficiency virus 
SMLN submandibular lymph node 
SPF specific pathogen free 
SSC-A side scatter area 
SU surface subunit of envelope glycoprotein 
TagRFP Tag red fluorescent protein 
TagRFP 657 Tag red fluorescent protein 657  
TAMRA 6-carboxytetramethylrhodamine quencher dye 
TCID50 tissue culture infectious dose 50%  
TCR T cell receptor 
TM transmembrane subunit of envelope glycoprotein 
TMB 3,3′,5,5′-tetramethylbenzidine substrate 
TM2 TM2 strain of FIV 
TNF-α tumour necrosis factor alpha 
TNFR tumour necrosis factor receptor 
TRIM5 tripartite motif protein 5 
Tween® 20 polyoxyethylene 
UK United Kingdom 
μg microgram 
μl microlitre 
μM micromolar 
V loop variable loop 
vif viral infectivity factor 
VSVG vesicular stomatitis virus 
v/v volume per volume 
W week 
w/v weight per volume 
w/w weight per weight 
WHO World Health Organization 
Y year 
YFP yellow fluorescent protein 
YY Yakuma Yellow reporter dye 
7-AAD 7-aminoactinomycin D 
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Chapter 1 Introduction  
 
Feline immunodeficiency virus (FIV) is an enveloped, RNA virus, which 
belongs to the genus Lentivirus within the Retroviridae family (Willett and 
Jarrett, 1995). Antibodies against FIV have been detected in more than 20 
species within the Felidae family, including bobcats (Lynx rufus), lions (Panthera 
leo), pumas (Puma concolor), spotted hyenas (Crocuta crocuta) and members of 
the Hyaenidae family, as well as domestic cats (Felis catus) (Harrison et al., 
2004, McEwan et al., 2008, Troyer et al., 2008, Lagana et al., 2013, Sykes, 
2013). As well as being an important veterinary pathogen, FIV shares many 
analogies with its human counterpart, human immunodeficiency virus (HIV) 
(Bendinelli et al., 1995, Bienzle, 2014). Both viruses target similar cell types and 
demonstrate similar clinical manifestations, with the progressive decline in CD4+ 
T lymphocyte numbers and inversion of the CD4:CD8 ratio being hallmarks of 
both infections (Bendinelli et al., 1995, Yamamoto et al., 2007, Willett and 
Hosie, 2008, Willett and Hosie, 2013, Sykes, 2013). These similarities illustrate 
the comparative value of the study of FIV infection as an alternative model for 
HIV infection in people, in addition to its veterinary significance (Gardner, 1991, 
Yamamoto et al., 2010, Bienzle, 2014, Moench, 2014).  
 
1.1 Virology 
 
1.1.1 Genomic Organisation 
 
The size of the FIV genome is approximately 9,500 base pairs. Similar to 
other retroviruses, long terminal repeats (LTR) border the 5’ and 3’ ends of the 
FIV genome (Figure 1-1). These LTR contain several elements important for 
transcriptional regulation (Miyazawa et al., 1994, Elder and Phillips, 1995). The 
FIV genome also contains the three major open reading frames (ORF), gag, pol 
and env, which are present in all retroviruses and encode the structural and non-
structural proteins (Talbott et al., 1989, Miyazawa et al., 1994). The gag gene 
encodes the matrix (MA, p17), capsid (CA, p24) and nucleocapsid (NC, p7) 
proteins required for the formation of mature viral particles (Elder and Phillips, 
1995, Affranchino and Gonzalez, 2010, Luttge and Freed, 2010). The pol gene of 
FIV encodes the enzyme deoxyuridine triphosphatase (DU, p14) in addition to the 
protease (PR, p13), reverse transcriptase (RT, p51) and integrase (IN, p31) 
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enzymes (Elder et al., 1992, Wagaman et al., 1993, Elder and Phillips, 1995). 
The DU enzyme is not present in any of the primate lentiviruses (Elder et al., 
1992); it prevents misincorporation of uracil into DNA during reverse 
transcription and therefore increases the fidelity of FIV replication (Lerner et 
al., 1995). This function of DU is similar to that of the accessory protein encoded 
by the vpr gene, which is present in the HIV genome but not the FIV genome 
(Miyazawa et al., 1994, Elder and Phillips, 1995, Mansky et al., 2000, Malim and 
Emerman, 2008, Strebel, 2013). In addition to vpr, FIV also lacks the vpu, nef 
and tat genes that are found in HIV (Talbott et al., 1989, Miyazawa et al., 1994, 
Elder and Phillips, 1995); the accessory proteins Vpu, Nef and Tat play important 
roles in antagonising intra-cellular antiviral responses in HIV infected cells 
(Malim and Emerman, 2008, Strebel, 2013). However, similar to HIV, FIV 
contains an accessory gene (vif) that encodes viral infectivity factor (Vif); the 
FIV and HIV Vif proteins have similar functions, counteracting the cellular 
protein apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3) (Elder 
et al., 2008, Malim and Emerman, 2008, Troyer et al., 2013, Strebel, 2013).  
 
 
 
Figure 1-1 Genomic organisation of FIV; LTR: long terminal repeat, gag; MA: matrix, CA: capsid, 
NC: nucleocapsid, pol; PR: protease, RT: reverse transcriptase, DU: deoxyuridine triphosphatase, 
IN: integrase, vif: viral infectivity factor, orfA: open reading frame A, rev: regulator of 
expression of virion proteins, env; envelope glycoproteins, SU: surface, TM: transmembrane 
(adapted from (Elder and Phillips, 1995, Kenyon and Lever, 2011)) 
  
Another unique element in the FIV genome is the open reading frame A 
(orfA), originally known as orf2 (Elder and Phillips, 1995). OrfA encodes a 77 
amino acid non-structural protein that has been shown to play a role in viral 
particle formation, the induction of cell cycle arrest and transactivation of viral 
protein expression (de Parseval and Elder, 1999, Gemeniano et al., 2003, 
Gemeniano et al., 2004). This transactivating function of FIV orfA is similar to 
that of HIV tat (de Parseval and Elder, 1999). Moreover, orfA influences CD134 
expression levels, host cell tropism and replicative capacity (Waters et al., 1996, 
Hong et al., 2010, Troyer et al., 2013). Immediately downstream of orfA is the 
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env gene, which encodes the surface (SU, gp120) and transmembrane (TM, gp41) 
subunits of the envelope (Env) protein (Talbott et al., 1989, Miyazawa et al., 
1994, Elder and Phillips, 1995). Similar to HIV Env, the FIV Env is a heavily 
glycosylated protein in which the numbers of potential N-linked glycosylation 
sites on SU and TM differ between strains (Talbott et al., 1989, Stephens et al., 
1991, Verschoor et al., 1993). The high-mannose glycans on Env play an 
important role in FIV and HIV immune evasion, by shielding neutralising epitopes 
from antibodies (Pejchal and Wilson, 2010, Yamamoto et al., 2010). Similar to 
the other lentiviruses, the rev (regulator of expression of virion proteins) gene 
sequence comprises two overlapping exons flanking env (Elder and Phillips, 
1995). Rev is responsible for the regulation of viral protein transcription by 
binding to viral mRNA at the Rev-responsive element (RRE) located downstream 
of the env gene (Cochrane et al., 1990, Olsen et al., 1990a, Olsen et al., 1990b, 
Phillips et al., 1992). 
    
1.1.2 Structure of FIV 
 
Under the transmission electron microscope, the mature FIV virion 
appears ellipsoid in shape, approximately 100 to 125 nanometers in diameter, 
with a typical lentiviral cone-shaped nucleocapsid (Pedersen et al., 1987). Like 
all retroviruses, FIV is an enveloped virus with a three-layered structure (Figure 
1-2). The genome-nucleocapsid complex comprises two identical, positive-sense, 
single strands of FIV genomic RNA, with helical symmetry, in association with the 
p7 nucleocapsid protein (NC). This complex is enclosed within an icosahedral 
capsid, formed by multimerisation of Gag p24 capsid proteins (CA, p24). The 
outermost envelope of FIV comprises a lipid membrane derived from the host 
cell membrane into which the trimeric glycoprotein spikes consisting of surface 
(SU, gp120) and transmembrane (TM, gp41) subunits of Env are inserted. The 
viral envelope is lined with the matrix protein (MA, p17), which provides the 
basic structure of the virion. In addition to the viral genome, the viral protease 
(PR, p13), reverse transcriptase (RT, p51) and integrase (IN, p31) enzymes also 
reside within the viral core. 
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Figure 1-2 Schematic representation of the mature FIV virion. The outer layer of the mature FIV 
virion is composed of a cellular lipid bilayer membrane (envelope) containing multiple trimeric 
glycoprotein spikes (SU, gp120 and TM, gp41). This outer layer is lined with the matrix (MA, p17) 
protein. The icosahedral core is formed by p24 capsid (CA) multimers and contains 2 identical 
genome-nucleoprotein (NC) complexes, with helical symmetry, and the reverse transcriptase 
(RT), protease (PR) and integrase (IN) enzymes.  
 
1.1.3 The replication cycle of FIV 
 
FIV binds the target cell via interactions between the SU of Env and the 
primary receptor CD134 on the target cell surface (Figure 1-3, Step 1) (de 
Parseval et al., 2004a, Shimojima et al., 2004). This interaction leads to a 
conformational change which allows an interaction with the co-receptor CXCR4 
to occur (Willett and Hosie, 2008). Target cell entry and FIV tropism are 
discussed in further detail below (Section 1.1.4). Co-receptor binding leads to 
membrane fusion and target cell entry (Figure 1-3, Step 2). After entering the 
target cell, the viral capsid core disintegrates and the nucleocapsid is released 
in the cytoplasm (Figure 1-3, Step 2). Next, the viral RNA is reverse transcribed 
into double-stranded DNA that interacts with cellular and viral proteins before 
being transported into the nucleus and integrated into the cellular genome as 
provirus (Figure 1-3, Step 3 and 4). Similar to the primate lentiviruses, the FIV 
provirus preferentially integrates into actively transcribed genes (Kang et al., 
2006). Depending on the cellular activation state, proviral DNA may be 
transcriptionally active or inactive (McDonnel et al., 2013, Sykes, 2013). Upon 
receiving an activation signal, either from cytokines or by other mechanisms, the 
proviral DNA is transcribed by the host cellular RNA polymerase into full-length 
RNA transcripts (Kenyon and Lever, 2011, Flint et al., 2015). Some of these full-
TM 
 membrane 
MA CA 
NC 
RT IN PR  
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length RNA transcripts are exported into the cytoplasm and serve as mRNA for 
viral protein production, whereas other transcripts become progeny viral 
genomes and are encapsidated into newly formed capsid cores (Figure 1-3, Step 
5) (Kenyon and Lever, 2011, Flint et al., 2015). This core structure then migrates 
to the cell membrane where mature Env proteins are clustered, the virus 
receives its envelope derived from the host cell membrane and mature Env 
trimers, buds from the cell membrane and exits the cell (Figure 1-3, Step 6) 
(Kenyon and Lever, 2011).   
 
 
 
Figure 1-3 Schematic representation of FIV replication cycle (adapted from (Sykes, 2013))  
 
1.1.4 Virus entry and target cell tropism 
 
 Virus entry is the first critical step of any viral infection, in which the 
interaction between the viral envelope and the receptor molecule on the surface 
of the host cell determines target cell tropism and pathogenesis. Similar to HIV, 
FIV utilises a two-receptor mechanism for infection (Elder et al., 2008, Willett 
and Hosie, 2008, Klasse, 2012), but unlike HIV, which utilises the CD4 molecule, 
the primary receptor for FIV infection is the T cell activation marker CD134 (de 
Parseval et al., 2004a, Shimojima et al., 2004). The interaction between FIV Env 
SU and CD134 (Figure 1-4, step 1) leads to a conformational modification of SU 
and a subsequent interaction between Env and CXCR4, the co-receptor for FIV 
infection (Figure 1-4, step 2). CXCR4 binding triggers the insertion of the fusion 
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peptide of TM into the cell membrane (Figure 1-4, step 3). To date, all FIV 
isolates utilise CXCR4 as the co-receptor and none interact with CCR5 (Kenyon 
and Lever, 2011, Willett and Hosie, 2008, Willett and Hosie, 2013). 
 
 
 
Figure 1-4 Schematic representation of FIV Env-receptor interactions and cell entry  
 
1.1.4.1 Envelope glycoprotein 
 
Similar to HIV, the mRNA transcribed from the FIV env gene is translated 
into a primary polyprotein on polyribosomes associated with the rough 
endoplasmic reticulum (RER), where the addition of N-linked carbohydrate 
occurs at the same time. The molecular weight of the Env precursor varies 
between FIV strains, depending on the number of potential N-linked 
glycosylation sites (Stephens et al., 1991, Verschoor et al., 1993). Approximately 
half of the Env mass is associated with the carbohydrate moieties. At the RER, 
Env monomers oligomerise and form trimers that are subsequently transported 
to the golgi complex and cleaved by cellular furin into mature SU (gp120) and TM 
(gp41) (McCune et al., 1988, Stephens et al., 1991, Verschoor et al., 1993). The 
mature SU and TM subunits are linked by a non-covalent association (Schulz et 
al., 1992) and the mature, trimeric gp160 glycoprotein is then transported to the 
cell surface, prior to incorporation into new virions (Affranchino and Gonzalez, 
2014). There are eight variable regions (V) in Env distributed amongst the 
constant regions (C), six are located on SU (V1 – V5) and three on TM (V6 – V8) 
(Pancino et al., 1993). The V3 and V5 loops on SU are involved, respectively, in 
the interaction with CXCR4 and CD134 (de Parseval et al., 2005, Willett et al., 
2006a, Willett et al., 2007, Sundstrom et al., 2008, Willett and Hosie, 2008, Hu 
et al., 2010, Willett et al., 2010, Hu et al., 2012).  
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Since Env is the only FIV protein exposed to the extracellular 
environment, it is under strong selective pressure from neutralising antibodies 
(NAb) and other restriction molecules. This leads to a high rate of mutation and 
the emergence of multiple Env variants during the course of infection (Hosie et 
al., 2002, Kraase et al., 2010, Willett et al., 2010, Beczkowski et al., 2014b). 
These variants often contain mutations in key amino acid residues responsible 
for the interactions between Env and cellular receptors which lead to altered 
cell tropism (see below in section 1.1.4.3) (Hosie et al., 2002, Kraase et al., 
2010, Beczkowski et al., 2014b).  
 
1.1.4.2 CD134  
 
CD134 is a member of the tumour necrosis factor receptor (TNFR) 
superfamily (Croft, 2010). A high degree of similarity was observed between 
feline and human CD134, in both amino acid sequence and structure (Shimojima 
et al., 2004, de Parseval et al., 2005). However, despite these similarities, 
human CD134 does not mediate FIV infection (Shimojima et al., 2004, de 
Parseval et al., 2005), which is one of the mechanisms prohibiting cross-species 
transmission of FIV. FIV has been shown to bind and infect feline CD134-
expressing target cell lines via a direct interaction between FIV Env SU and the 
CD134 molecule (de Parseval et al., 2004a, Shimojima et al., 2004). Also, pre-
treatment with soluble CD134 allows FIV infection of CD134-CXCR4+ target cells, 
presumably by inducing a conformational change, consistent with the model 
shown in Figure 1.4 (de Parseval et al., 2005, de Parseval et al., 2006). 
 
CD134 expression is highest on activated T lymphocytes, after antigen 
recognition, although lower levels of expression have been reported on human 
and murine B-lymphocytes and dendritic cells (DC) (Mallett et al., 1990, 
Gramaglia et al., 2000, Rogers et al., 2001, Croft, 2010). In the cat, CD134 
expression is restricted to activated CD4+ T lymphocytes (de Parseval et al., 
2004a, Shimojima et al., 2004, Willett et al., 2007). Activation of CD4+ T 
lymphocytes has 3 phases, namely the induction, proliferation and effector 
phases (Murphy and Janeway, 2012, Shipkova and Wieland, 2012). The induction 
phase requires 3 external signals; the first is a signal from T cell receptor (TCR) 
recognition of the major histocompatibility complex class II (MHC II)-peptide 
complex presented on professional antigen presenting cells (APC) (Murphy and 
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Janeway, 2012).  Secondly, CD28, a costimulatory molecule constitutively 
expressed on T lymphocytes, signals engagement with its cognate ligand B7.1 
(CD80) and B7.2 (CD86) expressed on the surface of the APC (Harding et al., 
1992, Dubey et al., 1995). After this initial induction phase, activated T 
lymphocytes undergo massive clonal expansion and cytokines in the 
microenvironment, the third signal, play an important role in T lymphocyte 
polarisation (Murphy and Janeway, 2012). In this proliferation phase, prior 
CD28/B7 engagement results in CD134 expression on T lymphocytes, usually 
within 24-28 hours (Gramaglia et al., 1998, Walker et al., 1999). CD134 
expression is important for T lymphocyte longevity and the generation of 
memory T lymphocytes (Gramaglia et al., 2000, Weinberg et al., 2004, Hori, 
2005, Song et al., 2008, Murphy and Janeway, 2012). In the absence of a 
costimulatory signal from CD134/CD134L (CD252) engagement, activated CD4+ T 
lymphocytes undergo apoptosis (Weinberg et al., 1998, Rogers et al., 2001). 
 
The high level of CD134 expression on CD4+ T lymphocytes is consistent 
with the selective infection of CD4+ T lymphocytes in the early phase of FIV 
infection and the decline in CD4+ T lymphocyte numbers observed during the 
course of infection (English et al., 1993, Willett and Hosie, 2013). However, as 
disease progresses, FIV tropism expands to include a broader range of target 
cells, such as B-lymphocytes, CD8+ T lymphocytes and cells of the 
monocyte/macrophage lineage (Brunner and Pedersen, 1989, English et al., 
1993, Dean et al., 1996, de Parseval et al., 2004a, Shimojima et al., 2004). The 
susceptibility to FIV infection of CD8+ T lymphocytes and CD14+ monocytes during 
the chronic phase of infection is intriguing, as these cells do not express, or only 
express at low levels, CD134 (0.1% and 0.2%, respectively) (de Parseval et al., 
2004a, Willett et al., 2007). Nonetheless, CD134 was shown to be upregulated 
when splenic macrophages were activated with lipopolysaccharide (LPS) (Willett 
et al., 2007). Increased levels of plasma LPS, as a result of microbial 
translocation, are frequently observed in HIV infected individuals in the later 
stage of infection (Sandler and Douek, 2012, Marchetti et al., 2013). Although 
this phenomenon has yet to be investigated in FIV-infected cats, it might explain 
the expanded tropism into cells of the monocyte/macrophage lineage displayed 
by FIV in the later phase of infection. Another explanation for the expanded 
tropism of FIV in late infection might be associated with the emergence of FIV 
variants that are less dependent on CD134 for infection (see 1.1.4.3 below). 
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1.1.4.3 Different CD134 usage amongst FIV strains 
 
In common with other members of the TNFR superfamily, the feline CD134 
molecule contains 3 cysteine rich domains (CRD 1-3) (Figure 1-4) (Bodmer et al., 
2002, Willett et al., 2006b). The receptor-binding site of FIV Env was first 
mapped to the CRD1 region of the CD134 molecule, in studies using the PPR 
strain of FIV (de Parseval et al., 2005). However, subsequent studies reported 
that some strains of FIV require additional determinants on CRD2 for infection 
(Willett et al., 2006a, Willett et al., 2006b). According to the requirement for 
CRD2 as well as CRD1, FIV strains could be assigned to 2 groups, CRD2-dependent 
or CRD-2 independent (Figure 1-5). It has been postulated that the additional 
determinants on CRD2 might provide CRD2-dependent strains with more efficient 
interactions with CD134, as CRD2-dependent isolates have been shown to be 
more resistant to antagonism by a monoclonal antibody recognising feline CD134 
as well as soluble CD134 ligand (Willett et al., 2009, Willett et al., 2007, Willett 
et al., 2010).  
 
It was observed that CRD2-dependent strains of FIV were isolated from 
cats during the acute phase of infection (GL8, TM2, CPG41 and NCSU1) (Hosie 
and Jarrett, 1990, Miyazawa et al., 1991, Diehl et al., 1995, Yang et al., 1996), 
whereas CRD2-independent strains were either lab-adapted or were strains that 
emerged after several years of infection (PPR, B2542 and GL8 V5 variants) 
(Phillips et al., 1990, Sodora et al., 1995, Willett et al., 2010). The emergence 
of CRD2-independent Env variants was observed in vivo, in both experimentally 
and naturally infected cats (Kraase et al., 2010, Beczkowski et al., 2014b). 
Therefore there appeared to be a relationship between CRD2-dependence and 
the selection of dominant Env variants during the course of FIV infection. This 
hypothesis was supported by the findings from a study conducted in cats 
experimentally inoculated with a reconstituted quasispecies composed of GL8 
and variants containing CRD2-dependent or -independent Envs (Willett et al., 
2013). Throughout the 21 weeks period of study, the variants of GL8 containing 
CRD2-dependent Envs replicated faster and these variants selectively expanded 
in all cats. There was no evidence that the failure of the variants with CRD2-
independent Envs variants to replicate was associated with either the presence 
of NAb or cellular immune responses (Willett et al., 2013).  
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Figure 1-5 Schematic representations of human, feline and chimaeric CD134 molecules. Oval 
shapes represent cysteine rich domains (CRD) 1 to 3. Green and blue ovals represent domains of 
human and feline CD134, respectively. A panel of cell lines (CLL-HHH, CLL-FFF and CLL-FFHH, 
described in Section 2.2.1.2) expressing different chimaeric molecules of CD134 were used to 
determine the CRD2 dependence of FIV strains. asummarised from (Willett et al., 2006b, Willett 
et al., 2010)   
 
1.1.4.4 Evolution of FIV CD134 usage 
 
The results of these in vivo studies provided strong evidence that CRD2-
dependent variants have a selective advantage over CRD2-independent variants 
in the early phase of FIV infection. As positive correlations between target cell 
numbers and viral replication have been reported in both HIV and SIV infections 
(Schwartz et al., 2002, Klatt et al., 2008), it is possible that CRD2-dependent FIV 
variants could infect and replicate more efficiently in the acute phase of 
infection due to the early expansion of activated CD4+CD134+ T lymphocytes. In 
contrast, later in infection, the decreasing numbers of CD4+ T lymphocytes 
removes this selective advantage and so CRD2-independent variants emerge. The 
expanded target cell tropism observed in the later phase of infection supports 
this hypothesis (Dean et al., 1996, English et al., 1993, Willett and Hosie, 2008, 
Willett and Hosie, 2013). The dynamics of the CD4+CD134+ T lymphocyte 
population and its role in FIV pathogenesis had not been addressed prior to this 
study, but were investigated and are reported in Chapter 4.   
FIV	strainsa	 permissive	for	entry	
early/CRD2-dependent:		
GL8,	TM2,	CPG41,	NCSU1	
no	 yes	 no	
late/CRD2-independent:	
PPR,	B2542,	GL8	V5	variants	
no	 yes	 yes	
CRD1 
CRD2 
CRD3 
human CD134 
CLL-HHH 
feline CD134 
CLL-FFF 
chimaeric CD134 
CLL-FFHH 
human 
feline 
33 
1.1.4.5 CXCR4 
 
CXCR4 was identified as a co-receptor for FIV following the observation 
that mutations in the V3 loop of Env led to the induction of syncytium formation 
in CrFK cells (Siebelink et al., 1995, Verschoor et al., 1995), similar to an 
observation for HIV (Feng et al., 1996).  The role of CXCR4 as an FIV receptor 
was confirmed when it was demonstrated that the addition of a CXCR4-specific 
antibody (12G5), the natural ligand for CXCR4 (stromal cell derived factor-1, 
SDF-1) or the anti-FIV Env monoclonal antibody vpg71.2 inhibited FIV-Env-
mediated target cell fusion (Willett et al., 1997, Hosie et al., 1998). To date, all 
primary and lab-adapted isolates of FIV require CXCR4 for infection (Willett et 
al., 1997, Richardson et al., 1999, Willett and Hosie, 2008). The key residues 
involved in the Env-CXCR4 interaction were mapped to the V3 loop of SU and the 
second extracellular loop of CXCR4 (Willett et al., 1998, Hosie et al., 2002, Hu 
et al., 2010, Hu et al., 2012). Similar to HIV, binding of the FIV Env to the 
primary receptor results in conformational changes in Env and the exposure of 
residues which were previously hidden, which permits binding to the secondary 
receptor (Figure 1-4). It is notable that late FIV strains, such as PPR, were shown 
to have a more “open” conformation, which was associated with the ability to 
infect target cells without prior CD134 binding (Hu et al., 2012). However, 
exposure of the key determinants on the V3 region of Env involved in CXCR4 
binding likely renders late strains of FIV more susceptible to antibody 
neutralisation (Hosie et al., 2002, Hu et al., 2012). This might explain why CRD2-
independent variants emerge only in the later phase of infection, when host 
immune responses are already weakened.   
 
1.2 Natural History of FIV infection 
 
Similar to HIV, FIV infection can be divided into three phases; the primary 
(acute), latent and terminal (immunodeficiency) phases (Figure 1-6) (Sykes, 
2013, Flint et al., 2015). The primary phase lasts 2-8 weeks, with mild fever, 
lethargy and peripheral lymphadenopathy being the most common clinical signs 
(Bendinelli et al., 1995, Hosie et al., 2009, Sykes, 2013). During this phase, FIV 
replicates exponentially and can be detected in plasma as early as 2 weeks post 
infection, with the peak viraemia being detected 8-12 weeks after infection, 
when virus is disseminated throughout the body (Bach et al., 1994, Beebe et al., 
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1994, Hosie et al., 2009, Sykes, 2013). The level of viraemia was shown to be 
positively correlated with the inoculum dose (Roche et al., 2013). Concurrently 
with the increase in plasma viraemia, there is a decline in lymphocyte 
populations, especially the CD4+ T lymphocyte subset.  
 
 
 
Figure 1-6 The course of FIV infection, showing the primary, latent and terminal phases. The X-
axis shows the timescale in weeks for the primary phase and in years for the latent and terminal 
phases. The left Y-axis shows CD4+ and CD8+ T lymphocyte numbers (cells/mm3). The right Y-axis 
shows the plasma viral loads. (adapted from (Sykes, 2013)) 
 
After reaching its peak, the decline in FIV load coincides with the 
development of FIV-specific immune responses and the appearance of both CD8+ 
T lymphocytes and FIV specific antibodies (Egberink and Horzinek, 1992, Willett 
et al., 1993, English et al., 1994, Beatty et al., 1996, Yamamoto et al., 2007). 
Concurrently, CD4+ T lymphocytes numbers also increase, but never regain pre-
infection levels. The progressive decline in CD4+ T lymphocytes, together with 
increasing numbers of CD8+ T lymphocytes, results in inversion of the CD4:CD8 
ratio. The decrease in plasma FIV load and the replenishment of CD4+ T 
lymphocytes marks the beginning of the latent phase of FIV infection, in which 
infected cats remain free of clinical signs (Hartmann, 1998, Yamamoto et al., 
2007, Hosie et al., 2009, Sykes, 2013). The duration of this phase is highly 
variable and can be life-long. In both HIV and FIV infections, the duration of the 
latent phase is strongly related to the level of viraemia and the numbers of 
immune-reconstituted CD4+ T lymphocytes at the start of this phase (Diehl et 
al., 1996, Mellors et al., 1996, Bajaria et al., 2002, Goto et al., 2002, Geskus et 
al., 2007). In FIV infected cats, changes in the CD4:CD8 ratio and CD8+ T 
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lymphocyte expansion are significantly correlated with viraemia (Roche et al., 
2013). In a proportion of infected cats, the decrease in CD4+ T lymphocyte 
numbers, (WHO recommends that HIV infected patients should be treated when 
counts fall below 350 cells/mm3 (2013)), which usually accompanied by an 
uncontrolled increase in plasma viral load, marks the beginning of the terminal 
phase of infection. Consequently, infected cats in this stage are highly 
susceptible to opportunistic infections, have an increased risk of neoplasia and 
are less responsive to treatment for some common infections (Hartmann, 1998, 
Yamamoto et al., 2007, Hosie et al., 2009, Hartmann, 2012, Sykes, 2013, Beatty, 
2014).    
 
1.3 Epidemiology 
 
In general, the seroprevalence of FIV in domestic pet cat populations is 
approximately 1-12% in healthy cats and can be as high as 44% in cats with 
clinical signs (Pedersen et al., 1987, Yamamoto et al., 1989, Courchamp and 
Pontier, 1994, Hartmann, 1998, Levy et al., 2006, Hayward and Rodrigo, 2010b). 
In the UK, the prevalence of FIV was estimated at 6% in healthy cats and 19% in 
sick cats (Hosie et al., 1989), although more recent estimates are required. 
Gender, age and outdoor access are considered to be important risk factors for 
FIV infection (Hartmann, 1998, Hosie et al., 2009, Hartmann, 2012, Sykes, 2013). 
A study in North America reported that male cats are approximately 4.7 times 
more likely to test FIV positive than female cats (Levy et al., 2006). Between 80-
90% of infected cats are older than 2 years, with the average age at the time of 
diagnosis being 6 - 8 years (Sykes, 2013). Free-roaming cats are also more likely 
to be infected than cats kept indoors (Hosie et al., 1989, Addie et al., 2000). 
Territorial fighting is most likely linked to the higher risk of infection of free-
roaming, adult male cats, as FIV transmission occurs mainly via biting (Pedersen 
et al., 1987, Yamamoto et al., 1989, Hartmann, 1998, Sykes, 2013). Vertical and 
sexual transmission of FIV do not occur commonly in nature but have been 
observed experimentally and infectious FIV can be recovered from the semen of 
FIV infected cats (Jordan et al., 1998b, Jordan et al., 1998a, Kolenda-Roberts et 
al., 2007). Vertical transmission from mother to kittens can also occur, with the 
risk of transmission being associated with the viral load of the pregnant queen 
(O'Neil et al., 1995, Burkhard and Dean, 2003). 
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1.4 FIV subtypes and global distribution 
 
FIV has been classified into five different subtypes/clades, designated A-
E, according to the nucleotide sequences of the env gene (Hosie et al., 2009, 
Stickney et al., 2013).  Unlike HIV, there is no clear geographical origin of FIV 
subtypes. Subtypes A and B are the most widely distributed and are detected 
worldwide, followed by Subtype C, which has been detected in Canada, Japan 
and New Zealand (Hosie et al., 2009, Hayward and Rodrigo, 2010b, Stickney et 
al., 2013) (Figure 1-7). Subtype D occurs in Japan, Thailand and Vietnam, while 
subtype E has only been reported in Argentina (Kakinuma et al., 1995, Pecoraro 
et al., 1996, Nakamura et al., 2003, Keawcharoen et al., 2006). In addition, env 
sequences showing evidence of recombination between 2 or more subtypes (A/B, 
A/C, B/D and A/B/C recombinants) were isolated from infected cats in several 
countries (Bachmann et al., 1997, Reggeti and Bienzle, 2004, Hayward and 
Rodrigo, 2008, Hayward and Rodrigo, 2010b, Beczkowski et al., 2014a). In the 
UK, subtype A is the predominant subtype, with a single reported sequence 
showing a likely A/C recombination (Samman et al., 2011). A new subtype was 
proposed, which emerged as a subclade within subtype B, following the analysis 
of strains isolated in Texas, USA and Portugal (Weaver et al., 2004, Duarte and 
Tavares, 2006). Moreover, distinct env sequences were obtained from a group 
FIV infected cats in New Zealand (Hayward et al., 2007, Hayward and Rodrigo, 
2008). These two putative subtypes were later designated as subtypes F and U-
NZenv, respectively, in addition to subtypes A – E (Weaver et al., 2004, Duarte 
and Tavares, 2006, Hayward et al., 2007, Hayward and Rodrigo, 2008).  
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Figure 1-7 Global distribution of FIV subtypes (adapted from (Hosie et al., 2009)) 
 
1.5 Immune responses to FIV infection 
 
 Similar to other retroviral infections, the integration of FIV proviral DNA 
into the genome results in persistent infection. Although FIV-specific immune 
responses do not effectively clear an infection, nevertheless they play important 
roles in the containment of virus replication as well as in FIV pathogenesis. The 
concurrent appearance of FIV-specific immune responses and the reduction in 
plasma viraemia at the beginning of the latent phase provides evidence that the 
immune responses are involved in the control of FIV production. 
 
1.5.1 Cell-mediated immune responses 
 
 FIV Gag-specific cytotoxic T lymphocytes (CTL) have been detected as 
early as 2 weeks after experimental infection (Callanan et al., 1992, Beatty et 
al., 1996). Responses against Env have also been reported, although with a 
slower onset (Flynn et al., 1995a, Flynn et al., 1995b, Beatty et al., 1996). Anti-
FIV CD8+ T lymphocyte responses were detected in both the circulation and in 
lymphoid tissues and involved both cytolytic and non-cytolytic mechanisms 
(Flynn et al., 2002, Paillot et al., 2005). Anti-FIV-CTL persist for the duration of 
FIV infection, although their apoptosis-prone nature and limited clonality partly 
explain their apparent inability to clear persistent infection (Song et al., 1992, 
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Tompkins et al., 2002, Paillot et al., 2005, Miller et al., 2013). Similarly, 
extensive CD4+ T lymphocyte activation and expansion also occur during the 
acute phase of infection (Bienzle, 2014). However, these activated CD4+ T 
lymphocytes, expressing high levels of CD134, are highly susceptible to FIV 
infection and so the increased availability of target cells results in increased 
viral production, followed by cell death by virus-induced cytolysis, activation-
induced cell death and CTL-mediated cytolysis, as occurs following HIV infection 
(Bendinelli et al., 1995, Hel et al., 2006, Tompkins and Tompkins, 2008, 
Swanstrom and Coffin, 2012).  
 
1.5.2 Humoral immune responses 
 
Antibodies recognising Gag and Env proteins have been detected later 
than CTL responses, at approximately 2 – 6 weeks after infection, and levels 
usually remain high (Yamamoto et al., 1988, Rimmelzwaan et al., 1994, 
Bendinelli et al., 1995, Willett et al., 2013). Whether antibodies recognising Env 
or Gag emerge first remains controversial and might depend on either the FIV 
strain used in the study or the sensitivity of antibody detection (Egberink et al., 
1992, Rimmelzwaan et al., 1994, Willett et al., 2013). However, similar to HIV, 
these early antibodies are generally non-neutralising (Tomaras and Haynes, 
2009, Bienzle, 2014). It has been shown in HIV infected individuals that the 
appearance of NAb is slower than the rapid evolution of Env, renders NAb 
ineffective in controlling disease progression (Moog et al., 1997, Richman et al., 
2003, Mahalanabis et al., 2009, Overbaugh and Morris, 2012). It is likely that a 
similar scenario exists for FIV infection, since no association was observed 
between the magnitude of NAb responses and either clinical outcome or survival 
time (Beczkowski et al., 2015b).  
 
1.6 Tissue compartmentalisation 
 
During the early stage of infection, FIV spreads into several lymphoid and 
non-lymphoid organs within the infected cat (Bach et al., 1994, Beebe et al., 
1994, Hurtrel et al., 1994). However, virus migration within the body is not 
without limits. Indeed, it is relatively restricted between compartments by 
anatomical barriers such as the blood-brain barrier (BBB) and the blood-
cerebrospinal-fluid barrier (Fletcher et al., 2011). And with its error-prone RT 
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enzyme and high replication rate, this could give rise to genetically distinct 
subpopulations between body compartments, the so-called “tissue 
compartmentalisation” that has been observed in HIV infection (Zhang et al., 
2002, Zarate et al., 2007).  
 
1.6.1 Definition of tissue compartmentalisation 
 
Tissue compartmentalisation represents the detection of a distinct viral 
population in one tissue as compared to the other tissues. This definition relies 
on phylogenetic tree analysis in which tissue compartmentalisation can be 
visualized as a separate branch (Zarate et al., 2007). As has been observed in 
several evolutionary studies, FIV and HIV evolve and continue to diverge from 
their ancestors over a period of time (Shankarappa et al., 1999, Hosie et al., 
2002). Assuming there is no restriction between compartments and virus spreads 
throughout the body, the viral sequences obtained from different tissues would 
be predicted to be interspersed randomly amongst each other (Figure 1-8A). In 
contrast, as shown in Figure 1-8B, in the presence of the blood-brain barrier that 
limits viral migration in and out of the central nervous system (CNS), virus 
becomes compartmentalised and starts to diverge from its ancestor, creating a 
subpopulation that evolves independently from virus within other tissues. 
 
1.6.2 Compartmentalisation vs. tissue reservoirs 
 
Tissue compartmentalisation is distinct from tissue reservoirs. In the case 
of compartmentalisation, viruses continue to undergo their normal replication 
cycle and evolve with time. However, due to the restriction of gene flow from 
other tissues, viral evolution in a secluded tissue is limited to a single gene pool, 
creating an independent viral population. In contrast, virus in a cellular 
reservoir, for example in resting memory CD4+ T cells, are kept in a latent state 
due to the limited transcription events in those cells (Alexaki et al., 2008). This 
results in a lower replication rate and less divergence from the founding 
ancestor (virus that disseminates throughout the body at the early stage of 
infection), compared to virus from non-reservoir but compartmentalised tissues 
(Nickle et al., 2003a). In order to distinguish between tissue 
compartmentalisation and tissue reservoirs, a phylogenetic tree containing viral 
sequences from different timepoints is required. Viral sequences from tissue 
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reservoirs would appear dispersed throughout the phylogenetic tree, since these 
sequences could infect reservoir cells and become latent at any time during 
infection (Figure 1-8C). In addition, it is important to consider that any tissue 
compartment might also act as a viral reservoir. 
 
 
 
Figure 1-8 Proposed models of phylogenetic trees generated from FIV sequences from four 
different tissues: central nervous system, CNS (green triangles), lymph node (blue squares), 
peripheral blood mononuclear cells, PBMC (red circles) and thymus (purple pentagons) at a 
single timepoint (A and B) or at five time points   (C). A) In the absence of any trafficking 
restrictions, viral evolution would occur at the same rate and be shared between each 
compartment throughout the body. Each tissue-derived sequence would randomly intersperse 
amongst the entire population. B) An example showing tissue restriction in the CNS. Virus within 
the CNS would evolve at a different rate compared to virus in other tissues. Sequences from 
three tissues would cluster together, while CNS sequences would segregate in a distinct branch. 
Note that all the sequences share the same ancestor and compartmentalised virus is more 
divergent than non-compartmentalised virus. C) Phylogenetic tree generated from four tissue-
derived sequences at five time points. Color shading from darker to lighter represents sequences 
collected at earlier to later time points. FIV continues to evolve from the first ancestor as 
disease progresses, reflected by the clustering of viral variants from the same time point in a 
sub-branch that diverges further with time. As observed in a single time point, viral sequences in 
the compartment diverged from the same ancestor similar to virus from other tissues, but evolve 
and cluster together as a separate branch. Note that sequences from thymus (a reservoir in this 
example) are dispersed throughout the phylogenetic tree over time and show less divergence 
from the founding ancestor (adapted from (Nickle et al., 2003b)). 
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1.6.3 Mechanisms of tissue compartmentalisation 
 
Several mechanisms have been proposed for tissue compartmentalisation. 
The first is “selective migration” of virus in which there is a tendency for some 
viral variants to preferentially migrate to particular tissues. This model is based 
on the fact that the cellular tropism of HIV and FIV is governed by amino acid 
variation in Env (Willett and Hosie, 2008). Therefore, it was suggested that 
different viral variants actively migrate to their preferred tissues according to 
their tropism. However, it was shown that the viral populations in PBMC, tonsil 
and rectum from acutely HIV infected patients are highly homogeneous, only 
becoming distinct and heterogeneous in the later, chronic phase (Zhang et al., 
1993, Zhang et al., 2002). These findings ruled out the “selective migration” 
hypothesis and paved the way to the more likely explanation of “parallel 
evolution”. This model proposes that, during the initial phase of infection, the 
dominant homogeneous virus population spreads throughout the body and 
becomes the founding ancestor for the tissue-specific microevolution that occurs 
during the later stages of infection. The presence of a dominant homogenous 
population after transmission might result from some selective process for that 
specific variants, such as the “mucosal gatekeeper” hypothesis proposed to 
explain the dominance of CCR5-tropic (R5) over CXCR4-tropic (X4) variants in HIV 
infection and/or to reflect the higher replicative capacity of some variants that 
dominate infection with a quasispecies, as has been speculated for FIV infection 
following infection via biting (Margolis and Shattock, 2006, Willett et al., 2013).  
 
Evolutionary mechanisms that drive variants derived from the same 
ancestor to form distinct populations involve both host and viral factors and vary 
between tissue compartments. It appears that immune selection is the strongest 
pressure that shapes FIV and HIV evolution (Rambaut et al., 2004). Viral variants 
bearing CD8+ CTL escape epitope mutations are readily observed in chronically 
HIV-infected patients. FIV-specific CTL, capable of exerting similar selective 
forces, has also been demonstrated in infected cats, although the evidence for 
selection is not as strong as for HIV (Beatty et al., 1996, Willett et al., 2013). 
HIV and FIV-specific antibodies also play important roles in disease control and 
intra-host evolution (Rambaut et al., 2004). For example, it was shown that HIV 
compartmentalisation in blood and the female genital tract correlated 
significantly with the density of N-linked glycosylation sites on Env, reflecting 
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differences in HIV-specific antibody responses between the two compartments 
(Kemal et al., 2003). Also, differences in the permissiveness of tissues for 
antibody and immune cell infiltration could affect the level of immune-mediated 
selective pressures and therefore result in variation in viral evolution between 
compartments.  
 
Another host factor, often disregarded, is the rate of cellular turnover. 
Due to their rapid replication rates, FIV and HIV virus progeny are produced at 
high rates in infected cells and rapidly infect other cells. This gives rise to a 
highly diverse viral population as a result of both reverse transcriptase-mediated 
mutations and immune-mediated selection, with the production of CTL that 
counteract actively infected cells and antibodies that bind free virions 
(Overbaugh and Bangham, 2001). However, FIV and HIV gene expression relies on 
cellular transcription factors and so the rate of virus replication and evolution 
depends on the rate of cell division (Alexaki et al., 2008). Therefore, FIV and HIV 
populations in tissues with higher cellular turnover rates might be predicted to 
be more diverse compared to tissues with lower cellular turnover rates.  
 
Other host factors, such as different levels of intrinsic viral restriction 
proteins such as tripartite motif protein 5 (TRIM5), tetherin and APOBEC3, could 
influence FIV and HIV evolution between tissue compartments (Dietrich et al., 
2011a, Dietrich et al., 2011b, Zielonka and Munk, 2011, Dietrich, 2012, Telenti 
and Johnson, 2012, Fourati et al., 2014). In addition, the levels of FIV and HIV 
accessory proteins, such as Vif, which counteracts APOBEC3, could also affect 
tissue-specific evolution (Shacklett and Luciw, 1994, Sheehy et al., 2003). 
However, there have been few studies investigating the roles of these host anti-
viral factors in tissue-specific viral evolution and more detailed investigations 
are required. 
 
1.6.4 Evidence of tissue compartmentalisation in FIV infection 
 
Tissue compartmentalisation has long been recognised in HIV infection, 
since different HIV variants have been detected in blood, lung, male-female 
genitourinary tract and the CNS (Wong et al., 1997, Zhang et al., 1993, Singh et 
al., 1999, Zhang et al., 2002, Kemal et al., 2003). However, little is known about 
this phenomenon in FIV infected cats. The most compelling evidence of tissue 
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compartmentalisation in FIV infection has been found in the CNS. Early reports 
documented behavioural changes in cats naturally infected with FIV, suggesting 
a neurological effect of FIV infection (Pedersen et al., 1987). This finding was 
confirmed by subsequent studies conducted in experimental cats demonstrating 
that FIV-specific antibody could be detected and FIV could be isolated from the 
CSF of infected cats and that astrocytes and microglia, but not endothelial cells, 
were infected with FIV (Dow et al., 1990, Dow et al., 1992). It was shown that, 
following inoculation with FIV intra-cerebroventricularly or intraperitoneally, 
compartmentalisation of FIV Env variants was rapidly established (Liu et al., 
2006). Moreover, considerable variation in the viral variants dwelling in different 
regions of the CNS, such as the frontal cortex, basal ganglia and choroid plexus, 
was also reported in this study, as well as in studies of HIV-1 and HIV-2 infection 
(Sankale et al., 1996, Shapshak et al., 1999). The intracranial 
compartmentalisation could have been the result of different evolutionary rates 
between tissues, since the FIV dynamics had been shown to differ between PBMC 
and CNS and also between different regions of the CNS (Ryan et al., 2003). Such 
findings of genetically different viral variants in different regions of the CNS 
suggested that tissue compartmentalisation of FIV might occur not only in 
different body tissues but also in subcompartments within individual organs.  
 
Although both FIV RNA and DNA have been detected in several organs, 
there is little evidence for FIV compartmentalisation in tissues other than the 
CNS (Bach et al., 1994, Beebe et al., 1994). Hayward et al used the “Maddison-
Slatkin” test to calculate the level of gene flow between seven tissues (lymph 
node, tongue, liver, lung, kidney, testis and brain stem) (Hayward and Rodrigo, 
2010a). This method determines whether sequences grouped in any given tissue 
type arose by a stochastic process or as a true gene flow restriction (Slatkin and 
Maddison, 1990). In this study, one of eight cats showed a significant result, 
however a monophyletic branch indicative of tissue-specific evolution was not 
observed (Hayward and Rodrigo, 2010a).  
 
1.6.5 Target cell availability and tissue compartmentalisation? 
 
Another host factor, rarely considered as a key player in the virus–host 
interaction is target cell availability. It was shown in SIV-infected macaques that 
the number of activated CD4+ T lymphocytes was directly correlated with the 
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level of viraemia (Klatt et al., 2008) and the observed relationship reflected 
their role as target cells rather than their roles in immune control of infection. 
Also, in an HIV in vitro model, higher numbers of CD4+ T lymphocytes were 
associated with increased viral production (Schwartz et al., 2002). In addition, 
the observation that R5 tropic SIV preferentially infected CCR5+ memory cells 
while X4 tropic viruses selectively infected resting, CXCR4+ naïve CD4+ T 
lymphocytes suggested roles for the type and quantity of resident cells in tissue 
compartmentalisation (Mattapallil et al., 2005, Nishimura et al., 2005).  
 
FIV infects its major target cell, the CD4+ T-helper cell, via an interaction 
between Env and the CD134 and CXCR4 molecules on the cell surface (Shimojima 
et al., 2004, Willett et al., 2006b, Willett and Hosie, 2008, Willett et al., 2013, 
Willett and Hosie, 2013). It has been shown that FIV tropism is dependent on 
residues in the V5 region of Env, which affect CD134 binding (Willett and Hosie, 
2008, Kraase et al., 2010, Willett et al., 2010, Willett et al., 2013). Therefore, 
we speculated that differences in receptor expression and/or target cell 
numbers in different tissue compartments could exert selective pressure on the 
FIV population within each compartment.  
 
Following transmission, FIV disseminates throughout the body into 
different tissue compartments. Once inside a tissue, the fittest variant, that 
which replicates most rapidly and outcompetes the others, is preferentially 
selected by the number of appropriate target cells, namely the number of CD4+ 
CD134+ T lymphocytes inside the tissue. This speculative process mirrors the 
selection of R5-tropic over X4-tropic HIV variants and the selective depletion of 
CCR5+CD4+ memory T lymphocytes in the gut associated lymphoid tissue (GALT) 
observed during the first 2 weeks of HIV infection (Mehandru et al., 2004, 
Mattapallil et al., 2005). In addition, the finding that R5 tropic SIV preferentially 
infected CCR5+ memory cells while X4 tropic virus selectively infected resting, 
CXCR4+ naïve CD4+ T lymphocytes, was consistent with the type and quantity of 
resident cells having a significant impact on tissue compartmentalisation 
(Mattapallil et al., 2005, Nishimura et al., 2005). In Chapter 3 of this thesis, 
studies are described in which the role of target cell availability in FIV tissue 
compartmentalisation was investigated in 21 tissue compartments and PBMC in a 
cohort of experimentally infected cats.  
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1.7 Scope and objectives of this study 
 
The aim of this study was to investigate the role of the CD134+ target cell 
in the pathogenesis of FIV infection.  It was hypothesised that target cell 
availability in different tissues, and at different time points, could exert 
pressure on the FIV variant population, leading to selection of the most fit 
variants.  
 
The objectives of this study were: 
 
1 To investigate tissue compartmentalisation in cats experimentally infected 
with FIV. 
2 To investigate the role of target cell availability in tissue 
compartmentalisation. 
3 To compare the numbers of CD4+CD134+ T lymphocytes between cats 
naturally infected with FIV and uninfected control cats. 
4 To examine the relationship between CD4+CD134+ T lymphocyte numbers 
and FIV tropism switching in cats naturally infected with FIV. 
5 To investigate the mechanism of target cell selection by FIV variants within 
a quasispecies. 
  
46 
Chapter 2 Materials and Methods 
 
2.1 Molecular biology 
 
2.1.1 Preparation of genomic DNA from buffy coat and tissue sample 
 
Genomic DNA (gDNA) was extracted from the buffy coats of blood samples 
or from tissue samples using QIAamp® DNA Blood mini kit (Qiagen Ltd., UK), 
according to the manufacturer’s protocol.  
 
Briefly, whole blood samples collected into ethylenediaminetetraacetic 
(EDTA) anti-coagulant were centrifuged at 200 x g for 10 min with the brake-off 
to separate the buffy coat suspension. Plasma was collected, aliquoted and 
stored at -80 degrees Celsius (°C) until required. The buffy coat layer was 
carefully aspirated and the cells were washed with phosphate buffer saline (PBS) 
(Invitrogen, Paisley, UK), pelleted and then resuspended in 200 l PBS. Next, the 
cells were transferred into 1.5 ml microcentrifuge tubes with 20 l of Proteinase 
K before 200 l of buffer AL were added. After briefly mixing, the mixture was 
heated to 56°C for 10 min.  
 
For tissue samples, 25 mg of tissue were disrupted using scalpel blades, 
transferred into 1.5 ml microcentrifuge tubes with 180 l of buffer ATL and 20 l 
of Proteinase K, mixed and incubated at 56°C for 3 h. The lysate was 
homogenized using a QIAshredder® column (Qiagen Ltd., UK) and incubated with 
200 l of buffer AL and 4 l of RNase at 70°C for 10 min.  
 
The resulting lysate, from either buffy coat or tissue sample, was then 
mixed with 200 l of absolute ethanol and transferred to a QIAamp® Minispin 
column for washing with 500 l of buffer AW1 and AW2, respectively. Finally, 
gDNA was eluted with 50 l of buffer AE after incubating at room temperature 
for 5 min. Eluted gDNA was quantified (Section 2.1.9), adjusted, aliquoted into 4 
aliquots at a concentration of 200 ng/l and stored at -80°C until use. 
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2.1.2 Preparation of total RNA from cell pellet and tissue sample 
 
Total RNA was extracted from blood cell pellets and cat tissue using the 
Qiagen RNeasy® mini kit (Qiagen Ltd., UK), as per manufacturer’s protocol.  
Briefly, 5 x 106 cells were harvested and pelleted by centrifugation at 300 x g for 
5 min. For tissue samples, 20 mg of tissue were disrupted with a scalpel blade. 
Six hundred l of buffer RLT were then added to the cell pellet or disrupted 
tissue. The suspension was next homogenized using a QIAshredder® column 
(Qiagen Ltd., UK). The resulting lysate was then mixed with 600 l of absolute 
ethanol and transferred to a QIAamp® Minispin column for washing with 700 l 
of buffer RW1 and 500 l of buffer RPE, respectively. Finally, RNA was eluted 
with 30 l of RNase-free water after incubating at room temperature for 5 min. 
Eluted RNA was quantified (Section 2.1.9) and used to make cDNA immediately 
(Section 2.1.4).   
 
2.1.3 Preparation of viral RNA from cell culture supernatant 
 
Viral RNA was prepared from cell culture fluids using the QIAGEN® Viral 
RNA minikit (Qiagen Ltd., UK) as per the manufacturer’s protocol. In brief, 140 
l of culture supernatant were added to 560 l of buffer AVL containing carrier 
RNA, mixed well and incubated at room temperature for 10 min. Five hundred 
and sixty l of absolute ethanol were then added to the mixture, mixed well and 
transferred into a QIAamp spin column (provided by the manufacturer). The 
column was washed twice with 500 l of buffer AW1 and buffer AW2, 
respectively. Viral RNA was eluted by adding 30 l of buffer AVE after incubating 
at room temperature for 5 min. Eluted viral RNA was quantified (Section 2.1.9) 
and used to make cDNA immediately (Section 2.1.4).   
 
2.1.4 Preparation of complementary DNA from RNA samples 
 
Complementary DNA (cDNA) was prepared using the Transcriptor High 
Fidelity cDNA Synthesis Kit (Roche Diagnostic, Mannheim, Germany) according to 
the manufacturer’s protocol. Briefly, 10.4 l of RNA were mixed with 1 l of 
Anchored-oligo(dT)18 primer (50 pmol/l) and heated at 65°C for 10 min. The 
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tube contents were immediately cooled on ice and then used as a template in 
the reverse transcription reaction as follows; 
 volume (l) 
5x Transcriptor High Fidelity Reverse Transcriptase 
Reaction buffer 
4 
Protector RNase inhibitor (40 units/l) 0.5 
Deoxynucleotide mix (dNTPs) (10mM) 2 
DTT 1 
Transcriptor High Fidelity Reverse Transcriptase 1.1 
 
The reaction was incubated at 50°C for 30 min, followed by 85°C for 5 
min and held at 4°C. The resulting cDNA was quantified (Section 2.1.9) and 
stored in 3.5 l aliquots at -80°C until required.  
 
2.1.5 Quantification of FIV proviral load by quantitative polymerase chain 
reaction (qPCR) 
 
Two hundred ng of each gDNA sample were used as a template in a 20 l 
real-time PCR reaction containing 20 pmol of primer, 10 pmol of probe and 
TaqMan® Universal PCR Master Mix (Applied Biosystems, Paisley, UK). Sequences 
of primers and probes are shown in Table 2.1.1. Tenfold-dilutions of plasmid 
DNA standard for each V5 variant (VR1012, (Hartikka et al., 1996, Willett et al., 
2013)) and FIV gag (pBR328-GL8-MYA), covering 10 to 108 copy numbers, were 
used to construct a standard curve (Figure 2.1). All FIV proviral load 
quantifications were normalized against 18S ribosomal DNA (rDNA) quantity. A 
standard curve of 18S rDNA was prepared using five-fold dilutions of gDNA 
extracted from the feline primary T lymphoblastoid cell line MYA-1 (Section 
2.2.1.1), extending from 5.12 pg to 400 ng (Miyazawa et al., 1989). All reactions 
were performed in triplicate using an ABI Prism® 7500 real time PCR system 
(Applied Biosystems, UK). Coefficients of variation (CV) were calculated and CV 
<25% was used to control for intra-test variation (Leutenegger et al., 1999). 
Absolute quantities were estimated by adjusting with 18S rDNA quantity and 
calculated using the following equation (adapted from (Klein et al., 1999)):  
 
𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 (𝑐𝑜𝑝𝑖𝑒𝑠 106𝑐𝑒𝑙𝑙𝑠⁄ ) = (
𝐹𝐼𝑉 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 (𝑐𝑜𝑝𝑖𝑒𝑠 𝑛𝑢𝑚𝑏𝑒𝑟)
18𝑆 𝑟𝐷𝑁𝐴 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 (𝑛𝑎𝑛𝑜𝑔𝑟𝑎𝑚)
) ∗  5000 
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2.1.6 Quantification of CD134 and CXCR4 messenger RNA (mRNA) by duplex 
qPCR 
 
  One hundred ng of cDNA were used as a template in a 20 l duplex qPCR 
reaction containing 20 pmol of primer, 10 pmol of probe and TaqMan® Universal 
PCR Master Mix (Applied Biosystems, UK). Sequences of primers and probes were 
as shown in Table 2.1.2. Tenfold-dilutions of plasmid DNA standard for feline 
CD134 (pDON-AI-fCD134) (Willett et al., 2006b) and feline CXCR4 (pBABEpuro-
fCXCR4) (Willett et al., 2002), from 10 to 108 copy numbers, were used to 
construct a standard curve (Figure 2.2). All reactions were performed in 
triplicate using an ABI Prism® 7500 real time PCR system (Applied Biosystems, 
UK). Coefficients of variation (CV) were calculated and CV <25% was used to 
control for intra-test variation (Leutenegger et al., 1999). Absolute quantities 
were estimated by adjusting with β–actin Ct (cycle threshold) value and 
calculated using the following equation (adapted from (Scott et al., 2008)): 
 
normalized quantity (plasmid copies number) = (
fCD134 or fCXCR4 Ct value
fβactin Ct value
) ∗  quantity 
 
 
 
Figure 2-1 Representative standard curves for the determination of FIV gag (left) and V5 (right) 
quantity, with a series of ten-fold dilutions of plasmid DNA standards, ranging from 10 – 108 copy 
numbers.  
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Figure 2-2 Representative standard curves for the determination of fCD134 (left) and fCXCR4 
(right) cDNA quantity, with a series of ten-fold dilutions of plasmid DNA standards, ranging from 
10 – 108 copy numbers.  
 
2.1.7 Polymerase chain reactions 
 
 Full-length FIV env or V5 segments were amplified from gDNA using the 
set of primers shown in Table 2-1-3. Phusion® high-fidelity DNA polymerase 
(New England Biolabs, UK), which has 50 times greater fidelity than regular Taq 
polymerse, was used for amplification to minimise the introduction of errors 
introduced during the PCR. All PCR reactions were performed using a GeneAmp 
PCR system 9700 thermocycler (Applied Biosystems, UK).  
 
The V5 loop region of FIV env was amplified using the primer pair 
Sal7799F and G8Not8030R in a 50 l reaction. The reaction mix and 
thermocycling conditions are shown in Tables 2-2 and 2-3 below, respectively. 
 
To amplify full-length env, 200 ng of gDNA were used as a template in a 
two-steps nested PCR. The first round PCR was performed using either 2F2/1R4 
or 1F4/XR2 primer pairs. The reaction mix and thermocycling conditions are 
shown in Tables 2-2 and 2-3 below, respectively. The purified PCR product from 
the first round PCR was used as the template for the second round PCR. The 
second round primers were designed with Sal 1 and Not 1 restriction sites to 
permit further cloning into the VR1012 expression vector. The second round 
amplification was performed using a different combination of primer pairs, 
shown in Table 2-1-3. 
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To confirm that the correct insert (~2,500 bp) was cloned into the VR1012 
expression vector, a colony PCR was performed using GoTaq® Flexi DNA 
polymerase (Promega, Southampton, UK) as per the manufacturer’s protocol. 
Individual colonies were picked and resuspended in 20 l DNase free water. Two 
microliters of this suspension were used as the template. The reaction mix and 
thermocycling conditions are shown in Tables 2-2 and 2-3 below, respectively. 
 
All PCR products were mixed with 6x loading dye (New England Biolabs, 
UK), examined by electrophoresis on a 1% agarose gel (Thermo Fisher Scientific, 
UK) containing 1 mg/ml ethidium bromide (Sigma Aldrich, Gillingham, UK) and 
visualised using an UV trans illuminator (Syngene Bio Imaging, Cambridge, UK). 
 
2.1.8 PCR product purification 
 
The correct PCR product bands were visualized over an UV trans 
illuminator (Syngene Bio Imaging, UK) and excised using sterile scalpel blades. 
DNA was purified from agarose gel fragments using the QIAquick® gel extraction 
kit (Qiagen Ltd., UK) as per the manufacturer’s protocol. In brief, each gel 
fragment was dissolved in three gel volumes of buffer QG at 56°C for 10 min. 
One gel volume of isopropanol was then added to the suspension. The suspension 
was mixed and transferred into a Qiaquick® column and spun down at 17,900 x g 
for 1 min and washed once with 750 l of buffer PE. DNA was eluted with 30 l 
of buffer EB after incubating at room temperature for 5 min. 
 
2.1.9 Nucleic acid quantification 
 
 Plasmid DNA, genomic DNA, total RNA, viral RNA and cDNA, were 
quantified using a NANOdrop 2000 spectrophotometer (Thermo Fisher Scientific, 
UK). 
 
2.1.10 Restriction enzymes digestion and ligation 
 
PCR products, either full-length env genes or V5 segments were double-
digested with Sal 1-HF® and Not 1-HF® restriction enzymes (New England 
Biolabs, UK). The expression vector VR1012 was also double-digested with the 
same enzymes in a larger quantity, checked for linearity by agarose-gel 
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electrophoresis, purified, aliquoted and frozen at -20°C until required. All 
digestion reactions were performed according to the manufacturer’s protocol. In 
brief, one unit of each enzyme was added to an appropriate amount of DNA, 
assuming that 1 g of DNA will be completely digested by one unit of enzyme 
within 1 h at 37°C, with Cutsmart® buffer (provided by the manufacturer).  
 
Each digested DNA fragment was then purified using the QIAquick® gel 
extraction kit (Qiagen Ltd., UK) as per the manufacturer’s protocol and ligated 
into the VR1012 vector using T4 DNA Ligase (Promega, UK) at 14°C overnight. A 
vector:insert molar ratio of 5:1 was used in each 20 l ligation reaction. For 
each ligation performed, a “vector only” control was included to determine 
ligation efficiency. 
 
2.1.11 Transformation  
 
The ligated construct was then transformed into Escherichia coli MAX 
Efficiency® DH5αTM Competent cells (Invitrogen, UK) using the heat shock 
method, as per the manufacturer’s protocol. In brief, 3 l of ligated construct 
were added to 30 l of bacteria, incubated on ice for 30 min, heat-shocked at 
42°C for 40 sec and then immediately returned on ice for a further 2 min. 
Transformed competent cells were cultured in 400 l of super optimal culture 
(SOC) medium (provided by manufacturer) at 37°C for an hour on an orbital 
shaker. Next, each culture was spread on a freshly prepared Luria-Bertani (LB) 
agar plate (Thermo Fisher Scientific, UK) containing 50 μg/ml of kanamycin 
(Sigma Aldrich, UK) and incubated at 30°C for 20-24 h. Single colonies were 
picked and either screened using the colony PCR method (Section 2.1.7) or 
further expanded for small scale DNA preparation (Section 2.1.10). A minimum 
of 50 colonies was picked for each sample.  
 
2.1.12 Small scale DNA preparation 
 
For the preparation of plasmid DNA, each individual colony was picked 
and cultured in 3 ml of LB broth (Thermo Fisher Scientific, UK) containing 50 
g/ml of kanamycin (Sigma Aldrich, UK) at 30°C for 20-24 h in an orbital shaker. 
Plasmid DNA was then prepared from the culture using the QIAGEN® spin 
miniprep kit (Qiagen Ltd., UK) as per the manufacturer’s protocol. In brief, 
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bacteria were pelleted by centrifugation at 17,900 x g for 4 min using a 
refrigerated microcentrifuge. Next, 250 l of buffer P1, with RNase A, were 
added to resuspend the pellet. The suspension was then lysed with 250 μl of 
buffer P2 for 5 min and neutralized by adding 350 l of buffer N3. A supernatant 
was prepared from the suspension by centrifugation at 17,900 x g for 10 min and 
was transferred into a QIAprep spin column. Each column was washed once with 
750 l of buffer PE. Plasmid DNA was eluted with 50 l buffer EB after 
incubating at room temperature for 5 min. To check for the presence of the 
correct insert (2,500 bp), plasmid DNA was double-digested with NotI/SalI 
(Section 2.1.10), examined on a 1% agarose electrophoresis gel containing 1 
mg/ml ethidium bromide (Sigma Aldrich, UK) and viewed using an UV trans 
illuminator (Syngene Bio Imaging, UK).  
 
2.1.13 Medium scale DNA preparation 
 
For the medium scale preparation of plasmid DNA (up to 1 g of DNA), 100 
l of the small scale culture were expanded in 100 ml LB broth (Thermo Fisher 
Scientific, UK) containing 50 g/ml of kanamycin (Sigma Aldrich, UK) at 30°C for 
20-24 h in an orbital shaker. Plasmid DNA was then prepared from the culture 
using the QIAGEN® Plasmid midiprep kit (Qiagen Ltd., UK) as per the 
manufacturer’s protocol. In brief, bacteria were pelleted by centrifugation at 
6,000 x g for 10 min at 4°C using swing bucket. Next, 4 ml of buffer P1, with 
RNase A, was added to resuspend the pellet. The suspension was then lysed with 
4 ml of buffer P2 for 5 min at room temperature and neutralized by adding 4 ml 
of buffer P3. The suspension was incubated on ice for 15 min and centrifuged at 
20,000 x g for 30 min at 4°C using swing bucket. Culture supernatant was 
transferred to a QIAGEN-tip, recently equilibrated with 4 ml of buffer QBT, and 
allowed to flow through by gravity. Next, the QIAGEN-tip was washed twice with 
10 ml of buffer QC. Plasmid DNA was eluted with 5 ml of buffer QF into a clean 
15 ml tube. Plasmid DNA was precipitated by the addition of 3.5 ml of 
isopropanol and centrifuged at 15,000 x g for 30 min at 4°C. The plasmid DNA 
pellet was washed with 1 ml of 70% ethanol and allowed to dry at room 
temperature for 10-15 min. Plasmid DNA was quantified (Section 2.1.9) and 
stored at -20°C until required.  
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2.1.14 Large scale DNA preparation 
 
For the large scale preparation of plasmid DNA (more than 2 g of DNA), 
100 l of the small scale culture was expanded in 200 ml LB broth (Thermo 
Fisher Scientific, UK) containing 50 g/ml of kanamycin (Sigma Aldrich, UK) at 
30°C for 20-24 h in an orbital shaker. Plasmid DNA was then prepared from the 
culture using the PureLink® Hi Pure Plasmid Filter DNA Purification Kit 
(Invitrogen, UK) as per the manufacturer’s protocol. In brief, bacteria were 
pelleted by centrifugation at 6,000 x g for 10 min at 4°C using a swing bucket 
rotor. Next, 10 ml of buffer R3, with RNase A, were added to resuspend the 
pellet. The suspension was then lysed with 10 ml of buffer L7 for 5 min and 
neutralized by adding 10 ml of buffer N3. A supernatant was prepared from the 
suspension by centrifugation at 20,000 x g for 10 min using a swing bucket rotor 
and was transferred to a High Pure filter column, recently equilibrated with 15 
ml of buffer EQ1, and allowed to flow through by gravity. The column was 
washed once with 50 ml of buffer W8. Plasmid DNA was then eluted with 15 ml 
of buffer E4 into a clean 50 ml tube. Plasmid DNA was precipitated by the 
addition of 10.5 ml of isopropanol and centrifuged at 20,000 x g for 30 min at 
4°C using swing bucket. Plasmid DNA pellet was washed with 5 ml of 70% ethanol 
and allowed to dry at room temperature for 10-15 min. Plasmid DNA was 
quantified (Section 2.1.9) and stored at -20°C until required.  
 
2.1.15 Plasmid DNA sequencing 
 
 Plasmid DNA was sequenced commercially using Sanger’s chain terminator 
method, either in a 96 well plate format by Beckman Coulter Genomics, Essex, 
UK, or in a single sample format by GATC biotech, London, UK. 
 
2.1.16 Sequences and phylogenetic analysis  
 
All sequences were analysed using DNADynamo version 1.423 (Blue Tractor 
Software, UK) and BioEdit Sequence Alignment Editor version 7.0.9.0 (Hall, 
1999). The full-length env was assembled using seven sequencing reads that 
overlapped by approximately 250 bp. (Table 2-1-3).  Phylogenetic analysis was 
performed using MEGA software version 5.1 (Tamura et al., 2011). First, multiple 
sequences were aligned using ClustalX alignment package in BioEdit software 
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and exported as a FASTA file. Initial nucleotide sequences translations were 
performed on ExPasy Bioinformatics Resources Portal, www.expasy.org (Swiss 
Institute of Bioinformatics). Phylogenetic trees were generated using the 
Maximum Likelihood method. Re-sampling tree evaluations were performed by 
Bootstraping with 1,000 replicates. The Tajima-Nei and Jones-Taylor-Thornton 
substitutional models were used to estimate the evolutionary distances of 
nucleotide and amino acids sequences, respectively.  
 
Table 2-1 Primers and probes used in this study  
 
All primers and TaqMan® probes used in this study were obtained 
commercially from Eurofins-MWG (Ebersberg, Germany) and/or Integrated DNA 
Technologies (Leuven, Belgium) and are listed below.  
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2-1-1 FIV proviral load quantification* 
 
V5 variants 
B14 sense:       5’-GTACAAATAGTAGTAGTACAAACAGTAGT-3’ 
B19 sense:       5’-ATATGAATTGTAATTGTACAAATAGCAGTACA-3’ 
B28 sense:       5’-CAAATAGTAGTAGTACAAATCGGCAAA-3’ 
B30 sense:       5’-GTACAAATAGTAGTAGTACAAATAGTACA-3’ 
GL8  sense:       5’-GCATTTCAATATGACAAAAGCT-3’ 
reverse antisense: 5’-GCTACGGGGTTATACCAATTTC-3’ 
V5 probe** FAM-5’-ATAGTGTTAAAATGGCATGTCCTAAAAATCAAGGCATCT-3’-BHQ1 
FIV gag 
 sense:       5’-CCATTCGAACGTCTGCCCTA-3’ 
antisense: 5’-TCACCCGTGGTCACCATG-3’ 
gag probe** FAM-5’-ATAGTGTTAAAATGGCATGTCCTAAAAATCAAGGCATCT-3’-BHQ1 
18s rDNA 
 sense:       5’-CCATTCGAACGTCTGCCCTA-3’ 
antisense: 5’-TCACCCGTGGTCACCATG-3’ 
18s probe** FAM-5’-CGATGGTAGTCGCCGTGCCTA-3’-BHQ1 
*adapted from (Willett et al., 2013) 
**FAM: 6-carboxyfluorescein reporter dye, BHQ1: Black Hole Quencher 1 dye 
 
2-1-2 Feline CD134 and CXCR4 mRNA quantification* 
 
feline CD134 
  sense:       5’-CAGGTTATGGGATGGAGAGTCG-3’ 
 antisense: 5’-TGCAAGGCTCGTAGTTCACG-3’ 
fCD134 probe FAM-TGACCAGGACACCAAGTGCCTCCAGTG-BHQ1 
feline CXCR4 
 sense:       5’-AAGGCAGTCCATGTCATCTACAC-3’ 
antisense: 5’-AGACCACCTTTTCAGCCAACAG-3’ 
fCXCR4 probe FAM-ACCTCTACAGCAGTGTCCTCATCCTGC-BHQ1 
feline β-actin 
 sense:       5’-GACTACCTCATGAAGATCCTCACG-3’ 
antisense: 5’-CCTTGATGTCACGCACAATTTCC-3’ 
fβ-actin 
probe 
YY-ACAGTTTCACCACCACCGCCGAGC-BHQ1 
 
*adapted from (Scott et al., 2008) 
**FAM: 6-carboxyfluorescein reporter dye, YY: Yakuma Yellow reporter dye, BHQ1: Black Hole 
Quencher 1 dye 
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2-1-3 FIV envelope cloning and sequencing primers 
 
V5 cloning* 
Sal7799F sense:       5’-GTTTACTATGAAGGTCGACGACCTTAT-3’ 
G8Not8030R antisense: 5’-GGGCGGCCGCTACCACTAAGTAATCTGGTT-3’ 
full-length env cloning 
first round primers**  
1F4 sense:       5’-TATTATTGGCARTTGCAATCTACMTTATC-3’ 
2F2 sense:       5’-CCAATAMCWTCCCAGTCCACCCTT-3’  
1R4 antisense: 5’-CCAATAMTCWTCCCAGTCCACCCTT-3’ 
XR2 antisense: 5’-CCTCAAAGGGAACAAATCAGCTCA-3’ 
second round primers* 
GL8_Sal1F sense:       5’-GGGTCGACACCATGGCAGAAGGGTTTGCAGCA-3’ 
M11_Sal1F sense:       5’-ACCTGGTCGACACCATGGCAGAGGGAGGATTTAATCAA-3’ 
M31_Sal1F sense:       5’-ACTGGTCGACACCATGGCAGAGGGAGGATTTACTCAA-3’ 
M46_Sal1F sense:       5’-ACTGGTCGACACCATGGCAGAGGGAGGATTTACTCAG-3’ 
M_Not1R antisense: 5’-ACAGCGGCCGCCATCATTCCTCCTCTTTTTCAG-3’ 
M31_Not1R antisense: 5’-ACAGCGGCCGCGATCATTCCTCCTCTTTTTCAGAC-3’ 
M46_Not1R antisense: 5’-ACAGCGGCCGCCATCATTCCTCCTCTTTTTCAGAC-3’ 
sequencing Primers 
VR1012F sense:       5’-CTTTTCTGCAGTCACCGTCG-3’ 
M780F sense:       5’-TGGAATGAGACTATAACAGG-3’ 
7822F sense:       5’-ACAAAAGCTGTAGAAATGTA-3’ 
VR1012R antisense: 5’-CTGGATCCAGGCGCCTGGTCTA-3’ 
M2090R antisense: 5’-GATTACATCCTAATTCTTGCATAG-3’ 
GL8_211 antisense: 5’-CCTCTTCCAGTTTTACCTCTTG-3’ 
M_Not1R antisense: 5’-ACAGCGGCCGCCATCATTCCTCCTCTTTTTCAG-3’ 
 
*contains Sal 1 and Not 1 restriction site, as highlighted in red, respectively 
**R is either A or G, M is either A or C and W is either A or T. 
 
2-1-4 Colony PCR primers 
 
VR1012F sense:       5’-CTTTTCTGCAGTCACCGTCG-3’ 
VR1012R antisense: 5’-CTGGATCCAGGCGCCTGGTCTA-3’ 
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Table 2-2 PCR recipes 
 
V5 PCR  
 volume (l) 
5x Phusion® buffer 10 
dNTP (10 mM) 1 
Sal7799F primer (10 mM) 2.5 
G8Not8030R primer (10 mM) 2.5 
DMSO* 1.5 
Phusion® enzyme 0.5 
template 2.5 
DNase free water 29.5 
 
Full-length env PCR, first round and second round 
 volume (l) 
5x Phusion® buffer 10 
dNTP (10 mM) 1 
forward primer (10 mM) 2.5 
reverse primer (10 mM) 2.5 
DMSO 1.5 
Phusion® enzyme 0.5 
template 2.5 
DNase free water 29.5 
 
Colony PCR 
 volume (l) 
5x GoTaq® buffer 4 
dNTP (10 mM) 0.4 
VR1012F primer (10 mM) 1 
VR1012R primer (10 mM) 1 
Mg2Cl 1.2 
goTaq® enzyme 0.1 
template 2 
DNase free water 10.3 
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Table 2-3 Thermocycling conditions for FIV full-length env and V5 PCR 
 
V5 PCR  
 number of cycles temperature (°C) time 
initital denaturation 1 98 30 sec 
denaturation  
35 
98 10 sec 
annealing 51 30 sec 
elongation  72 60 sec 
final extension 1 72 10 min 
hold 1 4  
 
Full-length env PCR, first round  
 number of cycles temperature (°C) time 
initital denaturation 1 98 30 sec 
denaturation  
35 
98 10 sec 
annealing 64.5 30 sec 
elongation  72 90 sec 
final extension 1 72 10 min 
hold 1 4  
 
Full-length env PCR, second round  
 number of cycles temperature (°C) time 
initital denaturation 1 98 30 sec 
denaturation  
35 
98 10 sec 
annealing 70.2 30 sec 
elongation  72 90 sec 
final extension 1 72 10 min 
hold 1 4  
 
 
Colony PCR for checking the insert 
 number of cycles temperature (°C) time 
initital denaturation 1 95 30 sec 
denaturation  
35 
95 10 sec 
annealing 60.5 30 sec 
elongation  72 90 sec 
final extension 1 72 5 min 
hold 1 4  
 
 
 
 
60 
2.2 Cell culture techniques 
 
2.2.1 Cell lines  
 
 All cell lines used in this study came from stocks stored long-term in liquid 
nitrogen. Frozen cells were thawed immediately, washed once with 10 ml of the 
appropriate culture medium and resuspended in 10 ml of the same medium in 
T75 culture flasks (Corning, Corning, USA). Cell lines were incubated at 37°C 
with 5% CO2. Cell lines were monitored daily and passaged or scaled up as 
required.  
 
All suspension cell lines were grown in R10; Roswell Park Memorial 
Institute 1640 medium (RPMI 1640, Invitrogen, UK) supplemented with 10% v/v 
heat-inactivated foetal bovine serum (FBS) (Perbio Science, Cramlington, UK), 2 
mM L-glutamine (Invitrogen, UK), 50 M 2-mercaptoethanol (Invitrogen), 100 
IU/ml Penicillin and 100 μg/ml streptomycin (Invitrogen).  
 
Adherent cell lines were grown in complete Dulbecco’s modified Eagle’s 
Medium (DMEM,Invitrogen, UK) supplemented with 10% v/v heat-inactivated 
foetal bovine serum, 2 mM L-glutamine (Invitrogen, UK), 100 IU/ml penicillin and 
100 g/ml streptomycin (Invitrogen, UK). 
 
2.2.1.1 Feline primary T lymphoblastoid cell line 
 
 The interleukin-2 (IL-2)-dependent feline primary T lymphoblastoid cell 
line MYA-1 was used in this study to produce replicative competent virus and as 
a target cell for FIV infection experiments. This cell line had been established 
following the prolonged culture of a specific pathogen free cat’s peripheral 
blood mononuclear cells (PBMC), which had been inoculated with blood from an 
FIV seropositive cat (Miyazawa et al., 1989).  MYA-1 cells express CD4, CXCR4 
and CD134 at levels similar to those on mitogen-activated T lymphocytes (Willett 
et al., 2013). MYA-1 cells were maintained in R10 culture medium supplemented 
with 100 IU/ml of recombinant IL-2 (kindly provided by Prof. Hattori, University 
of Tokyo, Japan). 
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2.2.1.2 Canine Chronic Lymphocytic Leukaemia cell line 
 
 The canine chronic lymphocytic leukaemia cell line, “CLL”, was 
established in our laboratory following the prolonged culture of PBMC isolated 
from a leukaemic dog. This cell line expresses CD4, CD8 and CXCR4 on its surface 
(Figure 2-3). CLL cells were used as target cells for FIV infection/competition 
studies following the stable transduction of different forms of recombinant 
feline CD134 described previously (Willett et al., 2006b). CLL-FFF is a CLL cell 
line stably expressing feline CD134 while CLL-FFHH stably expresses a chimaeric 
feline/human CD134 molecule containing the cysteine rich domain 2 (CRD2) of 
human CD134. CLL-FFF and CLL-FFHH could be differentiated from each other by 
surface staining with anti feline CD134 (7D6) and anti human CD134 (Ber-ACT35) 
(Figure 2-4).  Since CLL-FFHH expresses a chimaeric feline/human form of 
CD134, it is detectable by both antibodies while CLL-FFF only stains positive for 
anti feline CD134 (7D6). Both CLL variants were maintained in R10 medium, 
selected with Geneticin® (G-418, Thermo Fisher Scientific, UK) at 400 g/ml and 
passaged every 3-4 days.  
 
 
 
Figure 2-3 Surface markers staining of CLL-FFF (upper) and CLL-FFHH (lower); both cell lines 
are positive for CD4 (middle left), CD8 (middle right) and CXCR4 (right) expression. 
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Figure 2-4 CLL-FFF (upper) and CLL-FFHH (lower) could be differentiated by staining with the 
anti-human CD134 monoclonal antibody Ber-ACT35. CLL-FFHH expresses a chimaeric 
feline/human CD134 molecule containing the cysteine rich domain 2 (CRD2) of human CD134 and 
is stained by both anti human CD134 (Ber-ACT35, middle left) and anti feline CD134 monoclonal 
antibodies (7D6, middle right). In contrast, CLL-FFF expresses the natural form of feline CD134 
and stains positive for only feline CD134 (7D6, middle right). 
 
2.2.1.3 Feline Large Granular Lymphoma cell line 
 
 The feline large granular lymphoma cell line, “MCC”, was derived from an 
abdominal mass from a 13 year old castrated male cat (Cheney et al., 1990). The 
MCC cell line has large membrane bound granules, similar to natural killer 
precursor cells.  MCC cells express high levels of CXCR4 on their surface and, 
following stable transduction with feline CD134, have been used as target cells 
in the study of FIV-receptor interactions (Willett et al., 2006a, Willett et al., 
2006b, Willett et al., 2007, Willett et al., 2009). MCC-fCD134 cells were 
maintained in R10 medium, selected with Geneticin® (G-418, Thermo Fisher 
Scientific, UK) at 400 g/ml and passaged every 3-4 days. 
 
2.2.1.4 Human Embryonic Kidney 293 T cell line 
 
 Human embryonic kidney cells containing the simian vacuolating virus 40 
(SV40) large T-antigen (HEK293T) were used as producer cells for pseudotype 
production. This line originated from the HEK293 cell line, human embryonic 
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kidney cells transformed with sheared adenovirus 5 DNA (Graham et al., 1977). 
The SV40 large T-antigen in HEK293T cell permits episomal replication of 
transfected vector carrying the SV40 origin of replication and has been widely 
used for retroviral production as it yields high titers (Pear et al., 1993). HEK293T 
cells were cultured in 10 cm cell culture plates (Corning, USA) with complete 
DMEM. To harvest the cells, culture medium was removed, the cells were 
washed with sterile PBS and treated with 3 ml of 0.05% w/v trypsin (Invitrogen, 
UK) for 5 min at 37°C. Seven ml of fresh complete DMEM were added to stop the 
reaction. Cells were then centrifuged at 200 x g for 5 min and resuspended in 
fresh medium, counted (Section 2.2.3) and cultured for further use. 
 
2.2.2 Peripheral Blood Mononuclear Cells (PBMC) 
 
 Peripheral blood mononuclear cells (PBMC) were isolated from whole cat 
blood collected in EDTA by standard density-gradient centrifugation using Ficoll-
Paque PLUS (GE Healthcare Life Sciences, UK). One ml of blood in EDTA was 
centrifuged at 200 x g for 5 min. Plasma was collected and stored at -80°C for 
further use. The cellular fraction was then diluted with 5 ml of sterile PBS and 
layered over 3 ml of Ficoll-Hypaque PLUS (density gradient 1.077 g/l) in 15 ml 
sterile tubes and centrifuged at 400 x g for 30 min at 25°C using a swing bucket 
rotor with the brake off. The PBMC were aspirated from the interface, 
transferred to a fresh 15 ml tube and washed twice with 10 ml of sterile PBS. 
The PBMC were then resuspended in R10 medium.  
 
2.2.3 Cell counting 
 
Cell numbers and viability were determined by standard trypan blue 
staining (Invitrogen, UK), using a Neubauer haemocytometer (Weber Scientific 
International, Lancing, UK). Cell suspensions were mixed with trypan blue 
(Invitrogen, UK) at a ratio of 1:10 ratio (10 l cell suspension and 90 l trypan 
blue). Only viable cells, which remained unstained with trypan blue, were 
counted in all four quadrants of the haemocytometer. The total number of 
viable cells was calculated using the standard formula:  
 
total cell number (x 105 cells/ml) = [(total cell count / 4) x 10 (dilution factor)]  
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2.2.4 Cell cryopreservation 
 
 For the long-term storage of cell lines and PBMC, cells were cryopreserved 
in liquid nitrogen. Firstly, cell suspensions were centrifuged at 200 x g for 5 min 
at 25°C and resuspended in 1 ml of pre-cooled freezing medium per 1 x 107 
PBMC; freezing medium consisted of 10% dimethyl sulfoxide (DMSO) (Sigma 
Aldrich, UK) and 80% FBS. Cell suspensions were then transferred to 2 ml sterile 
cryo-tubes (Sarstedt, Beaumont Leys, UK) and placed in a freezing container 
(Nalgene, USA) at -80°C for 24 h before being transferred to a liquid nitrogen 
storage tank (-196 °C).  
 
2.3 Study specific methods 
 
2.3.1 HIV(FIV) pseudotype production 
 
HIV(FIV) pseudotypes carrying the firefly luciferase reporter gene 
(HIV(FIV)-luc) were prepared following the transient co-transfection of  the 
VR1012 vector containing full-length FIV env or V5 and the HIV pNL4-3 backbone 
containing the firefly luciferase gene in place of the nef  deletion (pNL4-3.Luc.R-
.E-, (He et al., 1995, He and Landau, 1995, Connor et al., 1995)).  
 
HIV(FIV) pseudotypes carrying different fluorescent proteins (HIV(FIV)-FP), 
carrying either green (GFP) , red (TagRFP) fluorescent tags, were prepared by 
the transient co-transfection of HEK 293T cells with three different expression 
vectors: the VR1012 vector containing a full-length FIV env or V5, the HIV gag 
backbone under the CMV promoter (pCMV-dR8.2 dvpr, (Stewart et al., 2003)) 
and a vector containing one of the fluorescent protein genes under the CMV 
promoter (pCCGW or pCCRW).  
 
HEK 293 T cells were cultured, 2 x 106 cells in 10 ml of complete DMEM 
per 10 cm plate (Corning, USA) overnight. The following day, at approximately 
70-80% confluence, HEK 293T cells were co-transfected with 5 g of VR1012-env 
and pNL4-3.Luc.R-.E-, or a mixture of VR1012-env (1.25 g), pCMV-dR8.2 dvpr 
(2.5 g) and pCCFPW (5 g) in 1 ml of serum free DMEM, for the luciferase and 
fluorescent protein carrying pseudotypes, respectively. Polyethylenimine (PEI) 
was used as the transfection agent at a ratio of 3:1 (weight/weight) of PEI:total 
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DNA. Cultures were maintained at 37°C, in an atmosphere of 5% CO2 for 72 h. On 
day 3, culture medium containing the pseudotypes was harvested, centrifuged at 
300 x g for 5 min, filtered through a 0.45 m filter (Sarstedt, UK), aliquoted and 
stored at -80°C until required.   
 
The infectivity of each luciferase pseudotype was determined by adding 
50 l of pseudotype to 50 l containing 106 cells/ml of CLL-FFF cells in the wells 
of a CulturPlateTM-96 assay plate (Perkin Elmer, Beaconsfield, UK). After an 
incubation period of 72 h at 37°C, 5% CO2, the luciferase activity was measured 
by adding 100 l of HTS steadylite substrate (Perkin Elmer, UK) per well of the 
HIV(FIV)-luc infection plate which was then read using a 1450 MicroBeta 
Luminometer (Perkin Elmer, UK). All tests were performed in triplicate. 
  
The infectivity of pseudotypes containing fluorescent proteins was 
determined by adding 500 l of each pseudotype into 500 μl of culture medium 
containing 1 x 106 cells/ml of CLL-FFF cells in 48 well plates (Corning, USA), 
followed by spinoculation at 300 x g for 60 min. Plates were cultured for 48 h at 
37°C, 5% CO2. On day 2, cells were harvested, washed with sterile PBS and read 
on a BD AccuriTM C6 flow cytometer using CFlow® Sampler software (BD 
Bioscience, Oxford, UK). All tests were performed in triplicate. 
 
2.3.2 FIV-CD134 usage 
 
 The HIV(FIV)-luc pseudotypes were tested for the ability to infect CLL 
cells expressing either the natural form  of feline CD134 (FFF) or the chimaeric 
feline/human CD134 molecule (FFHH). Since the chimaeric CD134 receptor 
(FFHH) contained human CRD2 rather than feline CRD2, pseudotypes that could 
infect both CLL-FFF and CLL-FFHH were defined as CRD2-independent. Fifty l of 
either CLL-FFF or CLL-FFHH cells (Section 2.2.1.2) at 1 x 106 cells/ml were 
cultured with 50 l of each HIV(FIV)-luc pseudotype and incubated for 72 h at 
37°C, in a humid incubator with an atmosphere containing 5% CO2. Luciferase 
activity was measured by adding 100 l of HTS steadylite substrate (Perkin 
Elmer, UK) into each well and plates were read using a 1450 MicroBeta 
Luminometer (Perkin Elmer, UK). All tests were performed in triplicate. 
Pseudotypes bearing the Envs of FIV clade A, Glasgow 8 (Genbank accession 
number X69496.1) and clade B B2542 (Genbank accession number U11820) were 
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used as reference pseudotypes for CRD2 dependent and CRD2 independent FIV 
entry, respectively (Beczkowski et al., 2014b). A pseudotype was considered to 
be “CRD2 dependent” if the FFF/FFHH ratio was similar to that of GL8 (high 
ratio) and “CRD2 independent” if it was similar to B2542 (ratio below 30). 
Pseudotypes with intermediate FFF/FFHH ratios such as the FIV/A strain KKS 
(Genbank accession number NC_001482.1) were designated as “intermediate” 
and were presumed to be evolving towards CRD-2 independent usage. 
 
2.3.3 Viral Neutralisation Assay 
 
Plasma samples were heat-inactivated at 56°C for 30 min before being 
diluted in R10 medium (dilution factors of 1:10, 1:100, 1:1,000 and 1:10,000). 
Twenty five μl of each plasma dilution were incubated with 25 l of HIV(FIV)-luc 
pseudotype (Section 2.3) in CulturPlateTM-96 assay plates (Perkin Elmer, UK) for 
1 h at 37°C, in an atmosphere of 5% CO2. Fifty l of CLL-FFF cells at 1 x 10
6 
cells/ml were added to each well and incubated for a further 72 h. Luciferase 
activity was measured following the addition of 100 l of HTS steadylite 
substrate (Perkin Elmer, UK) to each well and reading the plates on a 1450 
MicroBeta Luminometer (Perkin Elmer, UK). All tests were performed in 
triplicate.  
 
2.3.4 Protein immunoblotting 
 
Pseudotype concentrations were compared by measuring HIV CA p24 
capsid protein by immunoblotting. In brief, 1 ml of each pseudotype was 
centrifuged at 20,800 x g, 4°C for 2 h. After discarding the supernatant, the 
pellet was resuspended in 10 μl of protein loading dye (Invitrogen, UK), 
incubated at 95°C for 5 min and then run on a 4-12% NuPAGE® Bis-Tris Mini Gel 
in 2-(N-morpholino)ethanesulfonic acid (MES) containing running buffer (Life 
Technologies, USA) at 120 V for 1 h. Protein bands were then transferred onto a 
nitrocellulose membrane using the iBlot® Gel Transfer Device (Thermo Fisher 
Scientific, UK). The membrane was blocked with blocking buffer (1:4 v/v 
FBS:PBS containing 0.1% sodium azide (Sigma Aldrich, UK)) at 4 °C overnight. 
P24 bands were developed by incubating the nitrocellulose membrane with 
mouse anti-HIV p24 antibody (diluted 1:1000 v/v with blocking buffer, clone 183-
H12-5C, NIH AIDS Reagent Program, USA) at 37°C for 1 h followed by goat anti-
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mouse IgG DyLightTM 800 (diluted 1:1000 v/v with blocking buffer, Thermo Fisher 
Scientific, UK) at 37°C for 1 h. The fluorescence intensity of the p24 bands of 
each pseudotype was determined using the ODYSSEYTM system (LI-COR® 
Bioscience, Cambridge, UK). 
 
2.3.5 Flow Cytometry 
 
To measure the cell surface expression level of feline CD134 (FFF), 
chimaeric feline/human CD134 (FFHH) and feline CXCR4 on CLL cells, 1 x 106 
cells were stained with 5 l of the following antibodies on ice for 30 min: anti-
feline CD134-alexa fluor 647 (clone 7D6, AbD Serotec, Kidlington, UK), anti-
human CD134-PE-Cy7 (clone Ber-ACT35, BioLegend, London, UK) and anti-feline 
CXCR4 (clone 374606, R&D systems, Abingdon, UK). Cells were washed once with 
staining buffer (PBS + 1% w/v bovine serum albumin (Sigma Aldrich, UK) + 0.1% 
sodium azide (Sigma Aldrich, UK)), resuspended in 100 l of staining buffer and 
then 2.5 l of polyclonal goat anti-mouse IgG2A PE-Cy7 (AbCam, Cambridge, UK) 
were added to detect feline CXCR4 expression. Samples were resuspended in 1 
ml of staining buffer.  
 
To measure the proportions of CD4+, CD8+ and CD4+CD134+ T lymphocyte 
subpopulations, 200 l of whole blood in 5 ml polystyrene round-bottom tubes 
(BD Bioscience, UK) were lysed with 3 ml of 1X BD Pharm LyseTM Lysing Buffer 
(BD Bioscience, UK) and stained with 5 l of anti-feline CD4-FITC, anti-feline 
CD8-PE and anti-feline CD134-alexa fluor 647 for 30 min at room temperature. 
All antibodies were obtained from AbD Serotec, UK. Cells were then washed 
once with staining buffer and then the pelleted cells were resuspended in 1 ml 
of staining buffer.   
 
To identify each T lymphocyte subpopulation, lymphocytes were first 
selected from PBMC by plotting side scatter area (SSC-A) on the y-axis versus 
forward scatter area (FSC-A) on the x-axis.  Next, CD4+ and CD8+ lymphocyte 
subpopulations were selected by plotting the CD4-FITC area (CD4-FITC-A) and 
the CD8-PE area (CD8-PE-A) on the y-axis versus the event number on the x-axis 
(Figure 2-5). The CD4-FITC-area on the y-axis was plotted against the CD8-PE-
area on the x-axis to identify the single positive CD4+CD8- and CD4-CD8+ 
lymphocyte subpopulations (Figure 2-5). The CD4+CD134+ subpopulation was 
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sequentially gated from the CD4+ T lymphocyte population (Figure 2-5). Each 
positive subpopulation cut-off value was set according to the background level 
observed in the negative control for each individual sample. At least 10,000 
events were recorded and analysed for each sample. 
 
When required, PBMC were stained with carboxyfluorescein succinimidyl 
ester (CFSE) at a final concentration of 5 M (Invitrogen, UK) in order to measure 
proliferation. Briefly, CFSE was added to the cell suspension and incubated at 
37°C for 15 min. Cells were then washed once with sterile PBS, resuspended in 
warm R10 at 37°C for 30 min, washed again with sterile PBS and then cultured in 
12 well plates at 1 x 106 cells/well in R10. PBMC viability was then determined 
by staining with 7-aminoactinomycin D (7-AAD) (Thermo Fisher Scientific, UK).  
One l of 7-AAD was added to 106 PBMC in 1 ml of R10 medium, the cells were 
incubated on ice for 30 min and analysed immediately.  
 
All flow cytometry-based analyses were performed on a BD AccuriTM C6 
flow cytometer, using CFlow® Sampler software (BD Bioscience, UK). 
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Figure 2-5 Gating strategy for the identification of T lymphocyte subpopulations. Lymphocytes 
(P1) were identified by size (forward scatter area, FSC-A, X-axis) and granularity (size scatter 
area, SSC-A, y-axis) (upper left). The percentages of the CD4+ (M1), CD8+ (M2) and CD134+ 
subpopulations (M3) within the total lymphocyte population were measured using the CD4-FITC-A 
(upper middle), CD8-PE-A (upper right) and CD134-A647-A (lower left) histograms, respectively. 
The percentage of the CD134+ population within the CD4+ population (M4) was measured using 
CD134-A647-A (lower middle) in the M1 population. A scatter plot displaying CD4-FITC-A against 
CD8-PE-A (lower right) was used to measure the single CD4+ (Q1-UL) and CD8+ (Q1-LR) 
populations. 
  
2.4 Statistical analyses 
 
All statistical analyses were performed using Prism software version 6.0 
(Graphpad Software, La Jolla, USA). Two-tailed, Mann–Whitney and Kruskal-
Wallis tests with Dunns’ post tests were used to compare group medians. 
Fischer’s exact and Spearman tests were used to analyse the effects of risk 
factors and to determine correlations between two variables, respectively. Two 
way ANOVA with Tukey’s multiple comparisons were used to assess correlations 
between quantity of V5 variants and tissue compartments (Chapter 3). To 
analyse inter-relationships between multiple variables, principal component 
analysis (PCA) was performed using Unscrambler software version 9.7 (CAMO 
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Software, Oslo, Norway). P values less than 0.05 were considered to be 
statistically significant.  
 
2.5 Ethics statement 
  
The in vivo pathogenesis study, from which stored tissues were analysed 
for this project, was approved by the University of Glasgow Institutional Animal 
Care and Use Committee (OLAW Assurance A5181-01) “The control of feline 
retroviral infection in domestic cats” and was conducted under license from the 
UK Government Home Office under the Animals (Scientific Procedures) Act 1986. 
The use of recombinant viruses was approved by the Health and Safety Executive 
under The Genetically Modified Organisms (Contained Use) Regulations 2000. 
 
The use of blood samples obtained from the University of Glasgow 
Veterinary Diagnostic Service was approved by the Ethics & Welfare Committee 
of the School of Veterinary Medicine, University of Glasgow under the 
application “Developing an algorithm to predict the outcome for cats infected 
with feline immunodeficiency virus” (reference no. 22a/13). 
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Chapter 3 Tissue compartmentalisation in cats experimentally 
infected with FIV  
 
3.1 Introduction 
  
Following experimental infection of cats with single strains of FIV, it has 
been shown that the dominant homogeneous FIV population spreads into several 
lymphoid and non-lymphoid organs during the early stage of infection (Bach et 
al., 1994, Beebe et al., 1994, Kenyon and Lever, 2011). Together with 
anatomical barriers, the error-prone reverse transcriptase enzyme and high rate 
of viral replication could potentially give rise to genetically distinct 
subpopulations, evolved from a single founding ancestor, in different body 
compartments, so called “tissue compartmentalisation” (Zhang et al., 2002, 
Zarate et al., 2007, Fletcher et al., 2011). Tissue compartmentalisation has long 
been observed in HIV infection. Different HIV variants have been detected in 
blood, lung, male-female genitourinary tract and central nervous system (CNS) 
(Wong et al., 1997, Singh et al., 1999, Zhang et al., 2002, Kemal et al., 2003, 
Karris and Smith, 2011). However, little is known about this phenomenon in FIV 
infected cats other than in the CNS (Pedersen et al., 1987, Dow et al., 1990, 
Dow et al., 1992, Ryan et al., 2003, Liu et al., 2006, Fletcher et al., 2011). 
 
FIV transmission naturally occurs via biting (Hartmann, 1998, Yamamoto 
et al., 2007, Sykes, 2013). This route promotes transfer of the quasispecies 
rather than single virus variants, similar to HIV-1 transmission in intravenous 
drug users (IDU) (Bar et al., 2010). Analogous to the model of infection using 
single strains of virus, it is postulated that the variants within the FIV 
quasispecies also disseminate throughout the body into different tissue 
compartments following transmission to a new host (Bach et al., 1994, Beebe et 
al., 1994). Following infection, specific tissue microenvironments would select 
for the fittest variant, which is most able to replicate and so outcompetes the 
other variants, establishing its lineage within that tissue. Host and viral factors, 
such as target cell availability and tropism might play important roles in the 
selection of a distinct FIV population that evolved from the ancestral virus. FIV 
infects its major target cells, CD4+ T lymphocytes, via an interaction between its 
envelope glycoprotein (Env) and the CD134 and CXCR4 molecules on the cell 
surface (Shimojima et al., 2004, Willett et al., 2006b, Willett and Hosie, 2008, 
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Willett and Hosie, 2013, Willett et al., 2013). Moreover, FIV tropism is governed 
by sequence variation in the fifth variable loop (V5) of Env, which is involved in 
the interaction between Env and CD134 (Willett and Hosie, 2008, Kraase et al., 
2010, Willett et al., 2010, Willett et al., 2013). 
 
The number of appropriate target cells, namely CD4+CD134+ T 
lymphocytes, could also exert pressure on the quasispecies and preferentially 
select for the fittest variant within a particular tissue. This speculation is in line 
with the selection of CCR5 (R5) tropic over CXCR4 (X4) tropic HIV-1 variants and 
the selective depletion of CD4+CCR5+ memory T lymphocytes in GALT in the first 
2 weeks following HIV infection (Mehandru et al., 2004, Mattapallil et al., 2005, 
Flint et al., 2015). In addition, the finding that R5 tropic SIV preferentially 
infected CCR5+ memory cells while X4 tropic viruses selectively infected resting, 
CXCR4+ naïve CD4+ T lymphocytes also reflects the impact of the type and 
quantity of the resident cell populations on tissue compartmentalisation 
(Mattapallil et al., 2005, Nishimura et al., 2005).  
 
Therefore, we speculated that differences in the expression of receptors 
and/or numbers of target cells in different tissue compartments could exert 
selective pressure on the FIV population migrating to that compartment. In this 
chapter, tissue compartmentalisation in FIV infection was investigated in 
peripheral blood mononuclear cells (PBMC) and 21 tissues collected post mortem 
from 4 cats that had been experimentally inoculated with a reconstituted 
quasispecies comprising 6 closely-related FIV variants with different Env V5 
sequences (Willett et al., 2013). The expression levels of CD134 and CXCR4 
mRNA in the tissues were quantified and compared, together with the loads of 
each FIV V5 variant, in order to examine the effects of target cell availability 
and tissue specific selection. 
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3.2 Study Background 
 
This study was designed to examine in more detail the pathogenesis of FIV 
infection, by studying samples stored from experimental infections conducted 
previously (Figure 3-1). The emergence of CRD2-independent variants was 
observed in a cat experimentally infected with FIV clade A strain GL8 for 322 
weeks (Kraase et al., 2010). These late variants contained different amino acid 
sequences in the variable loops of Env, which were related to resistance to 
neutralising antibodies and CRD2-independent infection. The selective expansion 
of CRD2-dependent, GL8-like variants was observed in PBMC when a 
reconstituted quasispecies was inoculated into a cohort of four naïve cats that 
were then monitored for 21 weeks (Willett et al., 2013). Since the decreased 
replication of the CRD2-independent variants was not associated with either 
neutralising antibodies (NAb) or cytotoxic T lymphocyte (CTL) responses, it was 
most likely that CRD2-dependent variants replicated more efficiently in PBMC 
(Willett et al., 2013).  These findings suggested a link between replicative 
capacity and receptor usage.  Therefore we hypothesized that selective pressure 
from the number of target cells expressing the appropriate receptor molecules 
played a role in the selective expansion of the CRD2-dependent variants in early 
infection. 
 
 
 
Figure 3-1 The present study was an extension of two previous studies conducted by our group; 
a) 322 weeks post infection with FIV clade A strain GL8 (UK8, accession no: X69496.1), a group of 
FIV variants with different V5 loop sequences (B14, B19, B28 and B30) emerged in cat A613 
(Kraase et al., 2010), and b) GL8-like variants were dominant after infection of a reconstituted 
quasispecies into a cohort of four cats for 21 weeks (Willett et al., 2013). In the present study, 
tissues collected post mortem from these four cats were analysed for evidence of 
compartmentalisation.  
  
 
FIV A/GL8 Cat A613 
quasispecies 
GL8 like, 
B14, B19, 
B28, B30 
Cats 
A825 
A826 
A827 
A828 
322 weeksa 21 weeksb 
Tissue 
compartmentalisation 
study 
GL8 like variants 
were dominant 
env evolved over time  
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3.3 Study Approach 
 
 Firstly, tissue compartmentalisation was investigated by performing 
variant-specific quantitative polymerase chain reaction (qPCR) using genomic 
DNA (gDNA) extracted from peripheral blood mononuclear cells (PBMC) and 21 
frozen tissues (Table 3-1). Six sets of primers and probe were designed in order 
to determine the absolute proviral DNA load, based on the levels of gag and env 
of the GL8, B14, B19, B28 and B30 V5 variants. Next, the FIV V5 genes were 
amplified from the same gDNA template, cloned into an expression vector and 
analysed to confirm the qPCR results and the presence of tissue 
compartmentalisation. Finally, in an attempt to determine the roles of target 
cell availability, CD134 and CXCR4 transcripts were quantified in total RNA 
extracted from the same tissue samples.  
 
3.4 Samples 
  
Four cats (A825-828) had been inoculated intra-peritoneally with a 
mixture containing equivalent TCID50 of six distinct Env V5 variants (B14, B19, 
B28, B30, B31 and B32) (Figure 3-1) (Willett et al., 2013). These V5 variants had 
evolved in one cat infected with the FIV GL8 molecular clone over the six year 
period of infection (Kraase et al., 2010). The variants displayed distinct 
biological properties, including receptor-usage and sensitivity to FIV-neutralizing 
antibodies (Appendix 3-1) (Willett et al., 2010, Willett et al., 2013). PBMC and 
21 tissues (Table 3-1) were collected post-mortem, 21 weeks post infection, 
frozen immediately in liquid nitrogen and then stored frozen at -80°C.  
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Table 3-1 Tissue compartments investigated in this study 
 
Visceral organs Lymphoid organs 
Salivary gland Tonsil 
Thyroid gland Submandibular lymph node (SMLN) 
Lung Retropharyngeal lymph node (RPLN) 
Liver Prescapular lymph node (PRLN) 
Stomach Mediastinal lymph node (MDLN) 
Pancreas Spleen 
Small intestine Mesenteric lymph node (MSLN) 
Large intestine Popliteal lymph node (PLN) 
Kidney Bone marrow (BM) 
Urinary bladder Thymus 
Reproductive organs Peripheral blood mononuclear cells (PBMC) 
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3.5 Results 
 
3.5.1 FIV proviral load differed between tissue compartments 
 
 The six V5 variants (B14, B19, B28, B30, B31 and B32) contained within 
the reconstituted quasispecies inoculum differed only in env, as each contained 
the same gag-pol backbone (Willett et al., 2013). Therefore, a gag-specific 
quantitative PCR was performed first to determine the total FIV proviral load 
(PVL) in each of the 22 tissue compartments. The gag qPCR amplified the region 
most conserved among different FIV strains, to reduce the effects of potential 
mutations in the primer binding regions during the course of the study (Klein et 
al., 1999). As shown in Figure 3-2A, FIV provirus (determined by gag qPCR) was 
detected in all 22 compartments. The FIV PVLs were significantly different 
amongst the 22 compartments (p < 0.0001****, Kruskal-Wallis test). Thymus 
contained the highest PVL (49,907 copies/106 cells), followed by bone marrow 
and PBMC (26,491 and 17,083 copies/106 cells, respectively, Figure 3-2A). It was 
notable that a relatively high FIV PVL was detected in the thyroid gland (6,615 
copies/106 cells). Next, tissue compartments were categorized into three types, 
namely the visceral organs (11 tissues), the lymphoid organs (10) and PBMC 
(Table 3-2). Lymphoid organs and PBMC harboured significantly higher FIV PVLs 
compared to the visceral organs (medians of 1,856 and 17,083 vs. 229 copies/106 
cells, respectively) (Table 3-2, Figure 3-2B and Appendix 3-2). 
  
 Next, PVLs were determined using GL8 V5 primers and probes targeting 
the conserved region of GL8 V5 to quantify all V5 variants (Willett et al., 2013). 
From the 22 compartments examined in this study, FIV was undetectable using 
the GL8 V5 qPCR in five tissues, namely the salivary gland, pancreas, bladder, 
kidney and reproductive organs of all four cats (the lower limit of detection was 
10 copies/106 cells) (Figure 3-3 and 3-4). These five tissues also demonstrated 
the lowest PVLs by gag qPCR, confirming their low viral burdens (Figure 3-3A). As 
observed with the gag qPCR, the FIV PVL varied markedly between tissue 
compartments (Figure 3-3A). These differences were statistically significant, 
although slightly weaker for the GL8 V5 qPCR compared to the gag qPCR 
(Kruskal-Wallis test, p value = 0.0004***).  
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Although the highest PVL determined by GL8 gag qPCR was observed in 
the thymus of cat A825 (865,399 copies/106 cells), the median FIV load was 
highest in bone marrow when measured by GL8 V5 qPCR (142,050 copies/106 
cells) followed by thymus and mesenteric lymph node (71,216 and 22,409 
copies/106 cells, respectively) (Figure 3-3A). The thyroid gland also contained 
large amounts of FIV provirus (7,575 copies/106 cells) (Figure 3-3A). Similar to 
the gag qPCR, the GL8 V5 qPCR demonstrated that the PVLs in lymphoid organs 
were significantly greater compared to the PVLs of the visceral organs (median 
of 9,559 vs. 2,577 copies/106 cells, p =0.0011**) (Table 3-2, Figure 3-3B and 
Appendix 3-2). The lymphoid organs also contained higher PVLs than PBMC, 
although this difference was not statistically significant (9,559 vs. 6,199 
copies/106 cells, p = 0.2172) (Table 3-2 and Figure 3-3B).  
 
Although a similar lower limit of detection (10 copies/106 cells) was 
observed between the gag and GL8 V5 qPCR methods, the gag qPCR appeared to 
be more sensitive as it detected FIV provirus in 5 tissues in which virus was 
undetectable using the GL8 V5 qPCR (Figures 3-2A, 3-3B and 3-4A). However, 
greater PVLs (determined by GL8 V5 qPCR) were observed in most tissues, with 
the exception of submandibular lymph node (800 vs. 1,774 copies/106 cells), 
thymus (38,472 vs. 49,907 copies/106 cells) and PBMC (6,199 vs. 17,083 
copies/106 cells) (Figure 3-4A). Nevertheless, these differences were small and 
were not statistically significant in any of the 22 compartments investigated (p = 
0.1896, two-way ANOVA with Tukey’s multiple comparisons) (Figure 3-4A) 
Moreover, a strong positive correlation was observed between the FIV PVLs 
determined by the two methods (Spearman r = 0.9035, p < 0.0001****, Figure 3-
4B).  
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Figure 3-2 Comparisons of FIV PVL (copies/106 cells) as determined by gag quantitative PCR 
(qPCR) between 22 tissue compartments (A) and between three tissue types; visceral organs, 
lymphoid organs and peripheral blood mononuclear cells (PBMC) (B). Each bar represents the 
median with the range for four cats. The Y-axis is shown from the lower limit of detection (≤10 
copies/106 cells). Quantification of PVL was performed in triplicate. Kruskal-Wallis test (A) and 
Mann-Whitney test (B) 
 
 
 
Figure 3-3 Comparisons of FIV PVL (copies/106 cells) as determined by GL8 V5 qPCR between 22 
tissue compartments (A) and between three tissue types; visceral organs, lymphoid organs and 
peripheral blood mononuclear cells (PBMC) (B). Each bar represents the median with the range 
for four cats. The Y-axis is shown from the lower limit of detection (≤10 copies/106 cells). 
Quantification of PVL was performed in triplicate. Kruskal-Wallis test (A) and Mann-Whitney test 
(B) 
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Figure 3-4 Comparison of FIV PVL as determined by gag and GL8 V5 qPCRs in 22 compartments, 
each bar representing the median with the range for four cats. The Y-axis is shown from the 
lower limit of detection (≤10 copies/106 cells), two-way ANOVA with Tukey’s multiple 
comparisons (A). Spearman correlation between FIV PVL as determined by gag and GL8 V5 qPCRs 
(B). Quantification of PVL was performed in triplicate. 
 
Table 3-2 FIV PVL in three tissue compartments  
 
 visceral organsa lymphoid organsb PBMC 
gag 229 
(10 – 17,102) 
1,856 
(85 – 170,874) 
17,083 
(2,526 – 19,926) 
GL8 V5 2,577 
(132 – 14,309) 
9,559 
(110 – 865,399) 
6,199 
(1,771 – 7,633) 
B14** 681 583 
(495 – 6,953) 
2,175 
(2,074 – 5,231) 
B19 888 
(301 – 5,453) 
3,934 
(555 – 27,273) 
7,695 
(3,359 – 12,674) 
B28 3,586 
(1,005 – 31,101) 
4,278 
(691 – 1,397,646) 
1,686 
(154 – 8,747) 
B30 1,407 
(106 – 216,531) 
2,301 
(89 – 61,688) 
10,171 
(2,403 – 13,359) 
avisceral organs: salivary gland, thyroid, lung, liver, stomach, pancreas, small intestine, large 
intestine, kidney, urinary bladder, reproductive organs, blymphoid organs: tonsil, spleen, 
submandibular LN, retropharyngeal LN, prescapular LN, mediastinal LN, mesenteric LN, popliteal 
LN, bone marrow and thymus, *median (copies/106 cells with the range in brackets) was 
calculated from PVL of all tissues in the same category for four cats, **B14 was only detectable 
in prescapular lymph node, mediastinal lymph node and thymus of cat A825, liver of cat A826 
and PBMC of cats A825, A827 and A828 
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3.5.2 V5 variant PVL were highly diverse between tissue compartments  
 
The PVLs of each of the FIV V5 variants were measured using variant-
specific primers and probes, targeting the individual V5 loop sequence of each 
variant (Willett et al., 2013). B14 was rarely observed in tissues, only being 
detectable in the prescapular lymph node, mediastinal lymph node and thymus 
of cat A825, liver of cat A826 and PBMC of cats A825, A827 and A828 (Figure 3-
5A). This finding was not unexpected, since impaired replication of B14 had been 
observed thoughout the study period of 21 weeks (Willett et al., 2013). Overall, 
V5 variants were detected in all but five compartments; salivary gland, 
pancreas, bladder, kidney and reproductive organs of all 4 cats tested negative 
(Figure 3-5B to 3-5D). In addition to these five compartments, B28 was also 
undetectable in bone marrow of all four cats (Figure 3-5C). Similar to the results 
of the gag and GL8 V5 qPCR analyses, the quantities of V5 variants were 
statistically different between the tissue compartments (Kruskal-Wallis test, p = 
0.0002***, p = 0.0003*** and p = 0.002*** for B19, B28 and B30, respectively) 
(Figure 3-5B to 3-5D). The sample size of B14 was too small to permit statistical 
analysis (Figure 3-5A). 
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Figure 3-5 Comparisons of FIV PVL (copies/106 cells) between 22 tissue compartments as 
determined by B14 (A), B19 (B), B28 (C) and B30 (D) qPCR. Each bar represents the median with 
the range for four cats. The Y-axis is shown from the lower limit of detection (≤10 copies/106). 
Quantification of PVL was performed in triplicate. Kruskal-Wallis test 
 
Similar to the qPCR analyses for gag and GL8 V5, the PVL of B19 in PBMC 
and lymphoid organs was significantly higher than in the visceral organs (3,934 
and 7,695 vs. 888 copies/106 cells, p = 0.0009*** and p = 0.0118*, respectively) 
(Table 3-2 and Figure 3-6B). For B30, only the PVL in PBMC was significantly 
higher than in the visceral organs (10,171 vs. 1,407 copies/106 cells, p = 0.0404*) 
(Table 3-2 and Figure 3-6D). It was notable that the PVLs of B14 and B28 were 
relatively similar between tissue types (Figure 3.6A and 3.6C). For B14, this 
might be related to the small number of tissues in which virus was detected (one 
visceral organ, three lymphoid organs), which hindered statistical analysis. For 
B28, despite the high PVL in the thymus (median of four cats was 217,040 
copies/106 cells), the median loads in the visceral and lymphoid organs did not 
differ significantly (3,586 and 4,278, respectively) (Table 3-2 and Figure 3-6C). 
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Figure 3-6 Comparisons of FIV PVL (copies/106 cells) between three tissue types; visceral organs, 
lymphoid organs and peripheral blood mononuclear cells (PBMC) as determined by B14 (A), B19 
(B), B28 (C) and B30 (D) qPCR. Each bar represents the median with the range for four cats. 
Quantification of PVLs was performed in triplicate. The Y-axis is shown from the lower limit of 
detection (≤10 copies/106). Mann-Whitney test 
 
3.5.3 V5 variant PVL differed significantly between variants and tissue 
compartments 
 
 As shown above, the total FIV PVL as determined by both the gag and GL8 
V5 qPCR methods, and also the quantity of each of the V5 variants, varied 
significantly between tissue compartments, and lymphoid tissues were observed 
to be the main viral reservoir. We next investigated whether the PVL of each of 
the V5 variants (B14, B19, B28 and B30) varied within and between 
compartments. To address this question, a two-factor analysis of variance (two-
way ANOVA) was performed with the V5 variants and tissue compartments as 
column and row factors, respectively. Since none of the four V5 variants were 
detectable in salivary gland, pancreas, kidney, urinary bladder or reproductive 
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organs, these five compartments were excluded from the analysis. Figure 3-7 
summarises the FIV PVL determined using each qPCR method in 22 tissue 
compartments of four cats.  
 
The two-way ANOVA showed a significant interaction between tissue 
compartments and variants (accounting for 31.07% of total variance, p < 
0.0006***) (Appendix 3-3). This interaction indicated that the variations between 
each of the four V5 variant PVLs were statistically significantly different, as 
were the differences between the 22 tissue compartments examined. Moreover, 
statistically significant differences were not observed when total FIV PVLs 
(determined by gag and GL8 V5 qPCR) were analysed (p = 0.3114), confirming 
that the variability between each V5 variant, rather than the variations in PVL 
determined by different qPCR methods, accounted for the interaction observed 
between tissue compartments and variants (Appendix 3-3). 
 
The differences between the PVL of each V5 variant were statistically 
significant (accounting for 2.56% of total variance, p = 0.0494*). Significant 
variability was also observed amongst the 22 tissue compartments (accounting 
for 10.04% of total variance, p = 0.0186*) (Appendix 3-3). Using Tukey’s multiple 
comparisons, the PVL of B28 in thymus was the highest. It was significantly 
higher than the level in the other 17 tissue compartments examined (p < 
0.0001****) and it was also significantly higher than the PVL of B14, B19 and B30 
in all 17 compartments (p < 0.0001****).  No differences between variants were 
observed when total FIV PVLs  (determined by gag and GL8 V5 qPCRs) were 
included in the analysis. 
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Figure 3-7 Absolute quantity (copies/106 cells) of FIV PVL as determined by gag, GL8 V5, B14, 
B19, B28 and B30 qPCR in 22 tissue compartments. Log scale of PVL is indicated by the colour 
spectrum located at the top left. Yellow indicates PVL below the lower limit of detection (≤10 
copies/106). Quantifications of PVL were performed in triplicate. Median V5 variant (B14, B19, 
B28 and B30) or median gag and GL8 V5 PVLs of four cats (A825 – A828) were analysed by two-
way ANOVA with Tukey’s multiple comparisons  
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3.5.4 Lack of consensus pattern of compartmentalisation between cats 
 
In order to investigate whether there was a shared pattern of V5 variant 
selection within the 22 tissue compartments, a principal component analysis 
(PCA) was performed. PCA is a powerful statistical technique used to observe 
inter-relationships between large numbers of variables. Since our aim was to 
determine whether there was tissue specific-selection of V5 variants, the 22 
tissues were defined as “loading”, the determinants of the relationship while the 
PVL of each V5 variant in these tissues was defined as “score”, the hypothetical 
values that drive the relationship. In PCA, the original variables are plotted in a 
multidimensional space and then linearly transformed into “principal 
components (PC)”, each of which retains the maximal amount of information 
about the variables. If a V5 variant had been consistently selected in any given 
tissues in all four cats, the tissues (loading) should group together and lie in the 
same direction as the V5 variant (score) that drives the relationship on the PC 
plot.  
   
 
 
Figure 3-8 Relationship between tissue compartments and PVL of Env V5 variants. The figure 
shows a principal component analysis (PCA) bi-plot (loading and score) of the first two principal 
components (PC); PC1 on X-axis and PC2 on Y-axis. As shown in the lower left region of the 
figure, these 2 PC accounted for 56% (38% + 18%) of total variables. This PC value indicates the 
percentage of the original variable that could be explained by that PC. Tissue compartments 
(loading) and V5 variant PVL (score) are shown in red and blue, respectively. 
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 As shown in Figure 3-8, when the quantities of each V5 variant in each 
compartment of all four cats were analysed altogether, no consistent 
relationships were observed.  From the combined PC1 and PC2 value of 56%, the 
pattern observed here only accounted for approximately half of the variables, 
indicating that there was no dominant component when all four cats were 
analysed together. This was mainly due to the high variations between cats, 
reflected by the different tissue-dominant variants in each cat (Appendix 3-4 
and 3-5). Nevertheless, evidence of compartmentalisation of B28 in thymus was 
detected in three of the four cats. In cats A825, 826 and 827, the position of 
thymus on the loading plots was consistently driven by the quantity of B28 PVL 
(Appendix 3-5A to 3-5F). For cat A828, FIV PVL was undetectable in the thymus, 
explaining the lack of B28 compartmentalisation in the thymus for this cat 
(Appendix 3-5G and 3-5H).   
 
3.5.5 B28 was predominant in thymus but absent in bone marrow 
  
 Although the pattern of tissue-specific selection of V5 variants remained 
inconclusive, some findings were consistently observed in the bone marrow and 
thymus with variant B28. In all cats, B28 was uniformly absent from the bone 
marrow but demonstrated the highest PVL in the thymus (Figures 3-5C and 3-7). 
In addition, the association of B28 PVL and thymus was observed in PCA analyses 
of three of the four cats examined (Appendix 3-5A to 3-5F). To confirm these 
findings, a region of env spanning the entire V5 loop was amplified from proviral 
DNA prepared from bone marrow and thymus from all four cats. PCR amplicons 
were then cloned and the nucleotide sequences obtained. As shown in Figure 3-
9A, with the exception of cat A828 in which FIV provirus could not be detected 
in thymus using any of the qPCR methods, B28 was indeed the major variant 
within the thymus (76.0%, 116/150 clones). The second most dominant variant 
was B30 (12.66%, 19/150), followed by B19 (4.67%, 7/150), the GL8-like variants 
(B31+B32) (4.0%, 6/150) and B14 (2.67%, 4/150) (Figure 3-9A, bottom panel). 
This finding agreed with the qPCR result, confirming that B28 PVL was 
predominant in thymus (median of four cats = 192,167 copies/106 cells), 
followed by B30 (25,317 copies/106 cells) and B19 (16,600 copies/106 cells) 
(Figure 3-9A, top panel). B14 was only detected in cat A825 and the PVL was 
similar to that of B19.  
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The absence of variants B14 and B28 in the bone marrow, as 
demonstrated by qPCR, was confirmed by the colony sequencing results. As 
shown in Figure 3-9B, the GL8-like variants (B31+B32) were dominant in bone 
marrow (86.06%, 173/201), followed by B19 (8.95%, 18/201) and B30 (3.98%, 
8/201) (Figure 3-9B, bottom panel). B14 and B28 were not detected, even when 
50 colonies from each cat were screened. This observation was consistent with 
the quantities of the variants determined by qPCR: the PVL of B19 was higher 
than B30 (median PVL of four cats were 9,675 and 1,606 copies/106 cells, 
respectively) (Figure 3-9B, top panel). However, the absolute quantities of the 
GL8-like variants (B31+B32) could not be determined, since the GL8 V5 qPCR 
method detected all V5 variants. Nonetheless, the median FIV PVL as 
determined by GL8 qPCR was 108,883 copies/106 cells, which far exceeded the 
PVL of B19 (9,675 copies/106 cells) and B30 (1,606 copies/106 cells) combined, 
confirming that GL8-like variants predominated in the bone marrow, as had been 
observed by colony sequencing (Appendix 3-6). 
 
Taken together, the significantly different PVLs of each V5 variant 
observed, both within and between the tissue compartments examined, and the 
predominance of B28 in the thymus and its absence from the bone marrow, 
demonstrate that tissue specific selection had arisen following the experimental 
infection of FIV quasispecies and resulted in the expansion of particular variants 
over others in the tissues, i.e. “tissue compartmentalisation”.  
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Figure 3-9 Compartmentalisation of 
V5 variants, Top: FIV PVL in thymus 
(A) and bone marrow (B) as 
determined by each V5 variant 
specific qPCR for each cat. Bottom: 
Unrooted maximum likelihood 
phylogenetic trees, comparing env V5 
sequences derived from thymus (A) 
and bone marrow (B) of cats A825-
828.  Each tree contains 150 - 200 env 
V5 sequences, 50 from each cat (no 
PCR products were amplified from the 
thymus of cat A828), and five 
reference sequences. Coloured circles 
indicate sequence similarity to the 
reference sequences: GL8-like 
variants (B31 + B32) (pink), B14 
(orange), B19 (drab), B28 (green) and 
B30 (blue). The percentages and 
frequencies of each V5 variant are 
shown next to the relevant cluster. 
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3.5.6 Levels of CD134 and CXCR4 mRNA in tissue compartments 
 
Since the FIV V5 variant B28 was absent from the bone marrow but 
predominated in the thymus of all four cats, we speculated that the PVL of each 
V5 variant might be related to the number of CD134+ target cells in each tissue 
compartment. This speculation was based on the finding that the FIV V5 variants 
in this study showed distinct CD134 usage characteristics, reflected by different 
sensitivities to inhibition with neutralising antibodies, anti-CD134 antibody, 
soluble CD134 and CD134 ligand (Appendix 3-1) (Willett et al., 2010). Since these 
variants did not require CRD2 for infection, they might possess a selective 
advantage in low CD134+ cell compartments over CRD2-dependent variants such 
as their parental GL8.  
 
As all tissue samples had been stored frozen, it was not possible to test 
this hypothesis by direct enumeration of CD134+ T lymphocytes by flow 
cytometry. Therefore, a duplex quantitative PCR specific for feline CD134 or 
CXCR4 mRNA together with feline β-actin was used (Scott et al., 2008). From the 
22 compartments examined in this study, nine tissues with significant 
differences in FIV V5 variant PVL were selected for further investigation; thyroid 
gland, spleen, submandibular lymph node (SMLN), retropharyngeal lymph node 
(RPLN), prescapular lymph node (PSLN), mesenteric lymph node (MSLN), 
popliteal lymph node (PLN), bone marrow (BM) and thymus.  
 
As shown in Figure 3-10, the levels of CD134 mRNA in nine compartments 
differed significantly, both between and within cats (p < 0.0001****, two-way 
ANOVA with Tukey’s multiple comparisons). Cat A826 contained the highest level 
of CD134 mRNA, followed by cats A828, A827 and A825 (medians = 2,494, 1,897, 
1,715 and 1,190 plasmid copies, respectively) (Appendix 3-7). CD134 mRNA 
levels were highest in MSLN followed by PSLN, PLN and thymus (median = 3,484, 
2,505, 2,306 and 2,268 plasmid copies, respectively) (Appendix 3-8). The levels 
of CD134 mRNA of both MSLN and PSLN were significantly higher compared to 
the other tissue compartments (Table 3-3). Surprisingly, similar levels of CD134 
mRNA were observed in primary (bone marrow and thymus) and secondary 
lymphoid tissues (spleen, MSLN, PLN, PSLN, RPLN and SMLN) (median values of 
1,922 vs. 2,086 plasmid copies, p = 0.6038, Mann-Whitney test). This finding was 
unexpected, since CD134 is expressed on the surface of CD4+ T lymphocytes 
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following antigen stimulation, which generally occurs in the secondary lymphoid 
tissues (Reggeti et al., 2008). 
  
 
 
Figure 3-10 Comparison of CD134 mRNA levels in nine compartments of four cats, each bar 
shows the mean value with standard deviation (SD) of three replicates. Two-way ANOVA with 
Tukey’s multiple comparisons, *, **, *** and **** indicated p values of < 0.05, < 0.01, < 0.05 and < 
0.0001, respectively.  
 
Table 3-3 Statistical comparisons of CD134 mRNA levels between compartments* 
 
 thyroid spleen SMLN RPLN PSLN MSLN PLN BM 
spleen ns 
       SMLN ns ns 
      RPLN ** ns ns 
     PSLN **** **** **** **** 
    MSLN **** **** **** **** **** 
   PLN **** **** **** * ** **** 
  BM * ns ns ns **** **** * 
 thymus **** **** **** ns *** **** ns ns 
 
* Comparison of mean levels in four cats using Tukey’s multiple comparisons, the median value 
with the range of individual tissues are shown in Appendix 3-8, *, **, *** and **** indicate p values 
of < 0.05, < 0.01, < 0.05 and < 0.0001, respectively, ns = not significant  
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 Similar to CD134 mRNA, the levels of CXCR4 mRNA differed significantly 
between tissues and between cats (p < 0.0001****, two way ANOVA with Tukey’s 
multiple comparisons) (Figure 3-11). The level of CXCR4 mRNA was highest in cat 
A826 (13,787 plasmid copies), followed by cats A828, A827 and A825 (median 
values 6,838, 3,544 and 3,306 plasmid copies, respectively) (Appendix 3-8). 
MSLN contained the highest level of CXCR4 mRNA followed by PSLN, thymus 
gland, RPLN and SMLN (median values 36,428, 32,224, 17,281, 11,845 and 7,366 
plasmid copies, respectively) (Appendix 3-9). The levels observed in these five 
tissues were statistically significantly greater than those in the other tissues 
examined (Table 3-4). When the tissues were categorized into primary and 
secondary lymphoid organs, the levels of CXCR4 mRNA were similar, as had been 
observed with CD134 mRNA (4,985 vs. 6,540 plasmid copies number, p = 0.6337, 
Mann-Whitney test).  
 
 In all tissues except popliteal lymph node, the levels of CXCR4 mRNA were 
significantly higher than the levels of CD134 mRNA (median of 8,256 vs. 1,746, p 
= 0.0012**, Mann-Whitney test) (Figure 3-12). When individual tissues were 
examined, the CXCR4 mRNA quantity was significantly higher in MSLN (36,428 vs. 
3,484 plasmid copies number, p < 0.0001****), PSLN (32,224 vs. 2,505 plasmid 
copies number, p < 0.0001****) and thymus (17,281 vs. 2,268 plasmid copies 
number, p < 0.01**) compared to the other tissues (Appendix 3-8). 
 
 
 
Figure 3-11 Comparison of CXCR4 mRNA levels in nine compartments between four cats, each 
bar shows the mean value with standard deviation (SD) of three replicates. Two way ANOVA with 
Tukey’s multiple comparisons, * and **** indicates p values of < 0.05 and < 0.0001, respectively. 
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Table 3-4 Statistical comparisons of CXCR4 mRNA levels between compartments* 
 
 thyroid spleen SMLN RPLN PSLN MSLN PLN BM 
spleen ns 
       SMLN *** **** 
      RPLN **** **** **** 
     PSLN **** **** **** **** 
    MSLN **** **** **** **** **** 
   PLN * ns **** **** **** **** 
  BM * ns **** **** **** **** ns 
 thymus **** **** **** **** **** **** **** **** 
 
*Comparison of mean level of four cats using Tukey’s multiple comparisons, median value with 
the range of individual tissue were shown in Appendix 3-8, *, *** and **** indicate p values of < 
0.05, < 0.005 and < 0.0001, respectively, ns = not significant  
 
 
 
Figure 3-12 Comparison of CD134 and CXCR4 mRNA levels in each tissue compartment, each bar 
representing the median with the range for four cats, Two-way ANOVA with Sidak’s multiple 
comparisons, ** and **** indicate p values of < 0.01 and < 0.0001, respectively. 
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3.5.7 Relationships between the levels of CD134 and CXCR4 mRNA and FIV 
PVL 
   
Since the quantity of each V5 variant differed significantly and different 
levels of CD134 and CXCR4 mRNA were also observed between tissues, we next 
investigated whether there was any correlation between the level of CD134 or 
CXCR4 mRNA and the quantity of each of the V5 variants in each tissue (Table 3-
5 and Figure 3-13). Overall, the relationship between CD134 mRNA and total PVL 
as determined by gag and GL8 V5 qPCR was inconclusive, with very broad 95% 
confidence intervals (0.5887 to 0.02683 for gag and -0.2429 to 0.4957 for GL8 
V5)  (Table 3-5 and Figure 3-13A). This ambiguity was also observed for CXCR4 
mRNA (Table 3-5 and Figure 3-13B). The lack of correlation might be related to 
the different characteristics of each variant in the quasispecies (Appendix 3-1), 
as reflected by the high variations and different correlations observed between 
variants B19, B28 and B30 (Table 3-5). B14 was undetectable in most of the 
tissues examined and so could not be included in this analysis. While the PVL of 
B19 showed no statistically significant correlation with CD134 mRNA levels, the 
positive correlation with CXCR4 mRNA levels almost reached statistical 
significance (r = 0.3306, p = 0.0692) (Table 3-5). In addition, although not 
statistically significant, a negative correlation was observed between B28 PVL 
and CD134 mRNA (r = -0.3587, p = 0.0928). Positive correlations were observed 
between B30 PVL and both the levels of CD134 and CXCR4 mRNA (Table 3-5), 
although only the correlation with CXCR4 mRNA  (r = 0.4552, Spearman test) was 
statistically significant (p = 0.0078**). 
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Table 3-5 Relationships between CD134 and CXCR4 mRNA and FIV PVL* 
 
CD134 mRNA against  
 r 95% CI P value 
gag -0.3135 -0.5887 to 0.02683 0.0626 
GL8 V5 0.1468 -0.2429 to 0.4957 0.4473 
B14 na na na 
B19 0.008065 -0.3568 to 0.3709 0.9657 
B28 -0.3587 -0.6786 to 0.07568 0.0928 
B30 0.1748 -0.1895 to 0.4968 0.3306 
 
CXCR4 mRNA against  
 r 95% CI P value 
gag -0.2221 -0.5206 to 0.1247 0.1929 
GL8 V5 0.03448 -0.3463 to 0.4055 0.8591 
B14 na na na 
B19 0.3306 -0.03778 to 0.6199 0.0692 
B28 0.0009881 -0.4221 to 0.4237 0.9964 
B30 0.4552 0.1222 to 0.6961 **0.0078 
*Spearman correlation, B14 PVL in tissues was too low for inclusion in the analysis (na = not 
analysed), ** indicates p values of < 0.01 
 
 
Figure 3-13 Relationship between CD134 (A) and CXCR4 (B) mRNA and FIV PVL as determined by 
gag (opened purple circle), GL8 V5 (pink circle), B14 (yellow square), B19 (drab upward 
triangle), B28 (green downward triangle) and B30 (blue diamond) qPCR in nine tissue 
compartments; thyroid, spleen, SMLN, RPLN, PSLN, MSLN, PLN, bone marrow and thymus. Each 
symbol represents the mean value for individual tissues from each of the four cats. 
Quantifications of PVL and mRNA were performed in triplicate. Spearman test  
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It was reported previously in both humans (Soulie et al., 2012) and cats 
(Reggeti et al., 2008) that lymphocyte activation resulted in increased 
expression of CD134 and decreased CXCR4 expression. In addition, at least in 
human T lymphocytes, while CXCR4 is constitutively expressed, CD134 is only 
expressed on the cell surface after stimulation via the T cell receptor-peptide 
major histocompatibility complex (TCR-pMHC)) complex and CD28 signaling 
pathway (Gerard and Rollins, 2001, Croft, 2014). Therefore, we proposed that 
the CD134 mRNA:CXCR4 mRNA ratio might reflect the level of activated T 
lymphocytes in the tissues, while the CXCR4 mRNA:CD134 mRNA ratio might 
reflect the level of naïve cells. It was observed that the CD134:CXCR4 mRNA 
ratio was highest in PLN (0.86), followed by bone marrow (0.71) and spleen 
(0.42) (Appendix 3-9).  
 
We next examined relationships between the CD134:CXCR4 mRNA ratio 
and PVL, as determined using each primer and probe set. No significant 
correlation was observed between the total FIV PVL as determined by gag or GL8 
V5 qPCR and the CD134:CXCR4 mRNA ratio, most likely reflecting the high 
degree of variation, given the broad 95% confidence interval (Table 3-6). With 
the exception of the B14 variant, which was precluded from the statistical 
analysis because of the small sample size, a negative correlation was observed 
between the CD134:CXCR4 mRNA ratio and the PVL of the other V5 variants, 
namely B19 (r = -0.4391), B28 (r = -0.1123) and B30 (r = -0.4403);  this 
correlation was statistically significant for variants B19 and B30 (p values = 
0.0135* and 0.0103*, respectively) (Table 3-6 and Figure 3-14).  
 
Table 3-6 Relationship between CD134 mRNA:CXCR4 mRNA ratio and FIV PVL* 
 
 r 95% CI P value 
gag 0.1482 -0.1993 to 0.4626 0.3884 
GL8 V5 0.09543 -0.2913 to 0.4554 0.6224 
B14 na na na 
B19 -0.4391  -0.6923 to -0.08948 *0.0135 
B28 -0.1123 -0.5110 to 0.3260 0.6098 
B30 -0.4403 -0.6864 to -0.1039 *0.0103 
*Spearman correlation, number of copies of variant B14 in tissues was too small for analysis (na = 
not analysed), * indicates p values of < 0.05 
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Figure 3-14 Relationship between CD134 mRNA:CXCR4 mRNA ratio and FIV PVL as determined by 
gag (opened purple circle), GL8 V5 (pink circle), B14 (yellow square), B19 (drab upward 
triangle), B28 (green downward triangle) and B30 (blue diamond) qPCR in nine tissue 
compartments (A). Relationship between CD134:CXCR4 mRNA ratios and PVL of variants B19 and 
B30 (B).  Each symbol represents the mean value for individual tissues from each of the four 
cats. Quantifications of PVL and mRNA were performed in triplicate. Spearman test  
 
3.5.8 FIV infection associated with increased levels of CD134 and CXCR4 
mRNA in bone marrow and spleen but not thymus 
 
 Hyper-activation of the immune system is one of the key events in the 
pathogenesis of FIV infection (Silvotti et al., 1997, Tompkins and Tompkins, 
2008, Taniwaki et al., 2013). As CD134 and CXCR4 mRNA expression levels vary 
according to the activation status of the cell, changes in expression could reflect 
the level of immune activation of the tissue compartments. To investigate this 
issue, the expression levels of CD134 and CXCR4 mRNA in bone marrow, spleen 
and thymus were compared with those of age-matched, uninfected, specific 
pathogen free (SPF) cats.  
 
Similar to the FIV infected cats, the expression levels of CD134 and CXCR4 
mRNA differed significantly between compartments and between individuals 
amongst three uninfected SPF cats (p < 0.0001****, two-way ANOVA with Tukey’s 
multiple comparisons) (Figure 3-15 and Appendix 3-10). Of the three tissues 
examined, the thymus contained the highest amount of both CD134 and CXCR4 
mRNA (363 and 2,238 plasmid copies, respectively), followed by bone marrow 
(98 and 114 plasmid copies, respectively) and spleen (37 and 13 plasmid copies, 
respectively). As shown in Figure 3-16, FIV infection was associated with 
significantly increased expression of CD134 and CXCR4 mRNA in bone marrow 
and spleen, whereas the expression levels of both CD134 and CXCR4 mRNA in 
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thymus were similar in FIV positive and negative cats (Figure 3-16). The 
CD134:CXCR4 mRNA ratio was slightly higher in the bone marrow and thymus of 
FIV infected cats, but this difference was not statistically significant (1.20 vs. 
0.83 and 0.33 vs. 0.21, respectively). 
 
 
 
Figure 3-15 Comparisons of CD134 mRNA (A) and CXCR4 mRNA (B) levels in three compartments; 
bone marrow, spleen and thymus of three FIV negative SPF cats; each bar represents the mean 
with standard deviation (SD) of results measured in triplicate. Two-way ANOVA with Tukey’s 
multiple comparisons, * and *** indicate p values of < 0.05 and < 0.001, respectively. 
 
 
 
Figure 3-16 Comparisons of CD134 (A) and CXCR4 (B) mRNA levels in bone marrow, spleen and 
thymus in age-matched FIV negative (open bars) and FIV positive (shaded bars) cats.  Each bar 
represents the median with the range for three cats (FIV negative) and for four cats (FIV 
positive). Mann-Whitney test 
  
A
81
0
A
81
1
A
81
2
100
101
102
103
C
D
1
3
4
 m
R
N
A
 (
p
la
s
m
id
 c
o
p
ie
s
)
***
*** ***
A
81
0
A
81
1
A
81
2
100
101
102
103
104
C
X
C
R
4
 m
R
N
A
(p
la
s
m
id
 c
o
p
ie
s
)
bone marrow
spleen
thymus
***
*** *
A B
FI
V
 n
eg
at
iv
e
FI
V
 p
os
iti
ve
FI
V
 n
eg
at
iv
e
FI
V
 p
os
iti
ve
FI
V
 n
eg
at
iv
e
FI
V
 p
os
iti
ve
100
101
102
103
C
D
1
3
4
 m
R
N
A
 (
p
la
s
m
id
 c
o
p
ie
s
)
bone marrow spleen thymus
***
p < 0.0001 
***
p = 0.0006 p = 0.5698
FI
V
 n
eg
at
iv
e
FI
V
 p
os
iti
ve
FI
V
 n
eg
at
iv
e
FI
V
 p
os
iti
ve
FI
V
 n
eg
at
iv
e
FI
V
 p
os
iti
ve
100
101
102
103
104
C
X
C
R
4
 m
R
N
A
(p
la
s
m
id
 c
o
p
ie
s
)
*
p = 0.0101 
**
p = 0.0044 p = 0.7902
bone marrow spleen thymus
A B
98 
3.5.9 Thymus contained the lowest level of CD4+CD134+ T lymphocytes as 
measured by flow cytometry 
 
As significantly different levels of CD134 mRNA expression were observed 
in the nine tissue compartments investigated here (Figure 3-10), in order to 
confirm this findings, the percentages of CD4+CD134+ T lymphocytes were 
assessed in cells freshly isolated from samples of mesenteric lymph node (MSLN), 
spleen, thymus and PBMC from another group of four cats, experimentally 
infected with FIV for 44 weeks (ongoing study, unpublished data). As shown in 
Figure 3-17, compared to other tissue compartments, thymus contained the 
fewest CD4+CD134+ T lymphocytes (median of 1.35%, range 0.9% - 2.9%). This 
result was consistent with a previous study in FIV infected cats, using the same 
anti-feline CD134 antibodies, which demonstrated that thymus contained fewer 
CD4+CD134+ T lymphocytes than MSLN and spleen (Willett et al., 2007).  
 
 
 
Figure 3-17 Comparison of percentage of CD4+CD134+ T lymphocytes in PBMC, mesenteric lymph 
node, spleen and thymus.  Each bar represents the median with the range for four cats. The Y-
axis shows the percentage of CD134+ cells in the CD4+ T lymphocyte population. Mann-Whitney 
test, * indicates p value < 0.05 
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3.6 Discussion and Conclusion  
 
Tissue compartmentalisation is a phenomenon that has been well 
described for HIV and that likely exists also in FIV infection (Wong et al., 1997, 
Singh et al., 1999, Zhang et al., 2002, Kemal et al., 2003, Kenyon and Lever, 
2011). In this chapter, evidence of FIV compartmentalisation was reported, since 
we observed quantitative differences in the PVLs of the FIV Env V5 variants 
amongst 22 tissue compartments. The dominance of variant B28 in the thymus 
and its absence from the bone marrow, a result that was confirmed using 
conventional phylogenetic tree analysis, provided strong support for the 
existence of tissue compartmentalisation of FIV variants that differed only in 
sequence changes in the V5 loop of Env. Different levels of CD134 and CXCR4 
mRNA, transcripts of the primary receptor and co-receptor for FIV infection, 
were also observed between tissues, although it remained inconclusive whether 
these differences were associated with tissue-specific selection of FIV V5 
variants. To date, this is the most comprehensive study of tissue 
compartmentalisation in FIV infection. 
 
Several mechanisms have been proposed for tissue compartmentalisation. 
One of the strongest selective pressures that shapes both FIV and HIV evolution 
results from specific immune responses (Rambaut et al., 2004). Virus variants 
containing both neutralising antibody and CD8+ cytotoxic-T lymphocyte (CTL) 
escape mutations have been reported in patients chronically infected with HIV 
(Goulder and Watkins, 2004, Rambaut et al., 2004) and cats infected with FIV 
(Beatty et al., 1996, Hosie et al., 2002, Kraase et al., 2010, Samman et al., 
2010, Willett et al., 2013). The level of immune selection in tissue 
compartments is related to the permissiveness for the entry or infiltration of 
antibodies or immune cells, which could lead to differences in the viral variants 
selected between compartments. Therefore, the tissue compartmentalisation 
observed in this study might be associated with differences in antibody 
permeation between tissues, since Env V5 variants showed different sensitivities 
to neutralisation by homologous plasma (Willett et al., 2010).  However, the 
absence of neutralising antibodies against any of the six inoculated variants in 
the plasma of these four cats argued against the roles of neutralising antibody-
associated selections (Willett et al., 2013). In these four cats, strong cell-
mediated immune responses, determined by interferon-γ ELISpot (Enzyme-
100 
Linked ImmunoSpot) assays using inactivated whole GL8 virus, were observed. 
Furthermore, different responses were observed among cells derived from 
spleen, PLN, MSLN and PBMC, suggesting that there might have been different 
cell-mediated immune responses (CMI) exerting selective pressure in different 
tissue compartments. However, when CMI epitopes were mapped against whole 
Env- and V5-derived peptides, the relationships between T cell responses against 
epitopes unique to each V5 variant and their strength remained elusive (Willett 
et al., 2013). Nevertheless, since cell-mediated immune responses against FIV 
variants were observed in this cohort, further investigations would be necessary 
in order to explore the role of cellular immune responses in FIV tissue 
compartmentalisation. 
 
The tropism of FIV (Willett and Hosie, 2008, Willett and Hosie, 2013), HIV 
(McKnight et al., 1995, Mehandru et al., 2004, Obermeier et al., 2012) and SIV 
(Mattapallil et al., 2005, Nishimura et al., 2005) is governed by amino acid 
variation within Env, such that some viral variants preferentially dominate in 
particular tissues according to their tropisms. This appeared to be a likely 
explanation for the findings of this study, since different tropisms of the V5 
variants within the experimental inoculum had been observed previously 
(Appendix 3-1) (Willett et al., 2010). However, FIV tropism study appears to be 
more complex compared to HIV where, according to the ability of HIV to utilise 
CCR5 (R5), CXCR4 (X4) or both co-receptors (R5X4), two or three distinct target 
cell populations could be defined (Berger et al., 1998, Berger et al., 1999, 
Willett and Hosie, 2008). CCR5 is expressed mainly on memory T lymphocytes 
and cells from the monocyte/macrophage lineage such as macrophages and 
dendritic cells, whereas CXCR4 is expressed mainly on naïve T lymphocytes 
(Bleul et al., 1997, Lee et al., 1999). As a result, HIV compartmentalisation is, in 
part if not directly, under the influence of target cell availability within tissues. 
For example, CCR5-tropic viruses predominate in the CNS and GALT where CCR5+ 
macrophage/microglial cells and memory CD4+ T lymphocytes, respectively are 
present at high frequency (Albright et al., 1999, Mehandru et al., 2004, Peters et 
al., 2007, Douek et al., 2009).  
 
In contrast, FIV tropism cannot be defined by co-receptor usage, since all 
FIV isolates tested to date utilise CXCR4 for infection (Willett and Hosie, 2008).  
Rather, FIV tropism appears to be defined by the interaction of Env with the 
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primary receptor CD134 (Willett et al., 2006b, Willett et al., 2010, Willett and 
Hosie, 2013, Beczkowski et al., 2014b). FIV isolates recovered during the early 
phase of infection, such as GL8 and CPG41, require both CRD1 and CRD2 of 
CD134 (Willett et al., 2006b, Willett and Hosie, 2013).  In contrast, strains 
recovered during the later stages of infection, such as PRR, B2542 and the V5 
variants in this study, only require CRD1 and CXCR4, or utilise CXCR4 alone for 
infection (de Parseval et al., 2004b, de Parseval et al., 2005, Willett et al., 
2006b, Beczkowski et al., 2014b). The requirement for the additional amino acid 
motif 78NYE80 on CRD2 might reflect a stronger affinity and/or a more efficient 
interaction between the Env of early FIV strains and CD134 (Willett et al., 
2006a, Willett et al., 2006b, Willett and Hosie, 2013). In addition, since CRD2-
dependent viruses can bind CD134, even when bound by its ligand CD134L, this 
might give CRD2-dependent variants a replicative advantage over CRD2-
independent variants, as the ability to infect cells where CD134 is engaged by 
CD134L results in an increased number of target cells being available for 
infection (Takahashi et al., 2001, Soroosh et al., 2006, Song et al., 2008, Willett 
and Hosie, 2013). Moreover, it was reported that CD134-CD134L interaction lead 
to an enhanced HIV production (Takahashi et al., 2001). Thus, the expression 
levels of CD134, in terms of both the number of target cells expressing CD134+ 
and the level of cell surface expression, might be critical in the selection of the 
fittest variant(s) in the transmitted quasispecies, as well as in tissue 
compartmentalisation. This speculation was in part supported in this study by 
the observation that GL8 like variants were the most abundant variant in bone 
marrow (Figure 3-8B), as well as the negative correlations observed between B19 
and B30 PVLs and CD134:CXCR4 mRNA ratios, the surrogate marker for activated 
CD134+ T lymphocytes (Figure 3-14B). As the Envs of these late, CRD2-
independent variants bound CD134 with a lower affinity than the Envs of CRD2-
dependent variants, it is likely that the CRD2-independent variants were 
outcompeted by the fitter, CRD2-dependent GL8 in tissue compartments 
containing more CD134+ target cells, such as the bone marrow.  
 
Although the statistical significance varied, the PVLs of total FIV as well 
as each of the V5 variants were higher in lymphoid tissues than visceral organs 
(Table 3-2, Figure 3-2B, 3-3B and 3-6). This finding is consistent with studies of 
HIV-1 pathogenesis, in which HIV-1 was found to replicate extensively in 
secondary lymphoid organs where the main target cell, the CD4+ T lymphocyte, 
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is activated following an interaction with an APC (Fauci, 1993, Haase, 1999, Yukl 
et al., 2010). Differences in the FIV PVL between lymphoid organs and PBMC, on 
the other hand, were not statistically significant (Table 3-2, Figure 3-2B, 3-3B 
and 3-6). This might be explained by the continuous migration of activated 
CD4+CD134+ T lymphocytes from secondary lymphoid organs into the circulation 
(Evans et al., 2001, Murphy and Janeway, 2012). Nevertheless, it is important to 
consider the variation in PVL observed between tissues, since statistically 
significant differences were observed in all qPCR results (Figure 3-2A, 3-3A and 
3-5). It is possible that the high variability in the PVL between tissues decreased 
the statistical power when the median values of tissues were compared with the 
median in PBMCs. 
 
The detection of variant B14 in the thymus of cat A827 by single colony 
sequencing was intriguing, since B14 was undetectable in thymus by qPCR 
(Figure 3-9A). This finding might reflect the poor replicative capacity of B14 per 
se, regardless of the tissue compartment, as B14 was not detected in most of the 
tissues examined (Figure 3-5A and 3-7) and replicated poorly in PBMC throughout 
the 21 weeks study period (Willett et al., 2013). In contrast, variant B28 was 
dominant in the thymus, but had a low PVL in PBMC and was undetectable in 
bone marrow, providing evidence of tissue compartmentalisation (Figure 3-5C 
and 3-7). Given the consistency of this finding in all cats, this study provides 
evidence that strongly supports the preferential selection of variant B28 in 
thymus.  
 
The similar levels of CD134 and CXCR4 mRNA observed here between 
primary and secondary lymphoid tissues might reflect the heterogeneity of these 
tissues. It is generally accepted that the main function of the thymus is to 
educate precursor cells to develop into self-tolerant, mature T lymphocytes 
(Blom and Spits, 2006, Murphy and Janeway, 2012). Immature progenitor cells 
expressing CXCR4+ migrate to the thymus according to the high level of CXCL12 
expression on thymic epithelial cells (TEC) in the thymic stroma and 
subsequently develop into thymocytes (Ishii et al., 1999). It has been shown that 
CXCR4 is expressed at all stages of human thymocyte development, although 
studies have shown that expression levels vary at different stages (Kitchen and 
Zack, 1997, Zaitseva et al., 1998). This explains the high levels of CXCR4 mRNA 
observed in thymus of all four cats examined in this study. However, at least in 
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humans, the thymic medulla contains a venule, similar to the high endothelial 
venule (HEV) of lymph nodes, through which cells, including antigen-activated 
lymphoid cells, can enter the thymus from the circulation (Pabst, 2007). This 
route might allow CD4+CD134+ T lymphocytes to re-enter thymus. Nevertheless, 
we presume that the level of CD4+CD134+ T lymphocyte migration through the 
thymus is relatively low as thymus contains few CD134+ T lymphocytes as shown 
by flow cytometry (Figure 3-17). Moreover, FIV infection did not appear to 
impact upon the level of CD4+CD134+ T lymphocytes in thymus as the levels of 
CD134 mRNA were similar between FIV negative and FIV positive cats (Figure 3-
16). This unique environment in the thymus, where it was shown by flow 
cytometry that CD134 cell numbers and expression levels are low, but CXCR4 
expression is high, might allow CRD2-independent variants to outcompete CRD2-
dependent variants, consistent with the observed dominance of B28 in thymus. 
To prove this hypothesis, we attempted to directly compete GL8 and B28 
infectivity for thymocytes. However, this was unsuccessful because the feline 
cytokines required for maintaining thymocytes in culture are not available and 
so this important research question remains.  
 
The spleen is composed of three anatomically distinct zones; red pulp, 
marginal zone and white pulp, which share many similarities with lymph nodes 
(Mebius and Kraal, 2005, Murphy and Janeway, 2012). However, since the spleen 
lacks both HEV and afferent lymphatic vessels, lymphocytes migrate into the 
white pulp using different mechanisms compared to lymph nodes (Nolte et al., 
2002, Crivellato et al., 2004). It was reported in humans that lymphocyte 
migration to and through the spleen is several fold greater compared to the 
recirculation via lymph nodes (Pabst, 1988).  This unrestricted migration of 
target cells between the blood circulation and spleen likely explains the 
dominance of GL8 observed in the PBMC and spleen. It might also explain the 
discrepancy between CD134 mRNA levels and the percentage of CD4+CD134+ T 
lymphocytes determined by flow cytometry (Table 3-6, Figure 3-10 and 3-17). 
Spleen contained the highest levels of CD4+CD134+ T lymphocytes by flow 
cytometry but low levels of CD134 mRNA. Since the absolute mRNA level in this 
study was calculated by dividing the ct value of the CD134 mRNA with ct value of 
βactin, the presence of large numbers of non-activated cells led to an apparent 
decrease in the levels of CD134 mRNA. Similarly, bone marrow is a primary 
lymphoid organ for B lymphocytes (Murphy and Janeway, 2012), but also 
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contains dendritic cells, memory CD4+ and CD8+ T lymphocytes (Cavanagh et al., 
2005, Di Rosa and Pabst, 2005, Mazo et al., 2005). Therefore, although it is 
conventionally designated as a primary lymphoid organ, the bone marrow 
contains both progenitor and mature cells from the circulation, which might 
explain the dominance of GL8 over other V5 variants that was observed in the 
bone marrow, similar to the observations in the lymph nodes, spleen and PBMC.    
 
Further supporting evidence for the positive correlation between target 
cell availability and tissue compartmentalisation was provided by the detection 
of HIV in the CNS, even in patients with undetectable plasma viral loads 
(Canestri et al., 2010, Valcour et al., 2011). Although this finding might have 
been associated with the inability of anti-retroviral drugs to cross the blood-
brain-barrier, it did not rule out an effect of different target cell populations 
between the two compartments (Wynn et al., 2002, Potschka, 2010). HIV 
infiltration into the CNS led to downregulation of MHC class I and II and 
upregulation of Fas ligand in neurons, microglia and astrocytes that, in turn, 
limited the activation, proliferation and induced apoptosis of both CD8+ and 
CD4+ T lymphocytes (Massa, 1993, Massa et al., 1993, Bai et al., 2009, Choi and 
Benveniste, 2004). As a result, the decreased number of activated CD4+ T 
lymphocytes directly affected the composition of the virus population, as minor 
variants were more able to infect other target cells.  
 
Different viral burdens between tissue compartments were also evident in 
other tissues from an HIV infected patient with significantly higher levels of HIV 
DNA and RNA in GALT compared to PBMC (Yukl et al., 2010, Yukl et al., 2013). 
Moreover, it was reported that while HIV DNA predominated in CD4+CCR7+ 
central memory (CM) T lymphocytes in the circulation, CD4+CCR7- effector 
memory (EM) T lymphocytes harboured greater PVL in GALT (Yukl et al., 2013). 
This finding suggested that the cell types and their relative quantities in 
different compartments played important roles in tissue compartmentalisation, 
together with anatomical barriers.  
 
It is also important to consider the short duration (21 weeks) of this study 
when interpreting the data. It has been shown that the viral populations within 
tissues of patients acutely infected with HIV were homogeneous and only 
became distinct during the later, chronic phase of infection (Zhang et al., 1993, 
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Zhang et al., 2002). Therefore, it is possible that had the cats been infected for 
a longer period, a more diverse population might have been observed, as a result 
of the accumulation of mutations/deletions, which, in turn, could have affected 
the magnitude of compartmentalisation. 
 
Another limitation of this study was the inability to enumerate target cell 
numbers in tissues by flow cytometry, because tissue samples had been stored 
frozen. With this limitation, the target cell numbers in each compartment were 
measured indirectly, according to the levels of CD134 and CXCR4 mRNA. 
Discrepancies between mRNA and actual protein expression levels have been 
observed in previous studies and their correlations showed only 40% explanatory 
power (de Sousa Abreu et al., 2009, Maier et al., 2009, Vogel and Marcotte, 
2012). This is mainly related to the other regulatory mechanisms between 
transcripts and proteins (Maier et al., 2009). Similar discrepancies were also 
observed in this study, for example spleen contained low levels of CD134 mRNA 
(Appendix 3-9 and Figure 3-15) and yet showed the highest percentage of 
CD4+CD134+ T lymphocytes by flow cytometry (Figure 3-17). Likewise, the level 
of CD134 mRNA in thymus was relatively high (Appendix 3-8) but the percentage 
of CD4+CD134+ T lymphocytes was very low (Figure 3-17). Although the 
percentage of CD4+CD134+ T lymphocytes was analysed from a different cohort 
of cats, the consistency of the levels in each tissue type between cats confirmed 
the validity of the measurement  (Figure 3-17). However, this limitation 
confounded observations of a relationship between target cell numbers and FIV 
variants selection in tissue compartments. Further studies, combining the use of 
a cell sorter to separate different cell types from each tissue and variant 
specific qPCR to quantify the PVL of each FIV variant in the population, would 
provide a better understanding in the role of target cell specific selection and 
FIV tissue compartmentalisation. 
 
There are additional potential explanations for the lack of a clear 
demonstration of tissue compartmentalisation in FIV infection in this study. 
Firstly, the FIV viral load and PVL tend to be lower for FIV than for HIV or SIV 
infection, so that the PVL may be below the level of detection in some tissues. 
Secondly, FIV pathogenesis studies are normally conducted in small groups of 
cats (typically less than ten individuals) and so it is possible that a larger study, 
examining more infected cats and tissue samples, might be required in order to 
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detect a clear relationship between target cell numbers and tissue 
compartmentalisation. Finally, it has been suggested that a more sophisticated 
approach, combining both phylogenetic and statistical analyses, should be 
considered where a conventional tree-based analysis fails to demonstrate tissue 
compartmentalisation in FIV-infected cats (Zarate et al., 2007, Hayward and 
Rodrigo, 2010a).  
 
In conclusion, a correlation between sequence variation in the V5 region 
of FIV Env variants and tissue compartmentalisation was observed in this study. 
The impact of differences in cell tropism and/or target cell availability in FIV 
compartmentalisation was investigated but it is evident that this phenomenon 
results from complex host-pathogen interrelationships.  Further studies 
examining the mechanism underlying compartmentalisation will not only pave 
the way towards a better understanding of intra-host FIV dynamics and 
evolution, but will also shed light on the immunological mechanisms underlying 
this phenomenon. Ultimately, this information will assist the development of a 
successful and broadly protective FIV vaccine. 
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Chapter 4 Investigating the role of CD4+CD134+ T lymphocytes in 
the pathogenesis of natural FIV infection 
 
4.1 Introduction  
 
Feline immunodeficiency virus, FIV, infects its main target cell, the CD4+ 
T lymphocyte, via an interaction between the viral envelope glycoprotein (Env) 
and CD134, a secondary co-stimulatory molecule expressed exclusively on 
antigen-activated CD4+ T lymphocytes (Shimojima et al., 2004, Willett et al., 
2007, Willett and Hosie, 2013). It was shown previously that the Env-CD134 
interaction plays an important role in the selection of the dominant viral 
variants, cell tropism and the clinical outcome of FIV infection (Willett et al., 
2013, Willett and Hosie, 2013, Beczkowski et al., 2014b, Beczkowski et al., 
2015a). However, few data are available to describe the numbers and dynamics 
of CD4+CD134+ T lymphocytes in cats naturally infected with FIV. Therefore, the 
first aim of the studies described in this chapter was to measure CD4+CD134+ T 
lymphocytes and investigate potential relationships with FIV proviral load (PVL) 
and clinical status in a cohort of more than 200 FIV positive and negative cats 
exhibiting different clinical signs. 
 
It has been well documented that different FIV variants interact 
differently with CD134 (Willett et al., 2006b, Willett et al., 2009, Willett and 
Hosie, 2013). While FIV variants isolated from cats in the early phase of infection 
required both cysteine rich domain (CRD) 1 and CRD2 of CD134 for infection, 
variants isolated from cats in the later stage of infection were CRD2-
independent, either utilising CRD1 and the co-receptor CXCR4 or, rarely, 
utilising CXCR4 alone for infection (de Parseval et al., 2004b, de Parseval et al., 
2005, Willett et al., 2006b).  Moreover, the emergence of CRD2-independent 
variants in the late phase of infection has been reported in both experimentally 
and naturally infected cats (Kraase et al., 2010, Willett et al., 2013, Beczkowski 
et al., 2014b), suggesting that this switch in receptor usage has functional 
significance. 
 
It was shown in Chapter 3 that the tissue availability of CD4+CD134+ T 
lymphocytes could exert pressure on the composition of the FIV quasispecies, 
selecting for particular variants and leading to tissue compartmentalisation. We 
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speculated that CD4+CD134+ T lymphocyte availability at different stages of 
infection might also exert selective pressure, similar to that already observed in 
tissues, and could play a role in switching the tropism from a CRD2-dependent to 
a CRD2-independent interaction. Therefore, the second aim of this chapter was 
to investigate the relationship between the number of CD4+CD134+ T 
lymphocytes and the CRD2-dependence of FIV variants in this cohort of cats 
naturally infected with FIV.  
 
4.2 Study Population 
 
Two hundred and eight whole blood samples collected in 
ethylenediaminetetraacetic acid (EDTA) anticoagulant were included in this 
study. All samples had been submitted to Veterinary Diagnostic Services, School 
of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, 
University of Glasgow, between September 2014 and August 2015 and had tested 
negative for FeLV infection. Complete clinical histories and signalments were 
recorded from the accompanying sample submission forms (Appendix 4-13).  The 
samples examined comprised 114 that tested FIV negative and 94 that tested FIV 
positive. Details of the types and number of tests requested by the submitting 
veterinarian are shown in Appendix 4-1.  
 
4.3 Study Approach  
 
 Whole blood samples were analysed using flow cytometry to determine 
the percentages of CD4+ and CD8+ T lymphocytes, CD4:CD8 T lymphocyte ratios 
and percentages of CD4+CD134+ T lymphocytes (Section 2.3.5). FIV proviral loads 
(PVL) were determined in FIV seropositive cats using a quantitative PCR (Section 
2.1.5). Genomic DNA was extracted from the remainders of blood samples from 
cats diagnosed with FIV infection and was used as a template to amplify full-
length FIV env sequences by PCR (Section 2.1.7). Full-length FIV env genes were 
cloned into an expression vector to prepare HIV(FIV) pseudotypes (Section 
2.3.1). Each HIV(FIV) pseudotype was assessed for CRD2-dependence, as well as 
for susceptibility to autologous neutralisation (Section 2.3.2 and 2.3.3). These 
data, as well as PVL, lymphocyte subpopulation data, cats’ clinical histories and 
signalments, were then analysed for evidence of associations between the 
various parameters (Figure 4-1). PVL, lymphocyte subpopulation data, clinical 
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histories and signalments of individual cats are tabulated in Appendices 4-2 to 4-
7.  
 
4.3.1 Determination of CD134 usage by HIV(FIV) pseudotypes  
 
 CD134 usage of the HIV(FIV) pseudotypes was determined using the 
method described in section 2.3.2. The luciferase activity detected following 
infection of CLL-FFF and CLL-FFHH cells with each pseudotype was expressed as 
the FFF/FFHH ratio; these values were compared against the prototypic CRD2-
dependent and CRD2-independent pseudotypes (GL8 and B2542 respectively), in 
order to classify the CD134 usage of each pseudotype. A pseudotype was 
considered to be “CRD2 dependent” if the FFF/FFHH ratio was similar to that of 
GL8 (high ratio) or “CRD2 independent” if it was similar to that of B2542 (ratio 
below 30). Pseudotypes with ratios that fell in between these two extremes, 
such as FIV/A strain KKS, were designated “intermediate”; it was presumed that 
such Envs were evolving towards CRD-2 independent usage. 
 
 
 
Figure 4-1 Study approach 
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4.4 Results 
 
4.4.1 FIV seropositive cats were mainly adult, mixed breed and male  
 
The FIV infected cats in this study were predominantly male (83 male vs. 
10 female, 1 unknown) with a relative risk of 4.761 (95% confidence interval (CI) 
2.637 to 8.595) and an odds ratio of 11.55 (95% CI 5.412 to 24.64), Fisher’s exact 
test, p < 0.0001**** (Table 4-1, 4-2 and Figure 4-2A). The finding that male cats 
were 4.8 times more likely to be infected with FIV than female cats was 
consistent with the findings of a study conducted in North America in 2006 (Levy 
et al., 2006). Mixed breed was also considered to be a risk factor for FIV 
infection, with a relative risk of 9.560 (95% CI 1.406 to 65.01) and an odds ratio 
of 17.40 (95% CI 2.280 to 132.8), Fisher’s exact test, p = 0.0002***  (Table 4-1). 
FIV infected cats were also significantly older than uninfected cats (5 years 9 
months vs. 3 years, p = 0.0081, Table 4-2 and Figure 4-2B). These findings were 
consistent with several previous studies showing that adult, mixed breed and 
male cats have the highest risk of FIV infection (Levy et al., 2006, Hartmann, 
2012, Chhetri et al., 2015).  
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Table 4-1 Risk Factors for FIV infection in this study 
 
Risk Number of  
FIV positive 
Number of  
FIV negative 
Odds Ratio 
(95%CI) 
P valuea 
Genderb     
Male 83 46 -  
Female 10 64 11.55 
(5.412 – 
24.64) 
<0.0001**** 
Neuteringb     
Neutered male 35 25 -  
Intact male 16 7 0.4518 
(0.2195 – 
1.709) 
0.4519 
 Neutered female 3 33 -  
Intact female 1 2 0.1818 
(0.01251 – 
2.642) 
0.2838 
Breedb,c     
Mixed 87 95 -  
Purebred 1 19 17.40 
(2.280 – 
132.8) 
0.0002*** 
Number of cats in 
householdb 
    
Single cat 4 1 -  
Multiple cats 15 11 2.933  
(0.2866 – 
30.03) 
0.6236 
 
aFisher’s exact test, bOnly cats with the relevant information recorded on the submission form 
were included in this analysis, cCat breeds shown in Appendices 4-2 and 4-4. 
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4.4.2 Increased proportion of CD4+CD134+ T lymphocytes in FIV positive cats  
 
Similar to HIV infection, the percentage of CD4+ T lymphocytes was 
significantly lower in FIV infected cats compared to uninfected cats (18.12% vs. 
23.75%, p = 0.0013**) (Table 4-2 and Figure 4-2C) (Weiss, 1993). FIV infected 
cats also demonstrated significantly higher percentages of CD8+ T lymphocytes 
compared to uninfected cats (14.90% vs. 11.48%, p = 0.0154*) (Table 4-2 and 
Figure 4-2D). Decreased percentages of CD4+ T lymphocytes, together with the 
increased percentages of CD8+ T lymphocytes accounted for the observed 
decreased CD4:CD8 ratio in FIV positive cats compared to uninfected cats (1.330 
vs. 1.925, p < 0.0001****) (Table 4-2 and Figure 4-2E). FIV infected cats were also 
found to have significantly higher levels of immune activation, as demonstrated 
by an increased (greater than two fold) proportion of activated CD134+ T 
lymphocytes within the CD4+ T lymphocyte population (27.80% vs. 11.20%, p < 
0.0001****) (Table 4-2 and Figure 4-2F). 
 
Fourteen of the 94 FIV seropositive cats enrolled in this study displayed 
PVL below the limit of detection (< 10 copies/106 cells) (Table 4-3). The 
undetectable PVL in these cats could not be attributed to the sample 
preparation, since good quality genomic DNA was obtained and the housekeeping 
gene 18s rDNA was detected by qPCR (Section 2.1.5) (data not shown). Gender 
had no effect on PVL detectability, since both groups were predominantly male 
(Figure 4-3A). Most of the parameters (namely age, percentages of CD4+ and 
CD8+ T lymphocytes and CD4:CD8 ratios) of FIV infected cats with undetectable 
PVL appeared to be similar to those of their counterparts with detectable PVL 
(Table 4-3 and Figure 4-3B to 4-3E). Moreover, these parameters were not 
significantly different between FIV positive with undetectable PVL and FIV 
negative cats. This lack of statistical significance was most likely due to the 
small sample size of only 14 FIV positive with undetectable PVL cats. Thus, it 
was demonstrated that the percentage of CD4+CD134+ T lymphocytes was 
significantly higher in FIV infected cats compared to FIV negative cats, whether 
or not proviral DNA was detectable (11.20% vs. 26.98% and 33.70%, respectively, 
both p < 0.0001****) (Table 4-3 and Figure 4-3F). To our knowledge, the dramatic 
elevation of CD4+CD134+ T lymphocytes observed in the FIV infected cats in this 
study has not been reported previously.  
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Table 4-2 Demography, lymphocyte subpopulations and PVL data of study 
population according to FIV serology 
 
 FIV negative FIV positive 
Number 114 94 
Age 2Y 11M 
(1M – 17Y) 
5Y 9M** 
(7 M – 16Y) 
Gender (male:female) 46:64 
(4 unknown) 
83:10*** 
(1 unknown) 
CD4+ lymphocytes (%) 23.75 
(0.51-58.30) 
18.12** 
(0.03 – 42.94) 
CD8+ lymphocytes (%) 11.48 
(0.32-45.35) 
14.90* 
(0.34 – 53.16) 
CD4:CD8 ratio 1.92 
(0.27-17.15) 
1.33**** 
(0.04 – 7.16) 
CD4+CD134+ 
lymphocytes (%) 
11.20 
(1.15-71.31) 
27.80**** 
(5.10 – 96.96) 
FIV proviral load 
(copies/106 cells) 
n.a. 2,764 
(11 – 1,758,848) 
 
 
Age: Y = years, M= months and W = weeks, values are shown as group medians with range, CD4+ 
and CD8+ lymphocytes expressed as percentages of total lymphocytes, CD4+CD134+ lymphocytes 
shown as percentage of the CD4+ lymphocyte population, *, **, *** and **** indicate significantly 
different values at p values < 0.05, < 0.01, < 0.005 and < 0.0001 respectively, Fisher’s exact test 
and Mann-Whitney test. n.a. = not analysed 
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Table 4-3 Demography, lymphocyte subpopulations and PVL data in FIV infected 
cats with detectable or undetectable PVL 
 
 Detectable 
FIV proviral load 
Undetectable 
FIV proviral load 
Number 80 14 
Age 5Y 6M 
(7M – 14Y) 
5Y 9M 
(1Y – 16Y) 
Gender (male:female) 71:9 12:1 
(1 unknown) 
CD4+ lymphocytes (%) 18.57 
(0.03 – 42.94) 
17 
(7.03 – 38.16) 
CD8+ lymphocytes (%) 15.21 
(0.34 – 53.16) 
10.90 
(3.71 – 24.96) 
CD4:CD8 ratio 1.25 
(0.04 – 7.16) 
1.54 
(0.96 – 3.61) 
CD4+CD134+ 
lymphocytes (%) 
26.98 
(5.10 – 96.96) 
33.70 
(13.28 – 93.17) 
FIV proviral load 
(copies/106 cells) 
2,764 
(11 – 1,758,848) 
 
undetectable 
 
Age: Y = years, M= months and W = weeks, values are shown as group median with range, CD4+ 
and CD8+ lymphocytes expressed as percentages of total lymphocytes, CD4+CD134+ lymphocytes 
shown as percentage of the CD4+ lymphocyte population, Fisher’s exact test and Mann-Whitney 
test. 
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Figure 4-2 Effect of gender on FIV serostatus (A) and comparisons of Age (B), CD4+ percentage 
(C), CD8+ percentage (D), CD4:CD8 ratio (E) and CD4+CD134+ percentage (F) between FIV 
negative and positive cats. Horizontal lines depict group median values with interquartile ranges. 
Statistical significance was determined by Mann-Whitney test. The effect of gender and FIV 
serostatus (A) was determined by Fisher’s exact test and presented as relative risk and odds 
ratio. 95% CI: 95% confidence interval 
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Figure 4-3 Effect of gender on FIV proviral load (PVL) detection (A) and comparisons of Age (B), 
CD4+ percentage (C), CD8+ percentage (D), CD4:CD8 ratio (E) and CD4+CD134+ percentage (F) 
between FIV negative (left), FIV positive cats with detectable PVL (centre) and undetectable 
PVL (right). Horizontal lines depict group medians and interquartile range values. Statistical 
significance was determined using the Mann-Whitney test. The effect of gender and FIV PVL 
detection (A) was determined by Fisher’s exact test and presented as relative risk and odds 
ratio. 95% CI: 95% confidence interval 
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4.4.3 FIV serostatus and clinical status 
 
Sample submission forms (Appendix 4-13), submitted by the veterinary 
practitioner with each blood sample to be tested, contained tick boxes to 
indicate whether the patient was healthy or sick according to the veterinarian’s 
clinical examination. Although this information was not available for all of the 
cats, a sufficient sample size was collected to further categorise the cats into 4 
groups according to their clinical status; healthy FIV negative, sick FIV negative, 
healthy FIV positive and sick FIV negative cats (Table 4-4). This categorisation of 
cats was strictly restricted to the information provided, without any 
interpretation from the researcher.  
 
It was shown that FIV serostatus showed no correlation with clinical 
status, as determined by Fisher’s exact test (Figure 4-4A). This was mainly due 
to the similar proportions of sick cats in the FIV negative and positive groups 
(Table 4-4). The high proportion of sick animals in this study likely reflected that 
the blood samples had been submitted to Veterinary Diagnostic Services, either 
for virological screening or because the cats displayed clinical signs. Most of the 
healthy cats, both FIV seronegative and seropositive, were stray cats being 
screened for viral infections at the time of entering a sanctuary. Some healthy 
FIV negative cats were pedigree cats being screened prior to exportation. While 
the majority of FIV negative samples were submitted for feline retrovirus 
screening (FeLV antigen and FIV antibody) (45.61% (52/114)), the majority of the 
FIV positive samples were submitted for confirmation of FIV infection (FIV 
antibody) (80% (64/80)), following positive results in point-of-care tests 
(Appendix 4-1).  
 
4.4.4 Clinically ill FIV positive cats presumed to be in the terminal phase 
 
Clinically sick FIV infected cats tended to be older than the other cats 
within the study group (Table 4-4 and Figure 4-4B). This was not unexpected, 
since it takes some time after seroconversion for the clinical manifestations of 
immunodeficiency to become evident (Hartmann, 2012, Sykes, 2013). These cats 
also displayed the lowest percentages of CD4+ T lymphocytes (Table 4-4 and 
Figure 4-4C). This decline in CD4+ T lymphocytes was associated with low (almost 
inverted) CD4:CD8 ratios, a hallmark of immunodeficiency, being observed in the 
118 
sick FIV positive cats (1.10, p < 0.0001****) (Table 4-4 and Figure 4-4E) (Egberink 
and Horzinek, 1992, Yamamoto et al., 2007). The decreased percentages of CD4+ 
T lymphocytes and low CD4:CD8 ratios observed in these cats, together with 
their older ages, suggested that the clinically ill FIV positive cats were likely to 
be in the terminal, immunodeficiency phase of FIV infection.  
 
4.4.5 Clinically healthy FIV infected cats presumed to be in the earlier phase 
of infection, compared to their sick counterparts 
 
Since the healthy FIV infected cats were significantly younger than their 
sick counterparts (median age of 2 years and 6 months vs. 7 years and 9 months, 
p = 0.0018**) (Table 4-4 and Figure 4-4B), showed higher percentages of CD4+ T 
lymphocytes (24.60% vs. 15.87%, p = 0.0073**) and appeared clinically healthy, it 
is likely that these cats had been infected for a shorter period of time and/or 
might still be at an earlier stage of infection (Egberink and Horzinek, 1992, 
Yamamoto et al., 2007, Hartmann, 2012, Sykes, 2013). In addition, these cats 
also displayed three fold lower FIV PVLs, although this difference was not 
statistically significant (1,010 vs. 3,142 copies/106 cells, p = 0.0710) (Table 4-4 
and Figure 4-5D). However, with no dates of seroconversion being known, which 
is common for naturally infected cats, staging of FIV infection could only be 
estimated. 
  
4.4.6 Similar percentages of CD4+ T lymphocytes between sick FIV negative 
and healthy FIV positive cats 
 
The percentages of CD4+ T lymphocytes in healthy FIV negative, sick FIV 
negative and healthy FIV positive cats were similar (28.12%, 24.77% and 24.60%, 
respectively) (Table 4-4 and Figure 4-4C). Although a progressive CD4+ T 
lymphocyte depletion is a hallmark of FIV infection, in this study it was not 
possible to distinguish clinically healthy FIV infected cats from FIV negative cats 
on the basis of the percentage of CD4+ T lymphocytes alone. However, the 
higher percentage of CD4+ T lymphocytes in healthy FIV positive cats might be 
related to their better clinical status compared to their sick counterparts 
(24.60% vs. 15.87%, p = 0.0073**) (Table 4-4 and Figure 4-4C).  
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Although the healthy FIV negative cats demonstrated lower percentages 
of CD8+ T lymphocytes compared to the other three groups, this difference was 
not statistically significant (8.95% compared to 13.16%, 14.19% and 14.57%, 
respectively) (Table 4-4 and Figure 4-4D). The similar percentages observed 
between sick FIV negative and both healthy and sick FIV positive cats suggested 
that elevation of CD8+ T lymphocytes was a common finding associated with 
illness or infection.  However, when the percentages of CD4+ and CD8+ T 
lymphocytes were analysed together as CD4:CD8 ratios, healthy FIV negative 
cats were found to display significantly higher ratios compared to sick FIV 
negative cats (3.16 vs. 1.79, p = 0.0079**), healthy FIV positive cats (3.16 vs. 
1.46, p = 0.0395*) and sick FIV positive cats (3.16 vs. 1.10, p < 0.0001****).  It 
was notable that the CD4:CD8 ratios of sick FIV infected cats were lower than 
those of senior cats almost twice their age, reported previously (1.10 in this 
study vs. 1.35 in the study of (Campbell et al., 2004), age ranged from 10 to 14 
years old). This apparent acceleration of immunosenescence observed in sick FIV 
infected cats might be the direct result of persistent immune activation and 
immune dysregulation following FIV infection (Tompkins and Tompkins, 2008).  
 
From these findings, the CD4:CD8 ratio appears to be a more sensitive 
index for monitoring the progression of infection in FIV-infected cats, since it is 
influenced by both decreases in CD4+ T lymphocyte numbers and increases in 
CD8+ T lymphocyte numbers (Table 4-4 and Figure 4-4C to Figure 4-4E). 
However, the CD4:CD8 ratio could not be used to differentiate FIV infection 
from any other illness because values were similar between sick FIV negative 
cats and healthy FIV infected cats (1.79 vs. 1.46, p = 0.4772) (Table 4-4 and 
Figure 4-4E). 
 
4.4.7 Healthy FIV positive cats demonstrated the highest levels of 
CD4+CD134+ T lymphocytes  
 
In general, FIV infected cats, regardless of their clinical status, 
demonstrated significantly higher levels of CD4+CD134+ T lymphocytes compared 
to both healthy and sick FIV negative cats (Table 4-4 and Figure 4-4F). This 
elevation appeared to be specific to FIV infection rather than related to another 
infection or illness, since the percentages of CD4+CD134+ T lymphocytes in sick 
FIV negative cats and healthy FIV negative cats were similar (10.02% vs. 9.96%, p 
120 
= 0.4520) (Table 4-4 and Figure 4-4F). Although the difference was not 
statistically significant, most likely as a result of the small sample size (n = 17), 
the mean percentage of CD4+CD134+ T lymphocytes was higher in clinically 
healthy FIV positive cats compared to sick FIV positive cats (39.75% vs. 26.68%, p 
= 0.2210) (Table 4-4 and Figure 4-4F).  
 
4.4.8 Lower FIV proviral loads in healthy cats  
 
FIV PVL were three fold lower in clinically healthy cats compared to sick 
cats (1,010 vs. 3,142 copies/106 cells, p = 0.0710) (Table 4-4, Figure 4-5D) and 
the healthy cats harboured higher percentages of CD4+CD134+ T lymphocytes 
(39.75% vs. 26.68%, p = 0.2210) (Table 4-4 and Figure 4-4F). This finding might 
appear counterintuitive, if one assumes that FIV production is a dependent 
variable of infected cells in an active state, i.e. antigen activated CD4+CD134+ T 
lymphocytes (Weinberg et al., 2004, Hori, 2005).  However, the higher 
percentage of CD4+CD134+ T lymphocytes observed in the healthy cats might 
reflect a more intact immune system (as the healthy cats were younger), or it 
might reflect clonal expansion of primary T cells following antigen recognition, 
since it is likely that the healthy cats had been infected for a shorter period of 
time (Gramaglia et al., 2000, Zaunders et al., 2009). These high levels of CD134-
expressing, anti-viral T lymphocytes could in turn have facilitated control of FIV 
production since a CD134 signalling pathway has been shown to play an 
important role in the control of persistent viral infection (Boettler et al., 2012).  
 
On the other hand, a high FIV PVL in the presence of high percentages of 
CD4+CD134+ T lymphocytes in sick FIV positive cats (26.68% compared to 10.02% 
in healthy negative cats, p = 0.0006***) might reflect their collapsing immune 
systems.  As a result of chronic immune activation in response to persistent 
antigen presentation, similar to older cats, activated T lymphocytes in the later 
phase of FIV infection were shown to have reduced antigenic responses (Day, 
2010, Sykes, 2013). However, it was not possible to determine causality in this 
cross sectional study. In order to test these hypotheses, it would be necessary to 
examine qualitatively the FIV–specific T lymphocyte responses, using functional 
quality and/or viral suppression assays (Techakriengkrai et al., 2013, Tansiri et 
al., 2015). Nevertheless, such assays were beyond the scope of this study. 
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Table 4-4 Demography, lymphocyte subpopulations and PVL data of the study 
population according to FIV serology and clinical status 
 
 FIV negative (78, 36 unknown) FIV positive (46, 34 unknown)a 
 Healthy Sick Healthy Sick 
Number 21 57 17 29 
Age 2Y 11M 
(2M – 11Y 8M) 
3Y 
(1M – 16Y 10M) 
2Y 6M 
(2Y – 6Y 10M) 
7Y 9M***§§ 
(7M – 14Y) 
Gender 
(male:female) 
5:15 
(1 unknown) 
22:34 
(1 unknown) 
16:1 24:5 
CD4+ lymphocytes 
(%) 
28.12 
(11.76 – 46.01) 
24.77 
(2.88 – 58.30) 
24.60 
(4.21  – 37.50) 
15.87****§§§ 
(0.03 – 29.70) 
CD8+ lymphocytes 
(%) 
8.95 
(3.69 – 21.83) 
13.16 
(2.40 – 45.35) 
14.19 
(5.17 – 30.29) 
14.57 
(0.34 – 53.16) 
CD4:CD8 ratio 3.16 
(1.01 – 6.47) 
1.79** 
(0.27 – 17.15) 
1.46* 
(0.48 – 7.16) 
1.10****§§§ 
(0.04 – 4.40) 
CD4+CD134+ 
lymphocytes (%) 
10.02 
(1.4 – 71.31) 
9.96 
(1.15 – 66.27) 
39.75***§§§§ 
(7.75 – 96.96) 
26.68***§§§§ 
(5.10 – 67.83) 
FIV proviral load 
(copies/106 cells) 
n.a. n.a. 1,010 
(21 – 117,882) 
3,142 
(11 – 1,758,848) 
 
aFIV seropositive cats with undetectable PVL were not included in this analysis. Unknown = 
unknown health status, Age: Y = years, M= months and W = weeks, values are shown as group 
medians with range, CD4+ and CD8+ lymphocytes expressed as percentage of total lymphocytes, 
CD4+CD134+ lymphocytes shown as percentage of the CD4+ lymphocyte population, *, **, *** and 
**** indicate significantly different values compared to healthy FIV negative groups, with p values 
< 0.05, < 0.01, < 0.005 and < 0.0001 respectively, §§, §§§ and §§§§ indicate significantly different 
values compared to sick FIV negative groups, with p values < 0.01, < 0.005 and < 0.0001, 
respectively,  indicates significantly different values compared to healthy FIV positive groups 
with p value < 0.01, Statistical significance was determined using the Mann-Whitney test. 
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Figure 4-4 Effect of FIV serostatus and clinical status (A) and comparisons of Age (B), CD4+ 
percentage (C), CD8+ percentage (D), CD4:CD8 ratio (E) and CD4+CD134+ percentage (F) between 
groups according to their FIV serostatus and clinical status. Horizontal lines depict group median 
values with interquartile ranges. Statistical significance was determined by Mann-Whitney tests. 
The effect of FIV serostatus and clinical status (A) was determined by Fisher’s exact test and 
presented as relative risk and odds ratio. 95% CI: 95% confidence interval 
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4.4.9 Interrelationships between lymphocyte subpopulations in FIV negative 
cats 
 
In FIV negative cats, a positive correlation was observed between age and 
the percentage of CD8+ T lymphocytes (r = 0.2256, p = 0.0271*) (Table 4-5). As 
well as the weak negative correlation between age and percentage of CD4+ T 
lymphocytes (r= -0.1372, p = 0.1824), age showed a strong negative correlation 
with CD4:CD8 ratio (r= -0.3470, p = 0.0005***) (Table 4-5). This finding was in 
accordance with previous studies in which aged cats displayed decreased CD4+ T 
lymphocyte numbers, increased CD8+ T lymphocyte numbers and reduced 
CD4:CD8 ratios (Heaton et al., 2002, Day, 2010). Age also showed a significant 
positive correlation with the percentage of CD4+CD134+ T lymphocytes (r = 
0.3185, p = 0.0016**) (Table 4-5). Taken together, these findings led to the 
assumption that older cats had encountered a higher degree of immune 
activation compared to younger cats. This assumption is supported by the 
observation that CD134 is upregulated on activated CD4+ T lymphocytes after 
antigen recognition (Paterson et al., 1987, Weinberg et al., 2004, Sadler et al., 
2014). Moreover, it is most likely that antigen exposure increases with age. 
Here, the significant positive correlation between the percentage of CD4+CD134+ 
T lymphocytes and age observed in sick cats also supported this assumption (r = 
0.4994, p = 0.0001***)  (Table 4-7).  
 
 A significant positive correlation was observed between the percentages 
of CD4+ and CD8+ T lymphocytes in a group of FIV negative cats (r = 0.3615, p < 
0.0001****) (Table 4-5). When cats were categorised according to their clinical 
signs as either healthy or sick, the observed positive correlation between CD4+ 
and CD8+ T lymphocytes was only observed in sick cats (r = 0.3138, p = 0.0175*) 
and was not observed in healthy cats (r = 0.2922, p = 0.1987) (Table 4-6 and 
Table 4-7). This might reflect an expansion of total lymphocytes in the presence 
of infectious agents in sick cats, since lymphocytosis is a normal feature of 
infection. However, this positive correlation might be absent in particular 
conditions that lead to a biased elimination, or elevation, of specific lymphocyte 
subpopulations, such as the marked CD4+ T lymphocyte depletion that occurs 
following FIV infection and in some malignancies such as CD4+ large granular 
lymphocytosis (Lima et al., 2003, Roelke et al., 2006).   
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 As would be predicted, the CD4:CD8 ratio showed significant positive and 
negative correlations with the percentages of CD4+ and CD8+ T lymphocytes 
respectively in most categories (Tables 4-5 to 4-12). However, there was one 
exception; in FIV positive cats with undetectable FIV PVL, the positive 
correlation between the percentage of CD4+ T lymphocytes and CD4:CD8 ratios 
was not statistically significant (r = 0.4374, p = 0.1198) (Table 4-10), perhaps 
reflecting the limited number of cats in this group (n = 14). These significant 
correlations could simply be explained from the fact that CD4:CD8 ratio is their 
dependent variable. 
 
4.4.10 Interrelationships between lymphocyte subpopulations and PVL in FIV 
positive cats 
 
 In contrast to FIV negative cats, no correlations were observed between 
age and the variables analysed in any of the categories of FIV positive cats 
(Table 4-8 to Table 4-12). However, although not statistically significant, both 
CD4+ and CD8+ T lymphocyte numbers were negatively correlated with age 
(Table 4-8). This might reflect a decline in total lymphocytes with disease 
progression. Also, the positive correlation observed between CD4+ and CD8+ T 
lymphocyte numbers in FIV negative cats was absent in the FIV positive cats 
(Table 4-8 to Table 4-11), with the exception of the sick FIV positive cats (Table 
4-12). This significant positive correlation (r = 0.4015, p = 0.0309*) confirmed an 
overall decrease in all lymphocyte compartments and was a typical finding in FIV 
infected cats in the late stages of infection  (Table 4-12) (Sykes, 2013).  Similar 
to FIV negative cats, significant correlations were observed between CD4:CD8 
ratio and the percentages of CD4+ and CD8+ T lymphocytes according to their 
direct influences (Table 4-8 to Table 4-12).  
 
 A significant negative correlation was observed between the percentage 
of CD4+ T lymphocytes and FIV PVL (r = -0.2281, p = 0.419*) (Table 4-8 to Table  
4-9 and Figure 4-5A), consistent with CD4+ T lymphocytes being the main cellular 
targets for FIV infection. Similarly, a negative correlation was observed between 
the CD4:CD8 ratio and FIV PVL (Table 4-8 to Table 4-9 and Figure 4-5B), although 
this relationship was not statistically significant (r = -0.2127, p = 0.0582). 
Intriguingly, when FIV infected cats were categorised according to their clinical 
status as sick or healthy, a higher degree of negative correlation was observed 
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between age and PVL in healthy cats (r = -0.7111, p = 0.0524) (Table 4-11). 
However, this was not statistically significant, perhaps reflecting the small 
sample size (information about age was only available for 7 of 17 healthy FIV 
infected cats). This correlation might reflect the dynamics of FIV replication 
over time, in which the high PVL observed very early after infection, 
continuously decreases, approaching the viral set point as disease progress and 
remaining at that point until the terminal stage of infection (Yamamoto et al., 
2007, Sykes, 2013).  
 
4.4.11 A positive correlation between the percentage of CD4+CD134+ T 
lymphocytes and FIV PVL in healthy FIV infected cats 
 
A positive correlation was observed between the percentage of 
CD4+CD134+ T lymphocytes and FIV PVL in clinically healthy cats, but not in sick 
cats (Table 4-11 to Table 4-12 and Figure 4-5E to Figure 4-5F), despite the FIV 
PVL being lower in clinically healthy cats compared to sick cats (1,010 vs. 3,142 
copies/106 cells) (Table 4-4 and Figure 4-5D). In contrast, the percentage of 
CD4+CD134+ T lymphocytes appeared to be negatively correlated with FIV PVL in 
sick cats (r = -0.1399, p = 0.4692) (Table 4-12 and Figure4-.5F), although this 
was not statistically significant. CD4+CD134+ T lymphocytes might decline in 
number as the FIV PVL increases in sick cats during the terminal phase of FIV 
infection; it is possible that the collapsing immune system is no longer able to 
reconstitute the lost T lymphocytes and so the FIV PVL increases unabated 
(Egberink and Horzinek, 1992, Yamamoto et al., 2007, Sykes, 2013). 
 
126 
 
 
Figure 4-5 Correlations between percentage of CD4+ T lymphocytes and FIV PVL (A), CD4:CD8 
ratio and FIV PVL in all FIV positive cats (B), relationship between CD4:CD8 ratio and percentage 
of CD4+CD134+ T lymphocytes in FIV positive cats with detectable PVL (C), comparison of PVLs 
between healthy and sick FIV positive cats (D), relationship between percentages of CD4+CD134+ 
T lymphocytes and FIV PVL in healthy FIV positive cats (E) and sick FIV negative cats (F). 
Spearman correlation and Mann-Whitney tests, horizontal lines depict group medians with 
interquartile ranges (D).  
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Table 4-5 Interrelationships between age and lymphocyte subpopulations in FIV 
negative cats 
 
age against (n = 96) 
 r 95%CI p value 
%CD4 -0.1372 -0.3340 to 0.07101 0.1824 
%CD8 0.2256 -0.02025 to 0.4126 0.0271* 
%CD4CD134 0.3185 0.1201 to 0.4924 0.0016** 
CD4:CD8 -0.3470 -0.5163 to -0.1516 0.0005*** 
 
%CD4 against (n = 114) 
 r 95%CI p value 
%CD8 0.3615 0.1849 to 0.5154 <0.0001**** 
%CD4CD134 -0.2387 -0.4094 to -0.05180 0.0105* 
CD4:CD8 0.3787 0.2041 to 0.5300 <0.0001**** 
 
%CD8 against (n = 114) 
 r 95%CI p value 
%CD4CD134 0.07616 -0.1147 to 0.2616 0.4206 
CD4:CD8 -0.6422 -0.7413 to 0.5156 <0.0001**** 
 
%CD4CD134 against (n = 114) 
 r 95%CI p value 
CD4:CD8 -0.2512 -0.4204 to -0.06506 0.0070** 
 
Relationships between each pair of study parameters were determined using the Spearman 
correlation. *, **, *** and **** indicate significantly different values at p values < 0.05, < 0.01, < 
0.005 and < 0.0001 respectively. 
  
128 
Table 4-6 Interrelationships between age and lymphocyte subpopulations in 
healthy FIV negative cats 
 
age against (n = 17) 
 r 95%CI p value 
%CD4 -0.4454 -0.7692 to 0.06029 0.0736 
%CD8 0.2528 -0.2738 to 0.6627 0.3252 
%CD4CD134 0.1006 -0.4123 to 0.5651 0.6992 
CD4:CD8 -0.4810 -0.7870 to 0.01505 0.0516 
 
%CD4 against (n = 21) 
 r 95%CI p value 
%CD8 0.2922 -0.1729 to 0.6508 0.1987 
%CD4CD134 -0.5013 -0.7726 to -0.07527 0.0206* 
CD4:CD8 0.3610 -0.09724 to 0.6930 0.1078 
 
%CD8 against (n = 21) 
 r 95%CI p value 
%CD4CD134 -0.1156 -0.5311 to 0.3448 0.6178 
CD4:CD8 -0.7429 -0.8922 to -0.4472 0.0001*** 
 
%CD4CD134 against (n = 21) 
 r 95%CI p value 
CD4:CD8 -0.2221 -0.6053 to 0.2447 0.3333 
 
Relationships between each pair of study parameters were determined using the Spearman 
correlation. *, **, *** and **** indicate significantly different values at p values < 0.05, < 0.01, < 
0.005 and < 0.0001 respectively. 
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Table 4-7 Interrelationships between age and lymphocyte subpopulations in sick 
FIV negative cats 
 
age against (n = 53) 
 r 95%CI p value 
%CD4 -0.2295 -0.4769 to 0.05171 0.0984 
%CD8 0.05354 -0.2277 to 0.3266 0.7034 
%CD4CD134 0.4994 0.2573 to 0.6826 0.0001*** 
CD4:CD8 -0.3217 -0.5504 to -0.04818 0.0188* 
 
%CD4 against (n = 57) 
 r 95%CI p value 
%CD8 0.3138 0.05006 to 0.5366 0.0175* 
%CD4CD134 -0.1808 -0.4280 to 0.09156 0.1784 
CD4:CD8 0.4610 0.2203 to 0.6488 0.0003*** 
 
%CD8 against (n = 57) 
 r 95%CI p value 
%CD4CD134 0.03912 -0.2312 to 0.3038 0.7727 
CD4:CD8 -0.5817 -0.7351 to -0.3718 <0.0001**** 
 
%CD4CD134 against (n = 57) 
 r 95%CI p value 
CD4:CD8 -0.2414 -0.4784 to 0.02830 0.0704 
 
Relationships between each pair of study parameters were determined using the Spearman 
correlation. *, **, *** and **** indicate significantly different values at p values < 0.05, < 0.01, < 
0.005 and < 0.0001 respectively. 
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Table 4-8 Interrelationships between age, lymphocyte subpopulations and PVL in 
FIV positive cats 
 
age against (n = 64) 
 r 95%CI p value 
%CD4 -0.1448 -0.3836 to 0.1120 0.2535 
%CD8 -0.1158 -0.3581 to 0.1411 0.3623 
%CD4CD134 0.04375 -0.2114 to 0.2933 0.7314 
CD4:CD8 -0.009982 -0.2621 to 0.2434 0.9376 
FIV PVL -0.1288 -0.3902 to 0.1519 0.3534 
 
%CD4 against (n = 94) 
 r 95%CI p value 
%CD8 0.1860 -0.02338 to 0.3797 0.0727 
%CD4CD134 0.05221 -0.1579 to 0.2578 0.6173 
CD4:CD8 0.5251 0.3555 to 0.6611 <0.0001**** 
FIV PVL -0.2281 -0.4318 to -0.002193 0.0419* 
 
%CD8 against (n = 94) 
 r 95%CI p value 
%CD4CD134 0.1790 -0.03058 to 0.3735 0.0843 
CD4:CD8 -0.6229 -0.7358 to -0.4763 <0.0001**** 
FIV PVL -0.007572 -0.2332 to 0.2188 0.9469 
 
%CD4CD134 against (n = 94) 
 r 95%CI p value 
CD4:CD8 -0.1613 -0.3577 to 0.04874 0.1203 
FIV PVL 0.1517 -0.07689 to 0.3652 0.1791 
 
CD4:CD8 against (n = 94) 
 r 95%CI p value 
FIV PVL -0.2127 -0.4185 to 0.01400 0.0582 
 
Relationships between each pair of study parameters were determined using the Spearman 
correlation. *, **, *** and **** indicate significantly different values at p values < 0.05, < 0.01, < 
0.005 and < 0.0001 respectively. 
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Table 4-9 Interrelationships between age, lymphocyte subpopulations and PVL in 
FIV positive cats with detectable PVL  
 
age against (n = 54) 
 r 95%CI p value 
%CD4 -0.1805 -0.4342 to 0.09971 0.1915 
%CD8 -0.08810 -0.3548 to 0.1918 0.5264 
%CD4CD134 0.01797 -0.2586 to 0.2918 0.8974 
CD4:CD8 -0.03987 -0.3117 to 0.2380 0.7447 
FIV PVL -0.1288 -0.3902 to 0.1519 0.3534 
 
%CD4 against (n = 80) 
 r 95%CI p value 
%CD8 0.1330 -0.09590 to 0.3485 0.2397 
%CD4CD134 -0.02616 -0.2511 to 0.2005 0.8144 
CD4:CD8 0.5607 0.3833 to 0.6982 <0.0001**** 
FIV PVL -0.2281 -0.4318 to -0.002193 0.0419* 
 
%CD8 against (n = 80) 
 r 95%CI p value 
%CD4CD134 0.1783 -0.04974 to 0.3886 0.1136 
CD4:CD8 -0.6165 -0.7395 to -0.4538 <0.0001**** 
FIV PVL -0.007572 -0.2332 to 0.2188 0.9469 
 
%CD4CD134 against (n = 80) 
 r 95%CI p value 
CD4:CD8 -0.2068 -0.4135 to 0.02014 0.0657 
FIV PVL 0.1517 -0.07689 to 0.3652 0.1791 
 
CD4:CD8 against (n = 80) 
 r 95%CI p value 
FIV PVL -0.2127 -0.4185 to 0.01400 0.0582 
 
Relationships between each pair of study parameters were determined using the Spearman 
correlation. *, **, *** and **** indicate significantly different values at p values < 0.05, < 0.01, < 
0.005 and < 0.0001 respectively. 
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Table 4-10 Interrelationships between age and lymphocyte subpopulations in FIV 
positive cats with undetectable PVL  
 
age against (n = 10) 
 r 95%CI p value 
%CD4 -0.05455 - 0.8916 
%CD8 -0.2485 - 0.4918 
%CD4CD134 -0.01818 - 0.9730 
CD4:CD8 0.1277 - 0.7247 
 
%CD4 against (n = 14) 
 r 95%CI p value 
%CD8 0.4945 -0.06632 to 0.8179 0.0750 
%CD4CD134 0.4374 -0.1386 to 0.7922 0.1198 
CD4:CD8 0.2863 -0.3039 to 0.7178 0.3183 
 
%CD8 against (n = 14) 
 r 95%CI p value 
%CD4CD134 0.3582 -0.2294 to 0.7545 0.2090 
CD4:CD8 -0.6608 -0.8859 to -0.1837 0.0117* 
 
%CD4CD134 against (n = 14) 
 r 95%CI p value 
CD4:CD8 -0.08811 -0.6023 to 0.4778 0.7582 
 
Relationships between each pair of study parameters were determined using the Spearman 
correlation. *, **, *** and **** indicate significantly different values at p values < 0.05, < 0.01, < 
0.005 and < 0.0001 respectively. 
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Table 4-11 Interrelationships between age, lymphocyte subpopulations and PVL 
in healthy FIV positive cats with detectable PVL 
 
age against (n = 7) 
 r 95%CIa p value 
%CD4 -0.03742 - 0.8524 
%CD8 -0.4865 - 0.2190 
%CD4CD134 -0.01871 - 0.8810 
CD4:CD8 0.3742 - 0.3857 
FIV PVL -0.7111 - 0.0524 
 
%CD4 against (n = 17) 
 r 95%CI p value 
%CD8 -0.1176 -0.5767 to 0.3979 0.6526 
%CD4CD134 -0.1201 -0.5784 to 0.3958 0.6458 
CD4:CD8 0.7321 0.3747 to 0.9000 0.0012** 
FIV PVL -0.1054 -0.5684 to 0.4083 0.6873 
 
%CD8 against (n = 17) 
 r 95%CI p value 
%CD4CD134 -0.1544 -0.6012 to 0.3659 0.5530 
CD4:CD8 -0.6315 -0.8573 to 0.2018 0.0076** 
FIV PVL -0.2279 -0.6477 to 0.2980 0.3474 
 
%CD4CD134 against (n = 17) 
 r 95%CI p value 
CD4:CD8 -0.1398 -0.5915 to 0.3787 0.5869 
FIV PVL 0.4877 -0.006211 to 0.7904 0.0490* 
 
CD4:CD8 against (n = 17) 
 r 95%CI p value 
FIV PVL -0.02943  -0.5144 to 0.4698 0.9079 
Relationships between each pair of study parameters were determined using the Spearman 
correlation. *, **, *** and **** indicate significantly different values at p values < 0.05, < 0.01, < 
0.005 and < 0.0001 respectively. 
asample size was too small for the calculation of 95% confidence intervals. 
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Table 4-12 Interrelationships between age, lymphocyte subpopulations and PVL 
in sick FIV positive cats with detectable PVL 
 
age against (n = 26) 
 r 95%CI p value 
%CD4 0.2072 -0.2074 to 0.5588 0.3097 
%CD8 0.006519 -0.3921 to 0.4030 0.9748 
%CD4CD134 0.04255 -0.3611 to 0.4328 0.8365 
CD4:CD8 0.1194 -0.2920 to 0.4936 0.5612 
FIV PVL -0.1764 -0.5363 to 0.2379 0.3888 
 
%CD4 against (n = 29) 
 r 95%CI p value 
%CD8 0.4015 0.02966 to 0.6757 0.0309* 
%CD4CD134 0.05911 -0.3244 to 0.4259 0.7607 
CD4:CD8 0.4210 0.05316 to 0.6883 0.0229* 
FIV PVL -0.2463 -0.5698 to 0.1433 0.1977 
 
%CD8 against (n = 29) 
 r 95%CI p value 
%CD4CD134 0.3232 -0.06051 to 0.6236 0.0873 
CD4:CD8 -0.4506 -0.7070 to -0.08947 0.0142* 
FIV PVL -0.09310 -0.4535 to 0.2935 0.6310 
 
%CD4CD134 against (n = 29) 
 r 95%CI p value 
CD4:CD8 -0.2148 -0.5469 to 0.1757 0.2631 
FIV PVL -0.1399 -0.4904 to 0.2495 0.4692 
 
CD4:CD8 against (n = 29) 
 r 95%CI p value 
FIV PVL -0.1261 -0.4797 to 0.2626 0.5144 
 
Relationships between each pair of study parameters were determined using the Spearman 
correlation. *, **, *** and **** indicate significantly different values at p values < 0.05, < 0.01, < 
0.005 and < 0.0001 respectively. 
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4.4.12 Concurrent infections showed no effect on lymphocyte subpopulations 
in FIV negative cats with clinical signs 
 
As shown above, with the exception of the percentages of CD4+CD134+ T 
lymphocytes, similar lymphocyte subpopulations were observed between sick FIV 
negative cats and healthy FIV positive cats (Table 4-4 and Figure 4-4). Of note, 
decreased CD4:CD8 ratios, the hallmark of FIV infection, were also observed in 
sick FIV negative cats. In order to examine the underlying causes of these 
findings, lymphocyte subpopulations of sick FIV negative cats with and without 
diagnosed concurrent infections were compared.  
 
The most frequent major clinical sign in sick FIV negative cats in this 
study was gingivitis (23/57), in which nine of the cats tested positive for feline 
calicivirus (FCV) (Table 4-13 and Table 4-14). In addition, nine cats tested 
positive for feline coronavirus (FCoV), six tested Toxoplasma gondii positive and 
one was infected with Mycoplasma (Table 4-14). Unexpectedly, no differences in 
any of the parameters measured in this study were observed amongst sick FIV 
negative cats with and without these viral, protozoan and bacterial infections 
(Table 4-15 and Figure 4-6). Nevertheless, it was not possible to exclude the 
possibility that other, unidentified, pathogens might have led to the decreased 
CD4:CD8 ratio observed in these sick FIV negative cats.  
  
4.4.13 Higher PVL and CD4+CD134+ T lymphocytes in FIV positive cats with 
co-infections  
 
Gingivostomatitis and lethargy/vomiting were the two most frequent signs 
reported in the sick FIV positive cats in this study, consistent with previous 
studies (Hartmann, 2012, Sykes, 2013). However, in contrast to previous studies, 
no association was observed between FIV infection and gingivostomatitis in sick 
cats (8/35 vs. 23/57, Fisher’s exact test, p = 0.1126, Table 4-13 and Appendix 4-
9). Moreover, when these cases were analysed as proportions of the total study 
population, FIV seropositive cats appeared to have a lower risk of 
gingivostomatitis compared to FIV seronegative cats  (8/94 vs. 23/114, Fisher’s 
exact test, *p = 0.0198, Appendix 4-9).  
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In HIV infection, co-infection with other viruses such as hepatitis C virus 
(HCV) was associated with inverted CD4:CD8 ratios, even in clinically healthy 
patients with CD4+ lymphocyte numbers > 500 cells/mm3 and complete 
antiretroviral drug suppression of viral load (Brites-Alves et al., 2015).  However, 
in this study, co-infections were detected only in sick FIV positive cats, thereby 
preventing an analysis of the effect of co-infections in healthy cats (Table 4-14 
and Figure 4-6). Sick FIV positive cats with co-infections displayed slightly higher 
percentages of CD4+ T lymphocytes (17.20% vs. 15.98%) and lower percentages of 
CD8+ T lymphocytes (9.98% vs. 13.31%) than those without co-infections (Table 
4-15 and Figure 4-6). However, their median CD4:CD8 ratios were lower than 
those of cats without co-infections (1.16 vs. 1.32, Table 4-15 and Figure 4-6). 
This result appeared counterintuitive, as the CD4:CD8 ratio is dependent on the 
CD4+ and CD8+ T lymphocyte percentages and therefore higher CD4+ and lower 
CD8+ T lymphocyte percentages would give rise to higher CD4:CD8 ratios. The 
wide range of ratios observed in these cats, together with their small number (n 
= 7) might attribute to this apparently contradicting finding (Table 4-15).  
 
As shown in Table 4-15 and Figure 4-6E, the percentage of CD4+CD134+ T 
lymphocytes in sick FIV positive cats with co-infections was almost two-fold 
greater compared to cats without co-infections (51.25% vs. 26.58%). This 
increase was not associated with higher CD4+ T lymphocyte percentages as 
CD134+ T lymphocytes were sequentially measured as a proportion of the total 
CD4+ T lymphocyte population (Section 2.3.7). The FIV PVLs of the co-infected 
cats were also higher (8,695 vs. 3,143 copies/106 cells, Table 4-15 and Figure 4-
6F); however, no correlation was observed between CD4+CD134+ T lymphocyte 
numbers and PVL in either group (Appendix 4-10A). Interestingly, although not 
statistically significant, a strong negative correlation was observed between 
CD4+ T lymphocyte numbers and FIV PVL in sick FIV positive cats with co-
infections (r = -0.8286, Spearman test, p = 0.0583, Appendix 4-10B). Hence co-
infected cats might have shown more marked immune activation, with greater 
numbers of lymphocytes expressing CD134+ in FIV infected cats. Consequently 
the observed two-fold higher PVL might reflect the increased number of target 
cells and/or activation of latently infected CD4+ T lymphocytes. 
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Table 4-13 Major findings recorded in sick FIV negative and positive cats  
 
Findings FIV negative (n = 57)* FIV positive (n= 35)** 
decreased PCV 3 1 
gingivostomatitis 23 8 
lethargy and vomiting 7 8 
malignancies 0 1 
pyrexia 8 5 
respiratory signs 7 1 
positive rapid test kit result 0 6 
uveitis 3 3 
wound 1 2 
 
*No information provided for five cats from which samples were submitted for feline gingivitis 
profile (FHV & FCV isolation, FeLV Ag, FIV Ab). ** Both sick FIV positive cats with detectable and 
undetectable FIV PVL were included in this analysis. 
 
Table 4-14 Diagnosed co-infections of FIV negative and positive catsa 
 
 
 FIV negative (n = 114) FIV positive (n = 94)* 
healthy 
(n = 21) 
sick 
(n = 57) 
unknown 
(n = 36) 
healthy 
(n = 19) 
sick 
(n = 35) 
unknown 
(n = 40) 
Chlamydia 
felis 
  1    
feline 
calicivirus 
1 9   4  
feline 
coronavirus 
2 9 1    
feline 
herpesvirus 
  1    
feline 
parvovirus 
    1  
Mycoplasma  1     
Toxoplasma 
gondii 
 6 2  2  
 
aDiagnostic technique for each infection as follows; C. felis PCR, FCV by virus isolation, FCoV by 
antibody detection, FHV by PCR and/or virus isolation, FPV by PCR Mycoplasma by cell culture 
and T. gondii by antibody detection. FIV positive cats with both detectable and undetectable FIV 
PVL were included in this analysis. 
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Table 4-15 Demography, lymphocyte subpopulations and PVL of sick FIV 
negative and positive cats with and without co-infectionsa 
 
 sick FIV negative cats sick FIV positive catsb 
co-infections without  with  without  with  
Number 33 24 28 7 
Age 2Y 5M 
(1M – 12Y 8M) 
5Y 
(4M – 16Y 10M) 
7Y 9M*** 
(2Y – 14Y) 
7Y 6M 
(7M – 16Y) 
Gender  
(male:female) 
10:23 12:11 
(1 unknown) 
24:4 6:1 
CD4+ percentage 24.77 
(4.58 – 44.87) 
24.19 
(2.88 – 58.30) 
15.98**
§
 
(0.03 – 38.16) 
17.20 
(0.27 – 29.7) 
CD8+ percentage 12.33 
(2.4 – 24.86) 
13.67 
(2.52 – 45.35) 
13.31 
(0.80 – 53.16)  
9.98 
(0.34 – 22.43) 
CD4:CD8 ratio 1.79 
(0.58 – 5.88) 
1.82 
(0.27 – 17.15) 
1.32**
§
 
(0.04 – 3.15) 
1.16 
(0.58 – 4.40) 
CD4+CD134+ 
percentage 
9.41 
(1.15 – 66.27) 
10.54 
(2.74 – 24.96) 
26.58****
§§§§
 
(5.1 – 90.2) 
51.25** 
(6.30 – 67.83) 
FIV PVL 
(copies/106 
cells) 
n.a. n.a. 3,143 
(20 – 1,467,822) 
8,695 
(11 – 1,758,848) 
 
a Values are shown as group medians with range in brackets. bBoth sick FIV positive cats with 
detectable and undetectable FIV PVL were included in this analysis. Age: Y = years, M= months 
and W = weeks, CD4+ and CD8+ lymphocytes are shown as the percentage of total lymphocytes, 
CD4+CD134+ expressed as the percentage of CD4+ lymphocyte population, **, *** and **** indicate 
significantly different values when compared to sick FIV negative cats without co-infections, at p 
values < 0.01, < 0.005 and < 0.0001 respectively, § and §§§§ indicate significantly different values 
compared to sick FIV negative cats with co-infections, p values < 0.05 and < 0.0001, respectively, 
Statistical significance was determined using the Mann-Whitney test. 
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Figure 4-6 Comparisons of Age (A), percentage of CD4+ lymphocytes (B), percentage of CD8+ 
lymphocytes (C), CD4:CD8 ratio (D) and percentage of CD4+CD134+ lymphocytes (E) between 
groups according to their FIV serostatus and co-infections. w/o: without co-infections, w: with 
co-infections, Horizontal lines depict group median values with interquartile ranges. Comparison 
of FIV PVL (F) between sick cats with and without co-infections, healthy cats and cats of 
unknown clinical status. Statistical significance was determined using the Mann-Whitney test.  
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4.4.14 CD4+CD134+ T lymphocyte percentages decline following infection 
 
The decrease in the percentages of CD4+CD134+ T lymphocytes (39.75% in 
healthy FIV infected cats vs. 26.68% in sick FIV infected cats) was consistent with 
findings observed in a cohort of specific pathogen free (SPF) cats, 
experimentally infected with an FIV clade A isolate (ongoing project, 
unpublished). The decline presumably reflects disease progression from the early 
asymptomatic phase towards the later immunodeficiency phase.  As shown in 
Figure 4-7, the percentage of CD4+CD134+ T lymphocytes declined over a period 
of 44 weeks in these four cats experimentally infected with FIV (A831 – A834). It 
appears that the CD4+CD134+ T lymphocytes were partially replenished at four 
monthly intervals, suggesting an attempt at immune reconstitution in these cats. 
However, the percentages of CD4+CD134+ T lymphocytes were never restored to 
their original levels. Although the trend of declining CD4+CD134+ T lymphocyte 
numbers with time post infection was observed in all of these experimentally 
infected cats, without data from an age-matched uninfected control group, an 
age-related decline could not be discounted. Nevertheless, an age-related 
decline seems unlikely, as a significant positive correlation was observed 
between age and CD4+CD134+ T lymphocytes percentage in healthy FIV negative 
cats (Table 4-5). 
 
 
 
Figure 4-7 The declining trend in the percentage of CD4+CD134+ T lymphocytes was observed in a 
cohort of four FIV experimentally infected cats (A831 – 834) with time post infection.  
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4.4.15 Decreasing CD4+CD134+ T lymphocyte numbers might exert selective 
pressure on FIV population  
 
Previous studies have demonstrated that different FIV strains interact 
with CD134 differently (Willett et al., 2006b). While some pathogenic primary 
strains such as GL8 and NCSU1 required a more complex interaction or showed a 
stronger binding affinity for CD134, isolates from cats in later stages of 
infection, such as B2452, were less dependent on CD134; the laboratory-adapted 
strain FIV PET was the most extreme, requiring only CXCR4 for infection (de 
Parseval et al., 2004b, de Parseval et al., 2005, Willett et al., 2006b).  
Moreover, it had been shown recently that this change in the way FIV interacts 
with its primary receptor CD134 altered as disease progressed. FIV variants 
recovered from the early phase of infection required both CRD1 and CRD2 of the 
CD134 molecule, whereas viruses in the later phase were CRD2-independent, 
requiring only CRD1 for infection (Willett et al., 2013, Beczkowski et al., 2014b). 
This change towards a less stringent requirement for CD134 might explain the 
broader spectrum of target cells observed later in infection (English et al., 1993, 
Dean et al., 1996). However, the driving force behind the tropism switch has yet 
to be unravelled.  
 
Since the change from a complex to a more simple CD134 interaction of 
FIV variants occurred in parallel with the decline in CD4+CD134+ T lymphocytes 
over time, we speculated that target cell availability, i.e. CD4+CD134+ T 
lymphocyte numbers, might play a major role in the tropism switch, selecting 
for the fittest variant most capable of rapid replication. In order to test this 
hypothesis, a FIV-CD134 usage assay (Section 2.3.2) was conducted on HIV(FIV) 
pseudotypes bearing envelope glycoproteins (Env) obtained from both healthy 
(presumed to be in the early phase) and sick (presumed to be in the late phase) 
cats. 
 
4.4.16 High proportion of incomplete env genes detected in the cohort 
 
 Full-length env genes were successfully amplified from 8 of 17 healthy 
and 12 of 29 sick FIV infected cats, respectively (Table 4-16). The number of 
clones obtained was relatively similar between two groups, despite sick cats 
harbouring higher FIV PVL than healthy cats (median of four vs. three clones per 
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cat, p = 0.6291). After screening no fewer than 2,000 colonies, at least 50 
colonies for each sample, 141 env genes were obtained and submitted for 
sequencing. It was notable that the env genes from over half of the samples 
(11/20 cats) were incomplete, containing stop codons at the SU-TM junction 
(position 610, UK8) These incomplete sequences were included in a phylogenetic 
analysis but were excluded from CD134 usage and viral neutralisation assays, as 
these could not be used to prepare pseudotypes (Table 4-16).  
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Table 4-16 Number of env successfully cloned, used to prepare pseudotypes and 
tested for CD134 usage from 20 healthy and sick FIV positive cats  
 
 I.D. no of env 
cloned* 
average 
within 
population 
diversity** 
no of pseudotypes 
tested*** 
 
 
 
Healthy 
346271 7 0.00612 2 
346302 15 0.00014 3 
346363 6 0.02459 0 
346540 1 n/c 0 
347178 9  0.00067 5 
347251 11 0.00131 1 
364791 5 0.00023 0 
368352 3 0.00000 1 
 
 
 
 
 
 
Sick 
346096 9 0.00433 0 
346223 5 0.01552 0 
346224 4 0.00391 0 
346301 5 0.00034 0 
346541 3 0.01152 0 
346660 2 0.00000 0 
346938 27 0.00765 3 
347076 18 0.00179 4 
347175 2 0.01035 0 
347202 7 0.02942 2 
365045 1 n/c 1 
367133 1 n/c 1 
 
* The number indicated number of full SU or full-length env (SU+TM) sequences included in the 
phylogenetic analysis. 
** Mean within population diversity was calculated using nucleotide sequences spanning the 
complete SU region (UK8 position 1- 1830) using Maximum Composite Likelihood model on Mega 
5.1 (Tamura et al., 2011). Values shown represent the mean number of base substitutions per 
site within the population. n/c = incalculable 
*** Only unique env gene clones were used to prepare pseudotypes and tested in each cat.  Zero 
values indicate that the cloned env sequences were incomplete and thus could not be used to 
prepare pseudotypes.  
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4.4.17 Phylogenetic characterisation of FIV env genes 
  
The average diversity of the entire population was 0.074 as calculated 
using maximum composite likelihood on Mega 5.1 software (Tamura and Nei, 
1993, Tamura et al., 2011). This value was slightly lower than the diversity of 
FIV clade A isolates, reported previously as 0.091 (Samman et al., 2011). 
Different degrees of FIV population diversity within individual cats were 
observed, ranging from 0.0 to 0.02942 (Table 4-16). Although the env variants 
were less diverse in healthy cats compared to sick cats (median of 0.00067 (0.0 – 
0.02459) vs. 0.00599 (0.0 – 0.02942), p = 0.1674), this difference was not 
statistically significant.  
 
In order to determine the subtypes of the amplified FIV env variants, 
firstly a maximum likelihood (ML) tree was constructed using 141 deduced amino 
acid sequences comprising the full SU (UK8 position 1 - 610) obtained from 20 
cats (Table 4-16), together with 20 reference sequences from clades A, B, C and 
D, which were available from Genbank (Figure 4-8). Phylogenetic analysis 
indicated that all of the envs belonged to FIV clade A as their sequences 
clustered together with the clade A reference sequences (Bootstrap value = 99%, 
Figure 4-8), consistent with previous findings that clade A was the major FIV 
subtype circulating in the British Isles (Samman et al., 2011).  
 
On the SU tree, sequences from the same cats clustered together, with 
each forming a monophyletic branch. No evidence of separation of sequences 
from healthy and sick cats was observed; all sequences were intermingled with 
each other and with the reference sequences. Amongst the sequences from the 
same cat, a degree of polymorphism was evident, indicative of the existence of 
quasispecies within naturally FIV infected cats (Figure 4-8). Interestingly, more 
diverse intra-host env populations were observed in some cats. For example, 
clone 5 of cat 347202 (347202C5) was some distance from clone 4 amplified from 
the same cat (upper and lower red arrows respectively) (Figure 4-8). The SU 
gene from this cat was the most diverse, (average diversity 0.02942 (Table 4-
16)). Similar divergence was also observed in cats 346938 and 346363. Although 
the average diversity of cat 346938 was relatively low at 0.00765, one highly 
diverse sequence, clone 43, clustered and formed a monophyletic branch with 
sequences from cat 347202 (top blue arrow and bottom red arrow), some 
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distance from the other sequences from the same cat (bottom blue arrow) 
(Table 4-16 and Figure 4-8). Cat 346363 showed the second highest average 
diversity at 0.02459 (Table 4-16). Clone 1 from this cat was more closely related 
to sequences from cat 346224 and was distinct from the other sequences 
amplified (bottom and top green arrow) (Figure 4-8). 
 
It has been shown that the sequences from the region extending from 
variable loop 3 to variable loop 6 (V3-V6) of Env are the most polymorphic and 
these regions were used conventionally to define FIV subtypes (Kakinuma et al., 
1995). Moreover, a fifth clade of FIV, clade E, was identified using sequences 
comprising the V3-V5 region of Env (Pecoraro et al., 1996). Since no full-length 
Env references sequences were available for clade E, a separate maximum 
likelihood tree was constructed using deduced amino acid sequences spanning 
the V3-V6 region (UK8 position 360 - 610) of Env from the same dataset. As 
shown in Figure 4-9, the V3-V6 ML tree confirmed that all FIV Env in this study 
belonged to clade A. Sequences from the same cats clustered together and 
formed monophyletic branches as observed in the SU tree (Figure 4-8 and Figure 
4-9). Although their locations on the tree varied between each monophyletic 
branch, sequences 347202C5, 346938C43 and 346363C1 displayed similar 
relationships to those observed in the SU tree (Figure 4-8 and Figure 4-9).  
 
Figure 4-10 shows a ML tree constructed from 76 full-length Env (deduced) 
amino acid sequences from five healthy and five sick FIV infected cats, together 
with 20 full-length reference sequences available from Genbank. This ML tree 
confirmed that all FIV Env belonged to clade A. Clones 347202C5 and 346938C43 
appeared closely related and did not cluster with the other sequences, as 
observed in the SU and V3-V6 trees (Figure 4-8 to Figure 4-10). 
  
146 
 
Figure 4-8 Unrooted maximum likelihood tree of 141 full SU amino acid (UK8 position 1 - 610) 
from eight healthy and 12 sick FIV infected cats together with 20 reference sequences (Genbank 
accession numbers in brackets); Clade A; Dixon (L00608.1), Dutch (X60725), Dutch 19K1 
(M73964.1), Petaluma (M25381.1), PPR (M36968.1), refseqfiv (KKS) (NC_001482.1), Sendai1 
(D37813.1), SwissZ2 (X57001.1), UK2 (X69494.1) and UK8 (X69496.1), Clade B; Aomori 1 
(D37816), Aomori 2 (D37817.1), B2542 (USIL2989_7B), FC1 (AY621093), Sendai 2(D37814.1), TM2 
(M59418.1) and Yokohama (D37812.1), Clade C; FIVC (AF474246.1) and Clade D; Fukuoka 
(D37815.1) and Shizuoka (D37811.1). Percentage bootstrap values (1000 replicates) were shown 
next to branches. Branch length scaled to the number of amino acid substitutions. Note that 
347202C5 (top red arrow), 346938C43 (top blue arrow) and 346363C1 (bottom green arrow) were 
positioned apart from the monophyletic branches of all the others clones from the same cat, 
347202 (bottom red arrow), 346938 (bottom blue arrow) and 346363 (top green arrow). 
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Figure 4-9 Unrooted maximum likelihood tree of 141 amino acid sequences spanning V3-V6 loop 
(UK8 position 360 - 610) from eight healthy and 12 sick FIV infected cats, together with 26 
reference sequences (Genbank, accession numbers in brackets); Clade A; Dixon (L00608.1), 
Dutch (X60725), Dutch 19K1 (M73964.1), Petaluma (M25381.1), PPR (M36968.1), refseqfiv (KKS) 
(NC_001482.1), Sendai1 (D37813.1), SwizzZ2 (X57001.1), UK2 (X69494.1) and UK8 (X69496.1), 
Clade B; Aomori 1 (D37816), Aomori 2 (D37817.1), B2542 (USIL2989_7B), LevianoC1 (FJ374696.1), 
Leviano_C7 (FJ374697), Leviano_C8 (FJ374695),  Sendai 2(D37814.1), TM2 (M59418.1) and 
Yokohama (D37812.1), Clade C; FIVC (AF474246.1) and Clade D; Fukuoka (D37815.1) and 
Shizuoka (D37811.1) and Clade E; LP3 (D84496), LP20 (D84498) and LP24 (D84500).  Percentage 
bootstrap values (1000 replicates) were shown next to branches. Branch length scaled to the 
number of amino acid substitutions. Note that 347202C5 (top red arrow), 346938C43 (bottom 
blue arrow) and 346363C1 (bottom green arrow) were positioned apart from the monophyletic 
branch of all other clones from the same cat, 347202 (bottom red arrow), 346938 (top blue 
arrow) and 346363 (top green arrow). 
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Figure 4-10 Unrooted maximum likelihood tree of 76 full-length Env amino acid sequences from 
five healthy and five sick FIV infected cats, together with 20 reference sequences (Genbank, 
accession numbers in brackets); Clade A; Dixon (L00608.1), Dutch (X60725), Dutch 19K1 
(M73964.1), Petaluma (M25381.1), PPR (M36968.1), refseqfiv (KKS) (NC_001482.1), Sendai1 
(D37813.1), SwizzZ2 (X57001.1), UK2 (X69494.1) and UK8 (X69496.1), Clade B; Aomori 1 
(D37816), Aomori 2 (D37817.1), B2542 (USIL2989_7B), FC1 (AY621093), Sendai 2(D37814.1), TM2 
(M59418.1) and Yokohama (D37812.1), Clade C; FIVC (AF474246.1) and Clade D; Fukuoka 
(D37815.1) and Shizuoka (D37811.1). Percentage bootstrap values (1000 replicates) were shown 
next to branches. Branch length scaled to the number of amino acid substitutions. Note that 
347202C4 (top red arrow) and 346938C43 (top blue arrow) clustered together and far away from 
347202C5 (bottom red arrow) and the monophyletic branch of all the other clones from the same 
cat 346938 (bottom blue arrow). 
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4.4.18 CD134 usage and FIV clinical status 
 
From the 76 full-length env gene sequences obtained, 24 sequences were 
unique (Table 4-16). These 24 unique env genes were used to construct HIV(FIV) 
pseudotypes which were then tested for CD134-usage. CRD2 dependence of each 
pseudotype was determined using the assay described in Section 2.3.2).  
  
As shown in Table 4-18 and Figure 4-11, different degrees of CRD2 
dependency were observed among 24 pseudotypes bearing Envs from healthy 
and sick cats. A mixed population of FIV Env variants with different CD134 usage 
was observed in cats for which more than one pseudotype was tested (Table 4-
18), indicative of a quasispecies. We speculated that sick cats, having lower 
percentages of CD4+CD134+ T lymphocytes and tending to be older, might be 
expected to harbour more CRD2-independent FIV Env variants. Although two sick 
cats (346938 and 367133) gave rise to CRD2-independent Envs, compared to only 
one healthy cat (368352), similar numbers of FIV Env variants with CRD2-
dependent, intermediate and CRD2-independent usage were observed between 
the two groups (healthy; 4:4:1, compared to sick; 5:2:2). It was notable that the 
percentage of CD4+CD134+ T lymphocytes of the cat with only CRD2-independent 
using Env (healthy cat 368352 and sick cat 367133) was the lowest in the group; 
cat 368352 displayed 16.78% CD4+CD134+ T lymphocytes compared to the healthy 
group median of 28.19% and cat 367133 displayed 5.10% CD4+CD134+ T 
lymphocytes compared to the sick group median of 29.05%) (Table 4-17 and 
Appendix 4-6). The presence of CRD2-independent Env variants in cat 368352 in 
the healthy group was striking, since this cat was only two years old at the time 
of sampling and so was likely in the early phase of infection. Cat 368352 had a 
higher PVL compared to the other healthy FIV-infected cats (6,504 compared to 
a group median of 1,010 copies/106 cells) (Table 4-17). One possible explanation 
was that the transmitted population comprised both early and late variants. 
However, only three env genes were cloned from this cat and all were identical. 
In order to investigate this further, a larger population sample would be 
required.  
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Table 4-17 Demography, lymphocyte subpopulations and PVL of healthy and sick 
FIV positive cats from which functional pseudotypes were deriveda 
 
 Healthy (n = 5) Sick (n = 5) 
Age 3Y (2Y – 6Y 10M) 6Y 9M (6Y – 10Y) 
Gender (male:female) 4:1 5:0 
CD4+ percentage 24.17 (13.02 – 26.77) 13.0 (1.62 – 25.92) 
CD8+ percentage 15.56 (5.17 – 30.29) 16.20 (2.59 – 32.67) 
CD4:CD8 ratio 1.43 (0.66 – 4.86) 0.58 (0.29 – 3.15) 
CD4+CD134+ percentage 28.19 (16.78 – 67.37) 29.05 (5.10 – 51.25) 
FIV proviral load 
(copies/106 cells) 
1,010 (20 – 7,903) 2,982 (1,629 – 7,204) 
 
a Values shown as group median values with range in brackets. Age: Y = years and M = months, 
CD4+ and CD8+ lymphocytes are shown as percentage of total lymphocytes, CD4+CD134+ 
lymphocytes are shown as percentage of CD4+ population, Statistical significance were 
determined using Mann-Whitney test and Fisher’s exact test.  
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Table 4-18 CD134 usage and autologous neutralisation of HIV(FIV) pseudotypes 
bearing Env variants from healthy and sick FIV positive cats  
 
 I.D. env variants* CD134 usage** autologous 
neutralisation*** 
healthy 
346271 C6 
C10 
C11 
n.d. 
intermediate 
CRD2-dependent 
n.a. 
n.a. 
n.a. 
346302 C2 
C18 
C21 
CRD2-dependent 
intermediate 
intermediate 
n.a. 
n.a. 
n.a. 
347178 C2, C13 
C4 
C10  
C11 
C15 
n.d. 
n.d. 
CRD2-dependent 
CRD2-dependent 
n.d. 
n.d. 
n.d. 
no 
no  
n.d. 
347251 C14 intermediate no 
368352 C20 CRD2-independent yes 
sick 
346938 C5 
C24 
C43 
CRD2-dependent 
CRD2-independent 
CRD2-dependent 
n.a. 
n.a. 
n.a. 
347076 C4 
C5 
C9 
C31 
n.d. 
n.d. 
CRD2-dependent 
CRD2-dependent 
n.d. 
n.d. 
no 
no 
347202 C4 
C5 
CRD2-dependent 
intermediate 
no 
no 
365045 C2 intermediate no 
367133 C5 CRD2-independent no 
 
*Clones representing unique env genes isolated from each individual cat.  
**CD134 usage determined as ratio of ability to utilise feline CD134 (FFF) versus chimaeric feline 
x human CD134 (FFHH) (FFF:FFHH) for infection. Results shown were reproduced in 4 
independent experiments (Appendix 4-11).  
***n.a. = not analysed, due to inadequate plasma sample volume, n.a. = not determined, as 
luciferase activity of pseudotype was as low as vector control. 
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Figure 4-11 Representative result of CD134-usage assay for HIV(FIV) pseudotypes bearing Env 
variants derived from healthy (A) and sick (B) FIV infected cats. The infectivity of each 
pseudotype (indicated on the X-axis) in CLL-FFF (white bar) and CLL-FFHH (filled bar) is shown as 
mean luciferase activity (cpm, count per minute) with standard deviation (SD) of triplicate 
reads. CD134 usage was determined from the FFF:FFHH ratio, which was compared with the ratio 
for the prototypic GL8 for CRD2-dependent (blue arrow), KKS for intermediate (light green 
arrow) and B2542 for CRD-2-independent (yellow arrow) variants. The interpretations were made 
on the consensus readouts from 4 assay repeats (Appendix 4-11).   
 
4.4.19 Autologous neutralisation and FIV clinical status 
 
 Previously, it has been shown for HIV-1 that tropism switching is 
associated with escape from immune selective pressures (McKnight and 
Clapham, 1995, McKnight et al., 1995).  For FIV, it was also shown that a switch 
occurs between a complex, CRD2-dependent, CD134-FIV Env interaction to a 
simple, CRD2-independent interaction, associated with selective pressure from 
neutralising antibodies (Willett et al., 2008, Willett et al., 2010, Willett and 
Hosie, 2013). Since evasion from the immune response could influence FIV 
receptor usage, a virus neutralisation assay was performed using autologous 
plasma samples against the panel of HIV(FIV) pseudotypes bearing FIV Envs.  
  
 Unfortunately, due to limiting plasma sample volumes, neutralisation 
tests could be performed in only two healthy and four sick cats (Figure 4-12). 
Neutralising antibodies (NAb) were detected in only one of the healthy cats 
(368352, see Figure 4-12A). This finding was unexpected, since pseudotype 
368352 showed CRD2-independent CD134 usage (Table 4-18 and Figure 4-11) and 
the emergence of CRD2-independent variants had been linked to evasion from 
NAb in the previous study (Willett et al., 2008, Willett et al., 2010). In spite of 
being the only cat with detectable NAb, the FIV PVL of this cat was relatively 
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high, compared to the other healthy FIV-infected cats (6,504 vs. a group median 
of 1,010 copies/106 cells) (Table 4-17). One possible explanation was that the 
env used for pseudotype production was derived from proviral sequence and so 
might not represent the population of Env variants circulating at the time of 
sampling. However, without circulating viral RNA-derived envelope sequence, 
we were unable to test this hypothesis. 
 
 
Figure 4-12 Autologous viral neutralisation assay of HIV(FIV) pseudotypes bearing Envs derived 
from healthy (A) and sick (B) FIV positive cats. X-axis indicated 10-fold serial dilutions of plasma 
ranging from 1:10 to 1:10,000. Y-axis showed log luciferase activity (counts per minute).  
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4.5 Discussion and Conclusion 
 
 
In this chapter, the classical immunological parameters of FIV infection, 
i.e. levels of CD4+, CD8+ T lymphocytes and their ratios were investigated in a 
cohort of FIV+FeLV- cats. We confirmed that decreased or inverted CD4:CD8 
ratios were a hallmark of FIV infection, resulting from the combined effect of 
decreasing numbers of CD4+ T lymphocytes and expansion of the CD8+ T 
lymphocyte population (Figure 4-2C to Figure 4-2E) (Willett et al., 1993, 
Shimojima et al., 1998, Yamamoto et al., 2007, Hartmann, 2012, Sykes, 2013). 
The clinical signs observed in FIV infected cats in this study were consistent with 
those reported previously, in which gingivostomatitis and lethargy were the most 
common signs (Yamamoto et al., 2007, Hosie et al., 2011, Hartmann, 2012, 
Sykes, 2013). Similar to a previous study, no association was observed between 
the CD4:CD8 ratio and the health status of FIV infected cats (Beczkowski et al., 
2015a). Interestingly, similar CD4:CD8 ratios were observed between sick FIV 
negative cats and healthy FIV positive cats (Figure 4-4E). This finding suggested 
that low CD4:CD8 ratios are commonly seen in response to infections and not 
restricted to FIV infection.  
 
 The observation that senile cats usually displayed decreased CD4:CD8 
ratios, together with the negative correlation between age and CD4:CD8 ratio in 
FIV negative cats, led to the speculation that the decreased ratio was associated 
with aging (Table 4-5) (Heaton et al., 2002, Day, 2010). In addition, a previous 
study of an Italian HIV negative cohort of patients reported a link between 
CD4:CD8 ratios less than one and immunosenescence, the natural aging of the 
immune system (Mascolini, 2014). However, the low CD4:CD8 ratio was unlikely 
to be age-related in this study, as the median ages of both sick FIV negative and 
healthy FIV positive cats were similar to those of the healthy FIV negative cats 
(Table 4-4). Since the percentages of CD4+ T lymphocytes were similar to those 
of healthy FIV negative cats, the decreased CD4:CD8 ratios observed in sick FIV 
negative and healthy FIV positive cats might have reflected their increased 
percentages of CD8+ T lymphocytes (Table 4-4). 
  
CD8+ T lymphocytes proliferate in response to viral infection, therefore 
the low CD4:CD8 ratio observed in sick FIV negative cats might be related to 
other concurrent infections (Wherry and Ahmed, 2004). However, similar 
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CD4:CD8 ratios were observed between sick FIV negative cats, with or without 
detectable evidence of other infections (Table 4-15). The effect of FCV infection 
on the CD4:CD8 ratio has rarely been investigated and the few indirect 
observations reported in literature have been inconclusive. In one study, in 
which cats chronically infected with FIV were co-infected experimentally with 
FCV, FCV co-infection had no effect on the CD4:CD8 ratio (Reubel et al., 1994).  
In another study, proliferation of CD8+ T lymphocytes from FCV vaccinated cats 
was observed in vitro following re-stimulation with inactivated, but not 
infectious, FCV (Vermeulen et al., 2012). In this study, the FCV infected cats 
maintained high CD4:CD8 ratios (median 2.08, range 0.27 – 4.14), indicating that 
FCV infection had no effect on the CD4:CD8 ratio. In contrast, inversion of the 
CD4:CD8 ratio was reported in severe cases of human toxoplasmosis and also in 
cats experimentally infected with Toxoplasma gondii (Lin et al., 1992, Lappin et 
al., 1996, Darde et al., 1998). However, the median CD4:CD8 ratio was relatively 
high in sick FIV negative cats with T.gondii infection in this study (median 1.90, 
range 1.16 – 3.51). Therefore it was difficult to account for the low CD4:CD8 
ratios observed in sick FIV negative cats (with or without evidence of co-
infections), although it is possible that these cats were harbouring additional, 
unidentified infections since the panel of diagnostic tests conducted was not 
comprehensive.  
 
 Inflammatory oral disease, especially gingivitis and stomatitis, has been 
associated with FIV infection (Tenorio et al., 1991, Hosie et al., 2009, Hartmann, 
2012, Sykes, 2013). Kornya and colleagues reported a significantly higher risk of 
FIV infection in cats with inflammatory oral diseases, with stomatitis being the 
highest risk (Kornya et al., 2014). In this study, however, such an association was 
not observed (Appendix 4-9); a higher percentage of cats with gingivitis tested 
FIV negative than FIV positive (20.17% (23/114) vs. 6.38% (6/94)). The lower 
number of FIV-infected cats presenting with gingivitis in this study might be 
related to variations in virulence amongst infecting strains of FIV (Hosie et al., 
2000, Hosie et al., 2002, Stickney et al., 2013). In this study, all cats were 
infected with clade A isolates, confirming the results of a study conducted in UK 
in 2011 by Samman et al (Samman et al., 2011). The prevalence of gingivitis in 
sick FIV infected cats in this study (17.14% (6/35)) was similar to that observed 
previously (24% (6/25)) (Samman et al., 2011). Although several previous studies 
have suggested that isolates in FIV clades A and C were more virulent than clade 
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B isolates, the small number of experimental cohorts and differences in the 
definition of virulence made it difficult to make such comparisons (Kohmoto et 
al., 1998, Nishimura et al., 1998, Pedersen et al., 2001).   
 
Overall, similar percentages of lymphocyte subpopulations were observed 
between sick FIV positive cats with and without co-infections (Table 4-15 and 
Figure 4-6). Since only seven cats were co-infected, this sample number was too 
small to detect statistically significant differences. Nonetheless, FIV infected 
cats with co-infections displayed higher percentages of CD4+CD134+ T 
lymphocytes as well as higher FIV PVL (Table 4-15). The increased FIV PVL and 
co-infections observed in these cats were likely attributable to the cats being in 
the final stage of infection, with depleted immune systems and the loss of 
ability to respond to opportunistic infections (Yamamoto et al., 2007, Hartmann, 
2012, Sykes, 2013). However, it is possible that both groups of FIV-infected cats 
(with and without co-infections) were at similar stages of infection, since the 
median ages for both groups were similar (7Y 6M vs. 7Y 9M) (Table 4-15).  A 
causal relationship could not be established because of the cross-sectional 
design of this study, but cell-mediated immune responses against co-infecting 
agents might have led to expansion of an antigen-specific memory T lymphocyte 
population (Song et al., 2008, Hua et al., 2012, Croft, 2014). Such newly 
activated populations would then be infected readily with FIV as they express 
high levels of the CD134 receptor molecule, as shown in Figure 4-6E (de Parseval 
et al., 2004a). Moreover, if this population had already been latently infected, 
immune activation in response to new co-infection(s) might also have led to 
increased viral replication (McDonnel et al., 2013). Both of these mechanisms 
would result in increased numbers of CD134+ target cells and activation of 
latently infected CD4+ T lymphocytes could also contribute to the elevated FIV 
PVL that was observed in FIV infected cats with co-infections (Figure 4-6F). To 
confirm this hypothesis, a larger, case-controlled, study would be required.  
  
It is possible that FIV Env-CD134 engagement might trigger signal 
transduction, similar to the engagement of CD134L, the native ligand for CD134. 
However, there have been no reports of studies investigating this possibility. 
CD134L/CD134 engagement was shown to promote peripheral migration of T 
lymphocytes (Evans et al., 2001). These circulating antigen-specific T 
lymphocytes were functionally competent and long-lived, surviving for 196 days 
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after antigen-stimulation (Evans et al., 2001, Prell et al., 2003). This suggests 
that the elevated percentages of CD4+CD134+ T lymphocytes, which were 
observed only in FIV infected cats, might have arisen as a consequence of the 
FIV Env-CD134 interaction (Figure 4-2F, Figure 4-3F and Figure 4-4F). To confirm 
this relationship would require investigation of the CD134 signal transduction 
pathway using recombinant Envs of different FIV strains, ideally in the native 
trimeric conformation.  
 
In this study a positive correlation was observed between CD4+CD134+ T 
lymphocytes and FIV PVL only in healthy FIV positive cats. As the healthy cats 
were likely to be in the early phase of infection, it appeared that some FIV 
variants replicated better and so outcompeted other variants in the quasispecies 
(Figure 4-5E). It was shown previously that the CRD2-dependent FIV GL8 isolate 
was insensitive to CD134L antagonism (Willett et al., 2009, Willett et al., 2010). 
This finding suggested that the Env from GL8, isolated from early infection, 
could utilise CD134 for infection, even when bound by CD134L. The ability to 
utilise both free and CD134L-bound CD134 receptor molecules for infection could 
provide this strain of FIV with more target cells for replication. Moreover, the 
highly activated immune status and longer lifespan of CD134L- bound 
CD4+CD134+ T lymphocytes might also confer more efficient viral replication 
(Hori, 2005, Soroosh et al., 2006, Song et al., 2008). Although there was no 
direct evidence of CD134 signalling affecting FIV replication, it was shown in an 
HIV-1 in vitro model that the CD134L/CD134 interaction, similar to TNF-α 
stimulation, enhanced virus production (Takahashi et al., 2001). Since the level 
of TNF-α was shown to be linked with the level of FIV core protein production, it 
would appear likely that CD134L ligation could also augment FIV production 
(Kraus et al., 1996). Hence, this mechanism might explain the higher replicative 
capacity of early, CRD2-dependent variants observed in the earlier phase of 
infection such as GL8, compared to the CRD2-independent variants that emerge 
later in infection (Willett et al., 2013, Willett and Hosie, 2013).  
 
The positive correlation observed between CD4+CD134+ T lymphocytes and 
PVL might also reflect the classic pathogenesis of acquired immunodeficiency 
syndromes, with the initial T lymphocyte depletion stimulating the 
replenishment of lymphocytes from the memory pool (Grossman et al., 2006, 
Hua et al., 2012). Such migrating memory CD4+ T lymphocytes are of diverse 
158 
antigen specificity and continuously repopulate the lymphocyte population 
(Picker et al., 2004). However, it was shown, in SIV-infected macaques, that this 
process is incomplete; failure to repopulate the depleted lymphocytes coincided 
with the onset of immunodeficiency (Picker et al., 2004). Furthermore, these 
recently recruited, antigen-activated CD4+CD134+ T lymphocytes could in turn 
become fresh target cells (de Parseval et al., 2004a). Eventually this cycle would 
lead to the inability to replenish lost T lymphocytes, immune exhaustion, 
increasing PVL and the clinical signs of immunodeficiency, such as those 
observed in the sick FIV positive cats in this study. 
 
In order to characterise the FIV variants of the cats of this study, 141 full-
length env gene sequences were obtained from 20 of the cats naturally infected 
with FIV. Phylogenetic trees constructed from the deduced amino acid 
sequences of either the entire Env or spanning the V3-V6 loop, confirmed that 
FIV clade A is the predominant clade circulating in the UK, as reported in 2011 
(Samman et al., 2011). The average inter-host diversity of env in this study was 
7.4%; this was relatively similar to the diversity observed for FIV clade A isolates 
previously. In the USA, Sodora et al reported within subtype variation of 9.8% for 
clade A isolates (Sodora et al., 1994). In Western Europe, the average diversity 
of FIV clade A was 9.1% in the UK and 6.6% in the Benelux countries (Samman et 
al., 2011, Roukaerts et al., 2015). The average intra-host variation observed 
here (0.69%) was lower than had been reported in a previous study in the USA 
(3.7%, (Sodora et al., 1994)). This difference was unlikely related to the clinical 
status of the cats, since the CD4:CD8 ratios were similar in the two studies  
(median of 1.63 vs. 1.46 in this study). Moreover, no correlations were observed 
between the intra-host diversity and any of the parameters investigated in this 
study. However, the infecting strains differed; whereas the V3-V5 sequences of 
the isolates in the USA study were closely related to the FIV clade A Dixon strain, 
those in this study were divergent (Figure 4-10) (Sodora et al., 1994). Indeed, 
the similarly lower intra-host diversity observed in cats experimentally infected 
with FIV clade A GL8 (0.45%) also supported this speculation (Kraase et al., 
2010).   
 
In this study, we observed different CD134 usage of FIV variants, ranging 
from CRD2-dependent to CRD2-independent interactions.  These different CRD2 
requirements were detected at both population and within-host levels (Table 4-
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18 and Figure 4-11). Similar findings were also reported in two cohorts of cats 
naturally infected with FIV isolates assigned to clade B or recombinant A/B 
isolates (Beczkowski et al., 2014b). Together, these studies suggest that a broad 
spectrum of CD134 usage in FIV quasispecies is a common feature of natural FIV 
infection. However, the driving force behind this phenomenon remains to be 
elucidated. As shown in Chapter 3 and in some HIV studies, target cell 
availability could also exert selective pressure on the viral population (Klatt et 
al., 2008). Therefore, we speculated that the dominance of CRD2-dependent 
variants, detected more frequently in the early phase of infection, and the 
emergence of CRD2-independent variants in late infection were influenced by 
the dynamics of the CD4+CD134+ T lymphocyte population that gradually 
declined over the course of infection (Figure 4-7).  
 
While sick cats, which were presumed to be in the later stage of infection 
since they were significantly older age than the healthy cats, harboured more 
CRD2-independent variants, the small sample size made it difficult to draw firm 
conclusions. However, the preliminary findings from two groups of five cats 
encouraged us to investigate the effect of target cell availability in natural 
infection. Since these FIV env genes were amplified from genomic DNA, they 
could represent either recently integrated provirus or an ancestral founder virus 
and so might not reflect the population of FIV variants circulating at the time of 
blood collection (Finzi et al., 1999, Lambotte et al., 2004). Moreover, since the 
percentages of CD4+CD134+ T lymphocytes in the five healthy and five sick cats 
studied were similar (28.19% (16.78% – 67.37%) vs. 29.05% (5.1% - 51.25%), Table 
4-17), this might confound the speculated selective pressure of target cell 
availability and explain, at least in part, the similar proportion of 
early/intermediate/late viruses observed between the two groups of cats.  
 
The presence of NAbs has been shown to be a major selective pressure 
leading to the emergence of late, CRD2-independent variants (Willett et al., 
2008, Willett et al., 2010, Willett and Hosie, 2013). However, no association was 
observed between autologous neutralisation titres and the emergence of late 
variants in this study (Figure 4-12). The absence of correlation between CRD2-
usage and NAbs has also been reported in naturally infected cats (Beczkowski et 
al., 2014b).  Therefore, although selective pressure can be exerted by NAbs and 
cell-mediated immune responses, further studies will be required to define the 
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link between FIV tropism switching and host immune responses (Beatty et al., 
1996, Rambaut et al., 2004, Willett et al., 2010, Hosie et al., 2011, Willett et 
al., 2013). 
 
The finding that env genes from the same cat could be positioned 
distantly on the phylogenetic tree (Figure 4-8 to Figure 4-10) was consistent with 
the data showing different CD134-usage (Table 4-18 and Figure 4-11) and 
suggested that FIV genotype could be a useful FIV prognostic tool; the late 
phenotype (CRD2-independence) was associated with clinical signs of 
immunodeficiency (Beczkowski et al., 2014b, Beczkowski et al., 2015a). It has 
been demonstrated clearly in HIV infection that mutations within the V3 region, 
which result in changes in the net charge of V3, play a critical role in HIV 
tropism switching from CCR5- to CXCR4-usage (Obermeier et al., 2012, Montagna 
et al., 2014). Indeed, several HIV tropism prediction algorithms have been 
developed, each with different validities and clinical relevance (Obermeier et 
al., 2012, Montagna et al., 2014, Gupta et al., 2015). Hence, we hypothesise 
that FIV receptor usage might also be governed by a change in charge at pH 7.0 
of the FIV Env variable loops and, as our understanding about their relationship 
improves, a reliable FIV prognostic algorithm based on viral env sequences could 
be achieved. The development of such a tool would be one of many research 
opportunities arising from the findings of this study. 
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Chapter 5 Investigating the role of the target cell in the selection 
of FIV variants   
 
5.1 Introduction 
 
 Natural FIV transmission usually occurs via biting and exposure to 
contagious blood (Yamamoto et al., 2007). This route, similar to the route of 
transmission among HIV intravenous drug users (IDU), results in a mixed 
population of viral variants, termed the “quasispecies”, being transmitted at the 
same time (Bar et al., 2010). However, it was observed in a large proportion of 
HIV cases that infection is usually established by a single variant (Keele et al., 
2008). Host and viral factors, such as target cell availability and viral tropism, 
might play important roles in the selection that occurs before host immune 
responses are elicited. Studies described in previous chapters demonstrated that 
the number of CD4+CD134+ T lymphocytes also plays a role in tissue 
compartmentalisation (Chapter 3) and tropism switching (Chapter 4). In this 
chapter, an in vitro model was developed to test the hypothesis that the number 
of activated CD4+CD134+ T lymphocytes is a key determinant that preferentially 
selects for early variants of FIV.  
 
5.2 Development of a red fluorescent protein (RFP) carrying lentiviral vector  
 
Since the discovery of the first fluorescent protein “green fluorescent 
protein (GFP)” in 1992, several other fluorescent proteins (FPs) have been 
developed (Telford et al., 2012). However, their use is largely restricted to 
advanced platform confocal microscopy and/or flow cytometry with multiple 
excitation wavelengths. The flow cytometer in our institute, the Accuri C6, is a 
compact benchtop flow cytometer equipped with only four detectors and two 
standard lasers at 488 and 640 nm and so candidate FPs are limited. Yellow 
fluorescent protein (YFP) was available in our laboratory but was 
indistinguishable from GFP using this flow cytometer. An alternative was the red 
fluorescent protein (RFP) “DsRed” which could be detected in near-red channel 
(~580 nm), but its natural homotetrameric form greatly decreases its 
photostability, emission rate and brightness (Gross et al., 2000). Recently, a 
photostable monomeric RFP “TagRFP” was developed as a fluorescent tag for in 
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vivo cellular protein imaging (Shaner et al., 2008). Sharing the same emission 
wavelength as DsRed, TagRFP was a good candidate for a new FP-carrying 
pseudotype (Shaner et al., 2008). Therefore, a new lentiviral vector for the 
transduction of TagRFP was developed to facilitate this study. 
 
5.2.1 Development of pCSRW vector 
 
The TagRFP gene was double digested from the plasmid pLenti-C-EGFP-S-
TagRFP (kindly provided by Dr. Sam Wilson, Medical Research Council-University 
of Glasgow Centre for Virus Research) using the restriction enzymes BamHI-HF® 
and NotI-HF® (New England Biolabs, UK) and then ligated into BamHI/NotI double 
digested pCSGW, a lentiviral vector capable of expressing EGFP under the spleen 
focus-forming virus (SFFV) promoter, using T4 DNA Ligase (Promega, UK). The 
ligated construct was then transformed into Escherichia coli MAX Efficiency® 
DH5αTM competent cells (Invitrogen, UK) and cultured for small scale DNA 
preparation (Section 2.1.11 – 2.1.12). To check the insert, plasmid DNA was 
digested with BglI (New England Biolabs, UK) and examined by gel 
electrophoresis (Figure 5-1A). Plasmid containing the correct insert was then 
scaled up for large scale DNA preparation (Section 2.1.14). This plasmid was 
named “pCSRW” (Figure 5-4A).  
 
Plasmid pCSRW was used to prepare TagRFP-HIV(VSVG) pseudotypes by 
transient transfection together with pCMV-dR8.2 dvpr (Stewart et al., 2003) and 
pMD2.G (plasmid expressing the G protein of vesicular stomatitis virus (VSVG) 
into HEK 293T cells (Section 2.3.1). The plasmid pMD2.G was a gift from Didier 
Trono (Addgene plasmid # 12259)). To test the TagRFP-pseudotype, CLL-fCD134 
(Section 2.2.1.2) and MCC-fCD134 cells (Section 2.2.1.3) were used as targets. 
Cells were seeded at 2.5 x 105 cells per 500 μl per well in 48 well plates, 
followed by the addition of 500 μl of medium containing the TagRFP-pseudotype.  
The cells were spinoculated at 800 x g for 60 minutes at room temperature and 
the plates were incubated for 48 hours at 37°C, 5% CO2. On day two, the plates 
were read on an Accuri C6 Flow cytometer (Beckton Dickinson bioscience 
bioscience). Empty pseudotypes bearing no viral envelopes (produced by co-
transfection of empty VR1012 vector with pCMV-dR8.2 dvpr and pCSGW) were 
used as negative controls. The quantities of each pseudotype were determined 
according to the intensity of p24 CA protein staining following immunoblotting, 
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as the pseudotypes shared the same HIV Gag/Pol backbone (pCMV-dR8.2 dvpr) 
(Section 2.3.6) (Figure 5-6). The percentage of infected cells and mean 
fluorescence intensity (MFI) were analysed using CFlow Plus software version 
1.0.227.4 (Beckton Dickinson bioscience, USA).  
 
 
 
Figure 5-1 Illustration of pCSGW (lane 1) and pCSRW (lane 2), following digestion with BglI. The 
leftmost lane shows a virtual DNA ladder. pCSGW contains 2 BglI sites while pCSRW contains an 
additional site in the TagRFP gene, hence the appearance of two smaller bands at approximately 
3,000 bp and 5,500 bp (A). The plasmid map of pCSGW (B), in which the EGFP gene (position 
8260-9001, grey arrow) was replaced by TagRFP in pCSRW (Figure 5-4A)  
 
5.2.2 Lower infectivity and mean fluorescence intensity of TagRFP-
pseudotype  
  
The GFP-HIV(VSVG) pseudotype infected both MCC-fCD134 and CLL-
fCD134, although a higher percentage of CLL-fCD134 cells was infected 
compared to MCC-fCD134 cells (85.95% vs. 76.63% of GFP positive cells 
respectively) (Table 5-1). Similar results were obtained for the TagRFP-
pseudotype; the percentage of TagRFP positive cells was approximately 30% 
higher in CLL-fCD134 compared to MCC-fCD134 cells (21.45% vs. 14.19% 
respectively) (Table 5-1). However, the MFI of GFP- and TagRFP-positive cells 
were approximately ten and three times higher respectively in MCC-fCD134 cells 
compared to CLL-fCD134 cells (Table 5-1). The higher intensity of both FPs in 
MCC-fCD134 was readily observed under the fluorescent microscope (Figure 5-2). 
A B 
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Table 5-1 Percentage and mean fluorescence intensity (MFI) of VSVG-GFP or 
VSVG-TagRFP infection of MCC-fCD134 and CLL-fCD134 cells   
 
 GFP-HIV(VSVG) (pCSGW) TagRFP-HIV(VSVG) (pCSRW) 
 percentage MFI percentage MFI 
MCC-fCD134 76.63% 3,150,000 14.19% 37,000 
CLL-fCD134 85.95% 352,000 21.45% 11,600 
 
 
 
Figure 5-2 Representative images of MCC-fCD134 (top) and CLL-fCD134 (bottom) infected with 
HIV(VSVG)-GFP (pCSGW, left) or HIV(VSVG)-TagRFP (pCSRW, right) pseudotypes. 10x objective 
magnification on Evos fl microscope (AMG micro, USA) 
 
5.2.3 Higher FP expression under the CMV promoter 
 
Both GFP and TagRFP were expressed at lower intensities in CLL-fCD134 
cells compared to MCC-fCD134 cells. This difference did not appear to be related 
to CD134 expression levels, since CD134 expression (detected by the anti-feline 
CD134 antibody A647) on both cell lines was approximately 98%. Moreover, 
pseudotypes bearing VSVG infected a broad range of mammalian cell types, 
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including CLL-fCD134 and MCC-fCD134 cells (Marsh and Helenius, 1989). 
Therefore, it appeared the SFFV promoter functioned better in MCC-fCD134 cells 
compared to CLL-fCD134 cells. To investigate this possibility, a new batch of 
GFP-HIV(VSVG) pseudotypes was prepared using pCCGW (kindly provided by Dr. 
Sam Wilson). Plasmid pCCGW has a similar genomic organisation to pCSGW, 
except GFP expression is under the control of the CMV promoter (Figure 5-4). 
The infectivity and MFI of the two new GFP-pseudotypes were then compared.  
 
Under the CMV promoter, both the infectivity and GFP intensity were 
greater than had been observed under the SFFV promoter, although the increase 
in GFP intensity was more dramatic in CCL-fCD134 cells than MCC-fCD134 cells 
(Table 5-2 and Figure 5-3). In both cell lines, the percentage of infected cells 
increased by approximately 10%, with the infectivity in CLL-fCD134 reaching 
almost 100% (Table 5-2). The GFP intensity in CLL-fCD134 was 10 fold greater 
under the CMV promoter compared to the SFFV promoter (MFI of 4,3000,000 vs. 
352,000) (Table 5-2). These results indicated that the CMV promoter was more 
compatible with the target cells and therefore a new lentiviral vector expressing 
TagRFP under the control of the CMV promoter was developed, named “pCCRW”, 
using a similar protocol as described above for pCSRW (Section 5.2.1).  Using 
these new vectors, GFP and TagRFP-HIV(FIV) pseudotypes were prepared in 
order to investigate the role of the target cell in the selection of FIV variants 
within a quasispecies.  
 
Table 5-2 Percentage and mean fluorescence intensity (MFI) of VSVG 
pseudotypes carrying pCSGW or pCCGW in MCC-fCD134 and CLL-fCD134 cells    
 
 VSVG-GFP (pCSGW) VSVG-GFP (pCCGW) 
 percentage MFI percentage MFI 
MCC-fCD134 76.63% 3,150,000 89.32% 5,800,000 
CLL-fCD134 85.95% 352,000 99.92% 4,300,000 
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Figure 5-3 Representative images of MCC-fCD134 (top) and CLL-fCD134 (bottom) infected with 
VSVG pseudotypes carrying either pCSGW (left) or pCCGW (right). 10x objective magnification on 
Evos fl microscope (AMG micro, USA) 
 
 
 
Figure 5-4 Plasmid maps of pCSRW (A) and pCCRW (B), SFFV and CMV promoters are indicated by 
grey arrows for pCSRW and PCCRW, respectively. 
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5.3 Investigating the competition between infecting V5 FIV variants in the 
transmitted quasispecies for cell entry 
 
5.3.1 Development of competitive entry assay  
 
  The lower infectivity, as measured by the percentage of fluorescing cells 
and MFI, of the TagRFP-pseudotype was the result of a limitation of the Accuri 
C6 Flow cytometer. The optimal excitation wavelength for near-red FPs 
including TagRFP is ~550 nm (Shaner et al., 2008) and so under the blue laser at 
440 nm, the excitation and detection of TagRFP was suboptimal, approximately 
14-18%. Therefore, the proposal to directly compete two different HIV(FIV) 
pseudotypes, the first labelled with pCCGW (GFP) and the second with pCCRW 
(TagRFP), was not feasible. Therefore, to investigate the role of the target cell 
in FIV V5 variant selection after transmission, a competitive entry assay was 
developed. In this assay, the degree of competition was indirectly assessed by 
measuring the decrease in infectivity of a GFP-pseudotype (the principal) in the 
presence of a TagRFP-pseudotype (the competitor) (Figure 5-5). Although the 
suboptimal TagRFP excitation hindered its detection by flow cytometry, 
infection by TagRFP-pseudotypes could still be confirmed under the fluorescent 
microscope. 
 
In this assay, a pairwise competition for target cell entry was assessed 
between GFP pseudotypes bearing Envs of each of the V5 variants; GL8, B14, 
B19, B28 and B30 (principal) and TagRFP-pseudotypes bearing GL8 Env 
(competitor) or empty vector control (mock) (Figure 5-5A). CLL cells, expressing 
either feline CD134 (FFF) or the human/feline chimaeric CD134 molecule 
containing the CRD2 region of human CD134 (FFHH), were used as target cells 
(Figure 5-5A and Section 2.2.1.2). This assay was designed to mimic the natural 
setting where the number of target cells varies, both between tissue 
compartments (see Chapter 3) and at different phases of infection (see Chapter 
4). If the dominance of the CRD2-dependent GL8 Env, observed in CD4+CD134+ T 
lymphocyte-enriched compartments and during the earlier phase of infection, 
could be attributed to the higher entry fitness of the GL8 Env compared to the 
CRD2-independent V5 variants, then co-infection with GL8-TagRFP would 
significantly decrease GFP expression of the GFP-pseudotypes bearing the Envs 
of the V5 variants in CLL-FFF cells but not in cell lines expressing the chimaeric 
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CD134 (FFHH) molecule containing the CRD2 region of human CD134 (Figure 5-
5B). 
 
 
Figure 5-5 Outline of competitive entry assay (A); Each GFP-pseudotype (principal) bearing the 
Env of each of the V5 variants; GL8, B14, B19, B28 and B30 was competed with a TagRFP-
pseudotype bearing GL8 Env (competitor) or no Env (mock empty VR1012 vector control). 
Pairwise competition was performed in two target cells; CLL-FFF (expressing feline CD134 to 
detect CRD2-dependent entry) and CLL-FFHH (expressing chimaeric human/feline CD134 to 
detect CRD2-independent entry). GFP positive cells were measured after 48 hours. Schematic 
representation of predicted outcomes (B); in CLL-FFF cells, it was predicted that GL8-TagRFP 
and V5-GFP pseudotypes would compete with each other for receptor binding, resulting in green 
(V5-GFP), red (GL8-TagRFP) and yellow (co-infected) cells (left). In contrast, in CLL-FFHH cells, 
the CRD2-dependent GL8-TagRFP pseudotypes would not compete with V5-GFP and, as a result, 
green cells (V5-GFP) would predominate (right).  
 
Pseudotypes were prepared as described in Section 2.3.1. The quantity of 
each pseudotype was determined by HIV CA p24 immunoblotting (Section 2.3.6) 
(Figure 5-6) and concentrations were adjusted by diluting with R10 before the 
pairs of pseudotypes were mixed together, i.e. equal quantities of GL8-GFP were 
mixed with GL8-TagRFP or mock-TagRFP and similarly for the other V5 variants. 
One millilitre of each pseudotype pair was then added to each well of a 48 well 
plate (Corning, USA) containing 250 μl of either CLL-FFF or CLL-FFHH cells at 1 x 
105 cells/ml. Surface expression of CD134 and CXCR4 on each cell line was 
checked by flow cytometry to ensure a minimum of 99% of cells expressed the 
receptors (Section 2.3.7). Each pairwise competition was performed in 
triplicate. Each plate included six negative control wells, three inoculated with 
the empty VR1012-GFP and the remainder inoculated with VR1012-TagRFP 
pseudotypes. The plates were spinoculated at 800 x g for 60 minutes with no 
brake and then incubated for 48 hours at 37°C, 5% CO2. On day two, the plates 
were agitated to disperse the cells, which were then examined using an Accuri 
C6 Flow cytometer (BD bioscience). GFP and tagRFP signals from the negative 
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control wells were used to set cutoff values for the positive population and for 
fluorescence spill-over compensation. Experiments were performed three times. 
Percentage infection rates were calculated using the equation below:  
 
percentage infection = 
GFP positive 𝑝ercentage with competitor
GFP positive percentage with mock
 x 100 
 
 
 
Figure 5-6 Representative HIV CA p24 immunoblot. Pseudotypes were blotted onto a 
nitrocellulose membrane and detected following incubation with 1:1000 mouse anti-HIV p24 
antibody (183-H12-5C) followed by 1:1000 goat anti-mouse IgG DyLightTM 800. The fluorescence 
intensity was determined using the ODYSSEYTM system (LI-COR® Bioscience, Cambridge, UK) 
(Section 2.3.6). 
 
5.3.2 GL8 outcompeted V5 variants in CLL-FFF but not CLL-FFHH cells 
 
As shown in Figure 5-7A, in the presence of GL8-TagRFP, the percentage 
of cells infected with each V5 variant-GFP pseudotype decreased significantly. 
Moreover, the percentage of GFP positive cells decreased by 50% when GL8-GFP 
was competed with GL8-TagRFP (Figure 5-7A), confirming the reliability of the 
competitive entry assay. Examination of CLL-FFF cells by fluorescent microscopy 
revealed more red cells (GL8 infected cells) and yellow cells (co-infected cells) 
than green cells (B28 infected cells) (Figure 5-8 top panel). In contrast, co-
infection with GL8-TagRFP did not compete with V5 variants-GFP in target cells 
expressing chimaeric CD134 (CLL-FFHH) (Figures 5-7B and 5-8 bottom panel).  
 
p24  
GL8-GFP  B14-GFP  B19-GFP  B28-GFP  B30-GFP  GL8-RFP  VR1012-RFP  
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Figure 5-7 Representative result of competitive entry assay in CLL-FFF (A) and CLL-FFHH (B) 
cells. Each bar represents the average percentage of cells infected with the standard deviation. 
Statistical significance determined using paired T test.  
 
 
 
 
Figure 5-8 Representative images of CLL-FFF (top) and CLL-FFHH (bottom) cells, co-infected 
with GL8-TagRFP and B28-GFP pseudotypes and viewed under GFP (left), TagRFP (middle) and 
merged (right) channels. 10x objective magnification on Evos fl microscope (AMG micro, USA) 
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5.4 Investigating the role of CD8+ T lymphocytes as target cells  
 
 Inversion of the CD4:CD8 lymphocyte ratio is a key observation in both HIV 
and FIV infections (Yamamoto et al., 2007, Sykes, 2013). The inverted ratio 
results from both a decrease in CD4+ T lymphocytes as well as an increase in 
CD8+ T lymphocytes (Willett et al., 1993, Shimojima et al., 1998, Yamamoto et 
al., 2007, Hartmann, 2012, Sykes, 2013, Litster et al., 2014). Since the primary 
receptor for FIV infection, CD134, is expressed mainly on CD4+ T lymphocytes; 
inversion of the CD4:CD8 ratio might be another selective pressure on the FIV 
variants in the quasispecies during the course of infection (Willett et al., 2007, 
Willett and Hosie, 2013). As the number of CD4+CD134+ target cells declines, the 
increased number of CD8+ T lymphocytes (which may or may not express CD134) 
might select for FIV variants that are less dependent on CD134 for infection, 
such as the CRD2-independent V5 variants that emerged during the late stage of 
FIV infection (Kraase et al., 2010, Willett and Hosie, 2013). This hypothesis was 
supported by the observation that FIV targets cells other than CD4+CD134+ T 
lymphocytes, including CD8+ T lymphocytes, later in FIV infection (English et al., 
1993, Dean et al., 1996, Willett and Hosie, 2008, Willett and Hosie, 2013).  
 
The aim of this study was to investigate whether the appearance of CRD2-
independent V5 variants in the late stage of FIV infection was associated with 
the ability to infect CD8+CD134+/- T lymphocytes. To address this question, the 
susceptibility of CD8+CD134+/- T lymphocytes to infection by GFP-pseudotypes 
bearing V5-variant Envs was examined.  
 
5.4.1 In vitro expansion of T lymphocytes isolated from peripheral blood 
 
Peripheral blood mononuclear cells (PBMC) were isolated from blood 
collected in EDTA from FIV seronegative cats by standard density-gradient 
centrifugation using Ficoll-Paque PLUS (Section 2.2.2). To optimise the in vitro 
expansion of T lymphocytes, three freshly isolated cultures of PBMC were each 
subcultured into four wells of a 12 well plate in R10 medium. Cells in each well 
were then treated with 10 µg/ml phytohaemagglutinin (PHA) (Sigma–Aldrich, 
Germany), 5 µg/ml of concanavalin A (ConA) (Sigma–Aldrich, Germany), 200 
ng/ml mouse anti-feline CD3 monoclonal antibodies (in house) and 100 IU/ml 
recombinant feline IL-2 (in house), or R10 alone to serve as a negative control. 
172 
Cells were incubated at 37°C, 5% CO2 for 7 days before the expanded PBMCs 
were stained with anti-feline CD8-phycoerythrin and anti-feline CD134-
alexafluor 647 (AbD Serotec, UK) to determine their activation status, 
carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, USA)) to assess 
proliferation capacity and 7-aminoactinomycin D (7-AAD) (Invitrogen, USA) to 
measure viability (Section 2.3.7) (Appendix 5-1 and 5-2).  All analyses were 
performed using an Accuri C6 Flow cytometer with CFlow Plus software version 
1.0.227.4 (Beckton Dickinson bioscience, USA). 
 
All three stimulation protocols induced expansion of the PBMC cultures, to 
different degrees and with distinct characteristics. PBMC expansion following 
treatment with ConA and anti-feline CD3 was rapid; several small cellular 
clumps were observed at day four, increasing in size by day seven (Figure 5-9, 
bottom; middle-right and right). However, PHA stimulation resulted in the 
highest viability (95.54%), followed by anti-feline CD3 (85.55%) and Con A 
(74.59%) (Table 5-3 and Figure 5-10). The high viability of cells in the cultures 
stimulated with PHA might reflect its lower mitogenicity, since less cellular 
expansion was observed (3.67 fold) compared to ConA (7.75 fold) and anti-feline 
CD3 (4.44 fold), as shown in Table 5-3. Consequently, PHA appeared to be a 
good candidate for PBMC expansion, providing cells of high viability. However, 
PHA stimulation induced slower cellular proliferation and resulted in fewer cells, 
with final cell counts similar to those of the negative control. (Figure 5-9, 
middle-left). As insufficient cells were obtained following PHA-stimulation, these 
wells were excluded from further analyses. 
  
Table 5-3 Effect of each mitogen on PBMC viability and proliferation at day 
seven* 
 
 
mitogen** % viablility proliferation index*** 
no stimulant 95.89% (95.50% – 97.50%) 1 
phytohaemagglutinin 94.77% (94.50% – 97.34%) 3.67 (1.08 – 4.44) 
concanavalin A 72.05% (65.90% - 85.84%) 7.75 (4.53 – 25.77) 
anti-feline CD3 81.51% (80.64% - 94.51%) 4.44 (3.25 – 23.45) 
 
*Data shown as median values (with range) for three cats. **All mitogens supplemented with 100 
IU/ml recombinant feline IL-2. ***Proliferation index calculated as the cell number in mitogen-
treated culture/no mitogen control.  
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Figure 5-9 Representative images from inverted microscopy of PBMC at day 4 (top) and day 7 
(bottom), following stimulation with; R10 alone (left), PHA with IL-2 (middle-left), ConA with IL-
2 (middle-right) and anti-fCD3 antibody with IL-2 (right). 4x objective magnification on Evos fl 
microscope (AMG micro, USA).  
 
 
 
Figure 5-10 PBMC viability (A) and proliferation index (B) after stimulation with concanavalin A 
(ConA), phytohaemagglutinin (PHA) and anti-CD3 antibody (anti-CD3). All mitogens were 
supplemented with 100 IU/ml recombinant feline IL-2. Culture medium alone was used as a 
negative control. Proliferation index represents the ratio of cell number of culture with 
mitogen/no mitogen control. Each bar represents the median and range for three cats. Mann-
Whitney test. 
 
Both ConA and anti-feline CD3 antibody stimulation led to expansion of 
both CD4+ and CD8+ T lymphocyte subpopulations (Table 5-4 and Figure 5-11). 
However, there appeared to be a bias towards CD8+ T cell expansion following 
ConA stimulation, as reflected by a more marked inversion of the CD4:CD8 ratio 
in wells treated with ConA compared to anti-feline CD3 antibody (CD4:CD8 ratio 
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of 0.19 vs. 0.76)  (Table 5-4 and Figure 5-11). A similar degree of T lymphocyte 
activation, reflected by CD134 expression, was observed between the two 
cultures. Although anti-CD3 stimulation yielded higher viability and a more 
balanced CD4:CD8 population, the absolute lymphocyte numbers were 
insufficient for further investigations. This limitation reflected the small leftover 
sample volumes received from the diagnostic lab, usually less than 1 ml of 
blood. Therefore, ConA stimulation was adopted for the expansion of PBMC for 
subsequent experiments, as it induced more rapid expansion and higher 
lymphocyte numbers compared to anti-CD3 treatment. 
 
Table 5-4 Effect of concanavalin A and anti-feline CD3 antibody stimulation on 
lymphocyte subpopulations*  
 
 Con A** anti-feline CD3 
antibody** 
CD4+ percentage*** 19.8 (16.30 – 40.40) 44.90 (19.60 – 47.70) 
CD8+ percentage*** 80.10 (59.60 – 83.70) 59.10 (52.30 – 80.30) 
CD4:CD8 ratio 0.19 (0.17 – 0.25) 0.76 (0.24 – 0.91) 
CD134+ percentage*** 25.90 (11.90 – 39.90) 26.70 (8.10 – 34.30) 
 
*Data shown as median values (with range) for three cats. **All mitogens were supplemented 
with 100 IU/ml recombinant feline IL-2. ***Percentage of CD4+, CD8+ and CD134+ subpopulations 
in total lymphocytes. 
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Figure 5-11 Composition of lymphocyte subpopulations following ConA and anti-CD3 stimulation 
of PBMC. Left axis indicates percentage of CD4+, CD8+ and CD134+ subpopulations in total 
lymphocytes. Right axis indicates CD4:CD8 ratio. Each bar represents median and range of three 
cats. Mann-Whitney test. 
 
5.4.2 FIV infects CD4+CD134+ more efficiently than CD8+CD134+/- T 
lymphocytes 
 
 Next, PBMC from a further three cats (331776, 331777 and 331787) were 
treated with Con A and IL-2 in order to investigate the susceptibility of 
lymphocyte subpopulations to FIV infection. Expanded PBMC were first stained 
for CD4, CD8, and CD134 to determine the proportion of each lymphocyte 
subpopulation (Table 5-5).  In cats 331776 and 331787, both CD4+ and CD8+ T 
lymphocytes were expanded, but the former showed a higher proportion of CD4+ 
T lymphocytes whereas the latter was biased towards CD8+ T lymphocytes (Table 
5-5). In cat 331777, the expanded cultures contained mainly CD8+ T lymphocytes 
(Table 5-5). It was noted that CD134 was expressed on both CD4+ and CD8+ T 
lymphocytes, but whereas CD134 was expressed in almost 100% of the CD4+ T 
lymphocytes, expression in CD8+ T lymphocytes ranged from 14.7% - 87.60% 
(Table 5-6). Nonetheless, cell surface expression of CD134, as determined by 
mean fluorescence intensity, was higher on CD4+ than CD8+ T lymphocytes 
(median values 53,809 vs. 16,951, Table 5-6) 
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Table 5-5 Lymphocyte subpopulations of PBMC cultures*  
 
 %CD4 %CD4CD134 %CD8 %CD8CD134 
331776 49.4 48.9 21 20.6 
331777 0.7 0.7 92.9 14.2 
331787 18.1 17.9 55.7 34.9 
 
*values shown as percentage of total lymphocyte population 
 
Table 5-6 Proportions of CD134+ subpopulations and mean fluorescence intensity 
(MFI) of CD134 expression in CD4+ and CD8+ T lymphocytes  
 
 CD4+ T lymphocytes CD8+ T lymphocytes 
%CD134 MFI %CD134 MFI 
331776 99 53,809 87.6 16,951 
331777 99 50,879 14.97 4,738 
331787 97 54,834 60.9 19,362 
 
 In the culture from cat 331776 that contained a high proportion of CD4+ T 
lymphocytes (49.4% CD4 vs. 21% CD8, Table 5-5), the B28-GFP pseudotype 
preferentially infected CD8- T lymphocytes (6.8% in CD8- vs. 0.8% in CD8+) (Table 
5-7 and Figure 5-12 top panel). Moreover, even in the culture derived from cat 
331787 that contained more CD8+ than CD4+ T lymphocytes (18.1% CD4 vs. 55.7% 
CD8, Table 5-5), B28-GFP also infected more CD8- T lymphocytes, although the 
difference was less marked (3.1% vs. 1.0%) (Table 5-7 and Figure 5-12 bottom 
panel). In contrast, in the culture from cat 331777 that contained few CD4+ T 
lymphocytes (0.7% CD4 vs. 92.9% CD8, Table 5-5), the B28-GFP pseudotype 
infected more CD8+CD134- than CD8- T lymphocytes (2.4% vs. 0.4%) (Table 5-7 
and 5-12 middle panel). Although the B28-GFP pseudotype could infect the 
culture containing mostly CD8+ T lymphocytes (cat 311777, total GFP+ cells = 
2.8%), its infectivity was greater in cultures containing higher proportions of 
CD8- T lymphocytes (7.6% in cat 311776 and 4.2% in cat 311787).  
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Table 5-7 Percentage of GFP-positive cells in each lymphocyte subpopulation* 
 
 331776 331777 331787 
CD4 : CD8 49.4 : 21 0.7 : 92.9 18.1 : 55.7 
CD8+ 0.8 2.4 1.0 
CD8- 6.8 0.4 3.1 
CD134+ 6.0 0.0 3.0 
CD134- 1.6 2.8 1.2 
 
 
Figure 5-12 Representative contour plots of expanded lymphocyte cultures from three cats 
(331776, 331777 and 331787) that were infected with VR1012-GFP control (left column) and B28-
GFP pseudotypes (middle and right column). Top panel: cat no.331776 (CD4:CD8, 49.4%:21%), 
Middle panel: cat no. 331777 (CD4:CD8, 0.7%:92.9%) and Bottom panel: cat no. 331787 
(CD4:CD8, 18.1%:55.7%). The X-axes of each plot represent the log values for the fluorescence 
intensity of green fluorescent protein area (GFP-A) for VR1012-GFP and B28-GFP. The Y-axes in 
the left and middle columns represent log values for fluorescence intensity of phycoerythrin area 
(PE-A) for CD8-PE. The Y-axis in the right column show the log fluorescence intensity of Alexa 
fluor 647 area (A647-A) for CD134-A647. 
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The apparent selection of CD4+ T lymphocytes for FIV infection was likely 
associated with CD134 expression, as the majority of CD134+ T lymphocytes did 
not express CD8 (Figure 5-13). In addition, a trend was evident, demonstrating a 
positive correlation between the proportion of cells expressing CD134 and the 
percentage of cells infected (Figure 5-14). 
 
 
 
Figure 5-13 Representative contour plots of expanded lymphocyte cultures from three cats: 
331776, 331777 and 331787. The X-axis shows the log fluorescence intensity of the Alexa fluor 
647 area (A647-A)(for CD134-A647). The Y-axis shows the log fluorescence intensity of the 
phycoerythrin area (PE-A) for CD8-PE. 
 
 
 
Figure 5-14 Relationship between the percentage of CD134+ T lymphocytes in culture and 
infectivity of GFP-FIV pseudotypes. The X-axis shows the percentage of CD134+ T lymphocytes 
and the Y-axis shows the percentage of infected cells (GFP+) in the total lymphocyte population.  
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5.5 Discussion and Conclusion 
 
 The studies described in this chapter indicate that target availability 
exerts selective pressure on FIV quasispecies diversity. Findings from the 
competitive entry assay confirmed that pseudotypes bearing the Env of the 
CRD2-dependent strain GL8 infect CD134+ target cells more efficiently than 
pseudotypes bearing Envs of CRD2-independent V5 variants of GL8.  
 
The influences of the env gene on the efficiency of host cell entry have 
been shown previously for HIV (Ball et al., 2003, Rangel et al., 2003). However, 
some critical anti-retroviral drug (ARV) escape mutations in the pol gene also 
affected viral fitness (Rangel et al., 2003). Nevertheless, in the absence of these 
mutations in pol gene, the fitness of whole viruses and recombinant viruses 
expressing their Env on the HXB2 backbone were similar and in a statistically 
significant correlation, confirming the direct influence of Env in viral fitness 
(Rangel et al., 2003). In this chapter, by competing two pseudotypes bearing 
different Envs on the same backbone, the competitive entry assay permitted an 
investigation of the effect of Env polymorphisms on target cell entry.   
 
Although cell culture systems cannot mimic fully the target cell 
population, or the selective pressures exerted in vivo, the competitive entry 
assay developed here provided the first evidence of the impact of target cell 
availability in FIV selection. In this assay, target cells were provided in excess, 
i.e. there were sufficient target cells for infection by both the principal and 
competitor pseudotypes. Therefore, the effects of Env polymorphisms were 
assessed solely in terms of entry fitness in this scenario. This was evident when 
pseudotypes bearing the same Env (GL8) were competed against each other. 
Since these pseudotypes expressed the same Env, their entry fitness was, 
theoretically, equivalent and indeed target cells were infected with GFP- and 
TagRFP-tagged pseudotypes at a ratio of 1:1 (Figure 5-7A, first column). The 
competitive entry assay also demonstrated the greater entry fitness of 
pseudotypes bearing the Env of the CRD2-dependent GL8 over its CRD2-
independent variants for CD134+ target cells (CLL-FFF). Moreover, different 
entry fitness of pseudotypes bearing each V5 variant Env was also observed in 
which B19 was the fittest, followed by B28, B30 and B14 (Figure 5-7A).  
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 The observed higher entry fitness of GL8 for CD134+ target cell (CLL-FFF) 
infection is likely related to a high affinity interaction occurring between the 
GL8 Env and CD134 (Willett et al., 2007, Willett et al., 2010, Willett and Hosie, 
2013). It is possible that requirements for additional determinants on CRD2 
might provide GL8 Env with a higher binding affinity for CD134 compared to the 
CRD2-independent V5 variant Envs (Willett et al., 2007). The higher entry fitness 
of the CRD2-dependent GL8 Env for CD134+ target cells is consistent with 
previous findings in vivo, where the GL8 molecular clone replicated more 
efficiently in experimentally infected cats throughout a 21 week study period, 
compared to four other molecular clones with Envs of the CRD2-independent V5 
variants B14, B19, B28 and B30 in the same inoculum (Willett et al., 2013).  
 
Moreover, the higher entry fitness of GL8 for CD134+ target cells is 
consistent with the dominance of CRD-2 dependent viruses such as GL8 and 
NCSU1 early after transmission (de Parseval et al., 2004b, de Parseval et al., 
2005, Willett et al., 2006b). As CD4+CD134+ T lymphocytes are more abundant 
during the earlier phase of infection (Table 4-4 and Figure 4-4F), the higher 
entry fitness for CD134+ target cells would allow CRD2-dependent viruses to 
establish infection more efficiently than CRD2-independent viruses. However, 
the number of CD4+CD134+ T lymphocytes declines over the course of infection 
(Figure 4-7) and so the decreased proportion of CD134+ target cells likely exerts 
selective pressure on the virus population.  This would result in those FIV 
variants that require only a minimal interaction with CD134, such as the CRD2-
independent V5 variants described in this chapter, or field strains such as B2542, 
to predominate during the later stages of infection (Kraase et al., 2010, Willett 
and Hosie, 2013, Beczkowski et al., 2014b). 
  
One factor that influences viral entry fitness is entry stoichiometry. For 
HIV and FIV, stoichiometry is determined by the number of host cell receptors 
and viral trimers required for membrane fusion (Kuhmann et al., 2000, 
Brandenberg et al., 2015a). It was shown that different HIV isolates require 
between one to seven trimers per virion for productive membrane fusion 
(Brandenberg et al., 2015a, Brandenberg et al., 2015b, Zarr and Siliciano, 2015). 
It was notable that, while most of the primary isolates tested here required only 
two to three trimers for cell entry, laboratory-adapted isolates such as NL4-3 
and SF162 required many more (Brandenberg et al., 2015b).  
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Target cell entry by both HIV and FIV depends on the energy released 
following the conformational changes that occur in Env during sequential 
interactions with the primary cellular receptor and co-receptor (Elder et al., 
2008, Klasse, 2012, Harrison, 2015). In order for viral-cellular membrane fusion 
to occur, a certain energy threshold must be overcome (Klasse, 2012, Harrison, 
2015). Since Env has an open conformation in laboratory-adapted strains of HIV, 
the energetic state is low and therefore such strains require more trimers for 
infection (White et al., 2010, Munro et al., 2014, Brandenberg et al., 2015a, 
Munro and Mothes, 2015). It was reported that the Env of the CRD2-independent 
PPR strain adopted a similar open conformation (Hu et al., 2012). In addition, it 
is likely that the energy released following an interaction with determinants 
solely on CRD1 of the CD134 molecule is less than that released following an 
interaction involving both CRD1 and CRD2. Consequently, CRD2-independent 
variants would require more interacting molecules, both CD134 and Env trimers, 
compared to CRD2-dependent counterparts for successful membrane fusion. 
However, further studies focusing on FIV entry stoichiometry would be required 
to confirm this hypothesis. 
 
As well as the differences in Env structure, which are linked to 
conformational change-associated energy release, polymorphisms that alter Env 
processing and the number of trimers incorporated into the virion would also 
affect entry stoichiometry. For HIV, it was reported that mutations in gp120 
significantly decreased Env processing and resulted in increased numbers of 
uncleaved Env molecules (Blay et al., 2007). Although uncleaved Env could be 
incorporated into new virions, only cleaved Env was fusion competent (McCune 
et al., 1988, Herrera et al., 2005, Moore et al., 2006). Therefore viruses with a 
higher proportion of non-functional, uncleaved Env will have higher entry 
stoichiometry as more trimers will be required to increase the probability of 
there being sufficient functional molecules in the Env-receptor interaction. It 
was shown previously for HIV that V5 loop mutations altered Env processing and 
deletion of V5 led to virus assembly failure, which in turn hindered cell entry 
(Blay et al., 2007, Yuan et al., 2013). Therefore, it is possible that the lower 
entry fitness of the FIV V5 variants observed here, and their decreased 
infectivity in vivo, were related to the impact of their polymorphisms on Env 
processing (Willett et al., 2013). In addition to SU, polymorphisms within the HIV 
and FIV TM cytoplasmic tails have been shown to affect the intracellular 
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distribution of Env, which in turn affects Env incorporation into virions and viral 
replication capacity (Lambele et al., 2007, Affranchino and Gonzalez, 2014). 
Since the TM was identical in all of the V5 variants investigated here, however, 
it is more likely that V5 polymorphisms accounted for their lower replication 
fitness.  
 
In human beings, CD134 is predominantly expressed on activated CD4+ T 
lymphocytes (de Parseval et al., 2004a, Shimojima et al., 2004, Croft, 2010). 
However, human CD134 is not restricted to CD4+ T lymphocytes but is also 
expressed on CD8+ T lymphocytes (Watts, 2005, Croft, 2010). Upon encountering 
a specific peptide-MHC complex, both CD4+ and CD8+ T lymphocytes upregulate 
CD134, although the kinetics differ, with prolonged CD134 expression on CD4+ T 
lymphocytes compared to transient expression on CD8+ T lymphocytes (Croft, 
2010). CD134 signalling promotes the survival of both CD4+ and CD8+ T 
lymphocytes (Gramaglia et al., 1998, Bansal-Pakala et al., 2004). In contrast, 
feline CD134 expression was shown to be restricted to activated CD4+ T 
lymphocytes in the peripheral blood (Willett et al., 2007) and whether CD134 
was expressed on feline CD8+ T lymphocytes remained debatable. Indeed, in one 
study, CD8+ T lymphocytes did not express CD134, even after mitogenic 
stimulation (de Parseval et al., 2004a). However, it is possible that this finding 
was related to the sensitivity and specificity of the detection method that used a 
recombinant dimeric fusion protein, comprising PPR Env fused to the Fc portion 
of immunoglobulin G (IgG) to detect CD134 (de Parseval et al., 2004a). 
Subsequently, Willett et al. used the anti-feline CD134 antibody 7D6 to examine 
CD134 expression ex-vivo and in mitogen-stimulated PBMC (Willett et al., 2007). 
In freshly isolated PBMC, CD134 was detected mainly on CD4+ T lymphocytes and 
was not detected on CD8+ T lymphocytes. However, when PBMC were stimulated 
with mitogen, either using ConA or PHA, CD8+ T lymphocytes were shown to 
express CD134 (Willett et al., 2007). Expression of CD134 on ConA-stimulated 
CD8+ T lymphocytes was also observed in this study, although the level of 
expression varied markedly. While CD134 expression had been only 1 to 2% in the 
previous study (Willett et al., 2007), expression levels between 14 to 34.9% were 
observed in this study. Therefore, it appears likely that feline CD8+ T 
lymphocytes might also express CD134 in response to potent stimulation.  
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In this chapter, we investigated the susceptibility of CD8+ T lymphocytes 
to FIV infection using ConA-stimulated PBMC and observed that CD8+ T 
lymphocytes were susceptible to FIV infection, although less susceptible than 
CD4+ T lymphocytes (Brown et al., 1991, English et al., 1993, Willett and Hosie, 
2008). Intriguingly, in blood samples displaying a physiological range of CD4:CD8 
ratio, a preference for infection of CD4+ T lymphocytes was observed (Figure 5-
12). This is likely related to the level of CD134 expression, as the surface 
expression of CD134 was more than three times greater in CD4+ compared to 
CD8+ T lymphocytes (MFI of 53,809 vs. 16,951). This positive trend between 
CD134 expression and FIV infectivity had been observed previously in enriched 
splenic macrophages. LPS activation of macrophages led to a two-fold increase 
in CD134 expression, which in turn led to a two-fold increase in susceptibility to 
FIV infection (Willett et al., 2007). However, the preference for infection of 
CD4+ T lymphocytes might also be related to the higher proportion of CD134+ 
cells in the CD4+ T lymphocyte subpopulation. These findings not only confirm 
that FIV infects both CD4+ and CD8+ T lymphocytes, but also suggest a role for 
CD134 expression in the selection of FIV variants such as the CRD2-independent 
variants that emerged in the later stage of FIV infection (Brown et al., 1991).  
 
Due to sample limitations, insufficient target cells were available to 
conduct a competitive entry assay to determine whether CD4+ and CD8+ T 
lymphocytes specifically select for CRD2-dependent or CRD2-independent strains 
of FIV. It was proposed that in cultures containing high numbers of CD134+ target 
cells (derived from cats 331776 and 331787), GL8 would infect CD4+ T 
lymphocytes more efficiently than the CRD2-independent V5 variants as a result 
of the stronger interaction between GL8 Env and CD134 that was observed in the 
competitive entry assay. In contrast, it was predicted that in the culture with 
fewer CD134+ target cells (derived from cat 331777), the PBMC comprising 
mainly CD8+ T lymphocytes, CRD2-independent strains such as B28 would 
predominate, as shown in Figure 5-12 in which all B28-infected cells tested 
negative for CD134.  
 
These data, together with the results of the competitive entry assay 
support a role for CD134+ target cell availability in FIV pathogenesis. In the 
earlier phase of infection, CD134+ target cells, i.e. activated CD4+CD134+ T 
lymphocytes are abundant (as shown in Chapter 4). The higher entry fitness of 
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CRD2-dependent variants for CD134+ target cells would permit more rapid and 
efficient replication of such variants (Willett et al., 2013, Willett and Hosie, 
2013), leading to a marked decline in CD4+ T lymphocyte numbers in the acute 
phase of infection (Yamamoto et al., 2007, Hartmann, 2012, Sykes, 2013). As 
disease progresses, the number of CD4+CD134+ T lymphocytes progressively 
declines and this eventually leads to the emergence of CRD2-independent 
variants, which are less dependent on CD134 for infection (Kraase et al., 2010, 
Beczkowski et al., 2014b). Therefore, the appearance of CRD2-independent 
variants is most likely the result of selective pressure from the declining 
numbers of CD4+CD134+ target cells, which occurs concurrently with the 
expansion of FIV tropism towards CD8+ T lymphocytes and B-lymphocytes in the 
later stage of infection (Brown et al., 1991, Beebe et al., 1994, Dean et al., 
1996, Willett et al., 2007, Willett and Hosie, 2008, Kraase et al., 2010, Willett 
and Hosie, 2013, Beczkowski et al., 2014b).  
 
One of the main difficulties encountered during this study was the 
limitation in fluorescent reporter proteins. Using GFP and TagRFP, competition 
between FIV variants could only be investigated in pairs. It would be necessary 
to develop an assay allowing simultaneous infection of target cells with multiple 
pseudotypes, each with different Envs and fluorescent proteins, to more closely 
mimic the diverse polymorphism of FIV quasispecies. With such tools, it would be 
possible to unravel the role of target cell-specific selection in FIV infection more 
extensively. Recently, new red fluorescent proteins (RFP) with compatible 
excitation wavelength have been developed, which could be used to improve the 
flow cytometric assay described here. Another candidate fluorescent protein is 
the short-red fluorescent protein large stokes shift mOrange (LSSmOrange) 
(Shcherbakova et al., 2012, Pletnev et al., 2014) that, with its excitation and 
emission at 437 and 572 nm, respectively, could potentially solve the suboptimal 
excitation issue of TagRFP (Section 5.1). However, as LSSmOrange was 
developed for live cell imaging, its utility in flow cytometry-based techniques 
remains to be confirmed. Two other promising candidates are E2-Crimson and 
TagRFP657; both have a maximal excitation wavelength of 611 nm, which is 
compatible with a standard red laser (640 nm) and can also be detected by a far-
red detector (Strack et al., 2009, Morozova et al., 2010, Piatkevich and 
Verkhusha, 2011). Using these new FPs should permit the optimal detection of a 
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second pseudotype and might lead to the testing of three pseudotypes 
simultaneously in the future.  
 
 Another direction for further investigations is an examination of the 
impact of CD134 surface expression on FIV selection. It appears likely that the 
susceptibility of cells to FIV infection depends on the level of CD134 expression. 
This speculation is based on the observation that the CRD2-independent variant 
B28 used in this study selectively infected CD4+ T lymphocytes with higher 
surface expression of CD134. Selective infection of target cells expressing higher 
levels of CD134 would promote FIV infection. As CD134 is only expressed on 
activated T lymphocytes, targeting infection to cells with the most active 
cellular machinery would ensure successful infection following viral transmission 
(Gramaglia et al., 1998, Walker et al., 1999, Croft, 2010). In addition, the 
increased longevity of CD134+ T lymphocytes permits sustained FIV production 
and expansion (Gramaglia et al., 1998, Watts, 2005, Croft, 2010). Furthermore, 
signalling via CD134 increases T lymphocyte migration, which in turn promotes 
FIV dissemination (Evans et al., 2001, Prell et al., 2003).  
 
As a first step to addressing this issue, a novel CLL cell line with inducible 
CD134 expression was developed. This CLL cell line was transduced with pLKO-
fCD134-IP plasmid, a lentiviral vector which expresses feline CD134 under the 
CMV promoter (Appendix 5-3). The plasmid was produced by replacing TagRFP 
(the original plasmid was pLKO-TagRFP-IP, kindly provided by Dr.Sam Wilson) 
with fCD134 from pDON-AI-fCD134 following double digestion with BmtI and 
EcoRI (Willett et al., 2006b). This plasmid constitutively expresses the 
tetracycline repressor (TetR) protein, which in turn binds to a tet operator 
sequence (tetO) located downstream of the CMV promoter and inhibits CD134 
expression. Following the addition of tetracycline or doxycycline, TetR is 
released from tetO, turning on fCD134 expression (Wiederschain et al., 2009). 
However, the repression by TetR was incomplete, which resulted in basal CD134 
expression of approximately 80% CLL-FFF cells (Appendix 5-4). This leakage 
prevented further use of this cell line.  
 
Recently, there was a novel development in tetracycline inducible gene 
system technology. The pCMV-Tet3G expressed a gene of interest under the 
control of a TRE3G promoter (Clontech, Takara Bio Europe SAS, France). Unlike 
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pLKO-fCD134-IP, which relies on TetR control, this plasmid constitutively 
expresses Tet-on® 3G protein which is activated following the addition of 
doxycycline, then binds tetO and drives the TRE3G promoter (Kit manual). The 
manufacturer claims that activation of Tet-on, rather than repression, results in 
significantly lower basal expression levels and higher expression levels. Since 
efficient control of CD134 expression on the target cell surface will be necessary 
for the successful investigation of its role in FIV selection, further development 
of CLL-inducible CD134 cells could be pursued using this new pCMV-Tet3G 
plasmid.  A conundrum remains: if the susceptibility of cells depends on CD134 
expression, how do CRD2-independent variants infect CD8+ T lymphocytes more 
efficiently than CRD2-dependent variants, if CRD2-dependent variants display 
more efficient CD134-dependent entry? Surely the logical conclusion would be 
that CRD2-independent variants should only replicate in the absence of CD134 
expressing cells? 
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Chapter 6 Final Conclusion 
 
6.1 Introduction 
 
The current study was designed to investigate the role of CD134+ target 
cell availability in the pathogenesis of FIV infection. By examining CD134+ target 
cells in tissues as well as the peripheral blood of experimental and naturally 
infected cats, this study demonstrated that the number of target cells is one of 
the players, commonly disregarded, in the multifactorial host-virus interaction. 
Results from Chapter 3 have shown that the number of permissive target cells in 
the tissues could exert selective pressure on the FIV variant population, 
promoting the expansion of the fittest variant and leading to the phenomenon of 
“tissue compartmentalisation”. Moreover, the level of CD4+CD134+ T 
lymphocytes at different stages of infection could also play a role in FIV tropism 
switching and the emergence of variants less dependent on CD134 for infection.  
 
6.2 The role of CD134+ target cell availability in tissue compartmentalisation 
 
In Chapter 3, the effects of sequence variation in the V5 region of Env 
were examined and were shown to affect the utilisation of CD134 for infection, 
thereby leading to FIV tissue compartmentalisation. Moreover, a correlation was 
observed between the number of CD134+ target cells and the pattern of tissue-
specific selection, at least in the bone marrow and thymus. Although the 
elucidation of the direct mechanisms leading to the compartmentalisation of FIV 
variants was limited by the nature of the available tissue samples and the 
approaches adopted, we proposed that the numbers and types of target cells in 
tissues could exert a selective pressure on FIV variants migrating through the 
tissues together with anatomical barriers. A proposed model for the role of 
resident CD134+ target cell availability in FIV tissue compartmentalisation is 
depicted in Figure 6-1.  
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Figure 6-1 Proposed model for the role of resident CD134+ target cell availability in FIV tissue 
compartmentalisation 
 
Following transmission to a new host, before the appearance of FIV-
specific immune responses, FIV quasispecies disseminate throughout the body. 
Compartmentalisation of individual FIV variants within the quasispecies depends 
on the type and number of target cells inside the tissues. Tissue compartments 
with high levels of CD4+CD134+ T lymphocytes, such as draining lymph nodes, 
would support the more rapid and efficient replication of CRD2-dependent 
variants, reflecting the higher entry fitness of CRD2-dependent variants for 
CD134+ target cells. In contrast, tissues with fewer CD4+CD134+ T lymphocytes, 
such as the thymus, might select for CRD2-independent variants that are less 
dependent on CD134 for infection. 
 
6.3 The dominance of CRD2-dependent virus in the early phase 
 
It was suggested that differences in pathogenicity between R5 and X4 
variants of HIV might explain the early dominance of R5 viruses after 
transmission (Rodrigo, 1997). Since X4 viruses induce syncytium formation while 
R5 viruses do not, R5-infected cells would survive longer than cells infected with 
X4 variants, such that R5 virus replication would be more sustainable. However, 
this hypothesis might not extend to FIV infection as both CRD2-dependent and 
independent strains can induce syncytium formation (Shimojima et al., 2004, 
Dietrich et al., 2011b), because both require CXCR4 for infection and syncytium 
formation by FIV is dependent on CXCR4-binding (Willett et al., 1997, Willett et 
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al., 1998). Moreover, it was reported that the cell culture-adapted strain PETF14, 
which can infect target cells independently of CD134, was less virulent than the 
CRD2-dependent strain GL8 (Hosie et al., 2002). Thus, the early dominance of 
CRD2-dependent viruses is more likely attributable to other characteristics that 
provide some fitness advantage, rather than differences in pathogenicity. 
 
It has been shown in HIV-infection that specific immune responses play an 
important role in HIV tropism switching (McKnight and Clapham, 1995, McKnight 
et al., 1995). By analogy to HIV, differences in immune-evasion properties 
between CRD2-dependent and -independent FIV variants could contribute to 
their dominance in vivo. Data from previous studies suggest that CRD2-
independent variants might be more susceptible to specific antibody 
neutralisation as the Env of CRD2-independent variants adopts a more “open” 
conformation, exposing neutralisation epitopes (Hu et al., 2012), as well as 
lacking some potential N-linked glycosylation sites (Willett et al., 2008). The 
finding that mutations in key amino acid residues on the V3 and V5 loops of the 
Env of the FIV strain PETF14 in vivo, which resulted in the loss of CD134-
independent infectivity, restored the virulence of PETF14 to that of the CRD2-
dependent GL8 strain, provides further evidence that CRD2-independent virus 
strains are more susceptible to neutralisation (Hosie et al., 2002). Therefore, it 
is most likely that the early dominance of CRD2-dependent variants is associated 
with the Env of such variants being highly “shielded” from NAb.  
 
6.4 Emergence of CRD2-independent virus variants 
 
CRD2-independent viruses were reported in several experimental studies, 
following the inoculation of cats with a molecularly cloned strain of FIV (Hosie et 
al., 2002, Kraase et al., 2010). These studies strongly argued that CRD2-
independent viruses emerged as a result of de novo evolution of CRD2-
dependent variants. The late appearance of CRD2-independent variants is 
consistent with this argument. In HIV infection, the switching from R5 to X4 
tropism was reported to be a sequential process, requiring a step-by-step 
fixation of multiple mutations in the population before the switch was complete 
(Pastore et al., 2004, Salemi et al., 2007). Moreover, the FIV env gene has been 
reported to be genetically stable, with relatively low divergence over time 
(Ikeda et al., 2004, Motokawa et al., 2005, Beczkowski, 2013). Thus, the 
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emergence of CRD2-independent variants in the later stage of infection might 
merely be related to the slow evolutionary rate of FIV, which requires a longer 
time to accumulate sufficient mutations for the switch to CRD2-independence. 
However, the question is why?  If CRD2-independence decreases FIV entry fitness 
and renders the virus more susceptible to neutralisation, what might be the 
evolutionary advantage for virus that is less dependent on CD134 for infection?  
 
6.5 The role of target cell availability in the emergence of CRD2-independent 
virus variants 
 
In this thesis, it was discovered that the number of CD4+CD134+ T 
lymphocytes was dynamic at different stages of FIV infection. The very high 
levels of CD4+CD134+ T lymphocytes observed in the early phase gradually 
declined over the course of infection (Chapter 4). Also, CRD2-independent 
variants of FIV had lower entry fitness for CD134+ target cells than their CRD2-
dependent counterparts but were able to infect CD8+CD134+/- T lymphocytes 
(Chapter 5). Thus, by becoming less dependent on CD134 for infection, CRD2-
independent variants are capable of infecting a broader spectrum of target cells, 
sustaining the virus population in the later stage of infection, when activated 
CD4+CD134+ T lymphocytes are limiting. Considering these findings, we propose 
that the emergence of CRD2-independent variants of FIV is influenced by 
CD4+CD134+ T lymphocyte availability. Figure 6-2 illustrates the model proposed 
here for the clinical course of FIV infection.  
 
 
 
Figure 6-2 Proposed model for the role of CD134+ target cells in the emergence of CRD2-
independent variants of FIV 
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In the proposed model, the switch that has been observed between CRD2-
dependent FIV isolates with high CD134 affinity (such as GL8 and CPG41), which 
dominate in early infection and CRD2-independent isolates requiring a less 
stringent interaction (such as PPR), which arise during the later stages of 
infection, is related to the size of the CD134+ target cell population. During the 
primary infection phase, generalized immune activation results in increased 
numbers of CD134-expressing CD4+ T lymphocytes (blue solid line). These high 
numbers of activated CD134+ target cells favour the expansion of “early”, CRD2-
dependent variants (dotted red line) with a high affinity for CD134. As disease 
progresses, the numbers of CD4+CD134+ T lymphocytes decrease irreversibly, as a 
result of exhaustion and dysregulation of the immune system. This depletion of 
the CD134+ target cell population leads to the expansion of “late”, CRD2-
independent variants (dotted green line), which outgrow the CRD2-dependent 
variants.  
 
6.6 CRD2-independent virus variants hiding place? 
 
The proposed model, illustrated in Figure 6-2 above, is based on the 
assumption that a mixed population of CRD2-dependent and -independent 
viruses is transmitted in the quasispecies. The natural route of FIV transmission 
via biting and exposure to infected blood is consistent with this assumption 
(Hosie et al., 2009, Sykes, 2013). However, if both CRD2-dependent and –
independent variants were indeed transmitted together, where do CRD2-
independent viruses reside during the early phase of infection?  
 
According to the data presented in Chapter 3, we speculate that CRD2-
independent variants reside in tissue compartments such as thymus, in a latent 
stage. This speculation has its basis in a model proposed for HIV suggesting that 
HIV latency is generated during thymopoiesis (Brooks et al., 2001). The 
transcription machinery of immature thymocytes, which are highly active during 
the early stages of thymopoiesis, becomes quiescent after maturation. In the 
thymus, high CXCR4 expression and the lack of CD134 expression on thymocytes 
would provide CRD2-independent variants with a selective advantage over CRD2-
dependent variants (Kitchen and Zack, 1997, Zaitseva et al., 1998, Willett et al., 
2007). Therefore, if CD134-CXCR4+ immature thymocytes were infected with 
CRD2-independent variants during their development, they would become 
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latently infected naïve T lymphocytes awaiting activation after migrating out of 
the thymus into the periphery. This hypothesis is supported by HIV studies that 
suggested a role for the thymus in the emergence of X4 viruses. In HIV infected 
patients, there is a unidirectional flow of X4 viruses from the thymus to the 
lymph nodes that is consistent with the migratory route of CD4+ recent thymic 
emigrants (Salemi et al., 2007). In addition, in a group of maraviroc (CCR5 
antagonist)-treated patients, X4 viruses emerged from a pretreatment reservoir 
(Westby et al., 2006). However, the tissue in which these X4 viruses resided was 
not identified in the study. 
 
6.7 Concluding remarks 
 
In summary, this current study demonstrates the importance of target cell 
availability in the pathogenesis of FIV infection. Target cell types and numbers in 
tissues, as well as their dynamics were observed to play important roles in the 
selection and expansion of FIV quasispecies in both experimentally and naturally 
infected cats. Nevertheless, it is likely that the model proposed here is not 
restricted to FIV infection but most likely applies to any viral infection in which 
a heterogeneous population is transmitted simultaneously, such as HIV or HCV.  
Improved understanding of the pathogenesis of infection will inform the future 
development of vaccine strategies that will be effective in preventing 
transmission of virulent circulating viral variants.  
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Appendices 
 
Appendix 3-1 Characteristics of V5 variants in terms of CD134 usage, sensitivity 
to neutralising antibodies and FIV-CD134 antagonists* 
 
 GL8 B19 B30 B14 B28 
CRD2- 
dependenta 
yes no no no no 
Nabsb + - - - - 
α-CD134c - +/- +/- + + 
sFc-CD134d + + + - - 
sFc-CD134Le - - - + + 
 
*adapted from (Willett et al., 2010), B14, B19, B28 and B30 were FIV variants with different V5 
loop sequences (V5 variants), which emerged at 322 weeks post infection with FIV clade A strain 
GL8 (UK8, accession no: X69496.1) in cat A613 (Kraase et al., 2010). Env of these V5 variants 
were observed with different characteristics including CD134-usagea, sensitivity to neutralizing 
antobidiesb and different FIV-CD134 antagonistsc-e. aCD134 CRD2-dependency as determined by 
FFF/FFHH ratio (section 2.3.2); yes = CRD2-dependent, no = CRD2-independent (Willett et al., 
2010). Sensitivity to neutralising antibodies and FIV-CD134 antagonists; + = sensitive, +/- = 
intermediate and - = resistant, bsensitivity to neutralizing antibodies (NAbs), pseudotypes was 
incubated autologous plasma of cat A613 collected post-mortem (Willett et al., 2010). 
csensitivity to anti-feline CD134 antibody, clone 7D6 (α-CD134) (Willett et al., 2007), target cells 
were incubated with antibodies 30 minutes before infection, dsensitivity to soluble-Fc tagged-
CD134 (sFC-CD134) (Willett et al., 2009), pseudotypes were cultured with SFC-CD134 30 minutes 
before infection and esensitivity to soluble-Fc tagged-CD134 ligand (sFc-CD134L) (Willett et al., 
2009),  target cells were incubated with sFc-CD134L30 minutes before infection. Different 
sensitivity to FIV-CD134 antagonists possibly reflects CD134-binding affinity. It is very likely that 
interactions between CD134 and Env of B14 and B28 variants (dark blue highlighted) are weaker 
than that of B19, B30 (blue highlighted) and GL8 as they were sensitive to α-CD134 and sFC-
CD134L antagonisms. Sensitivity of B19 and B30 to the antagonists are very similar to GL8, 
although they are intermediately sensitive to α-CD134 antagonism.  
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Appendix 3-2 Comparisons of FIV PVL (copies/106 cells) between visceral (11) and lymphoid 
organs (10) as determined by gag (A, C) and GL8 V5 (B, D) quantitative PCR (qPCR). A and B 
showed median cumulative quantity of each tissue type with range for four cats. C and D showed 
median of median quantities for each tissue type with range for four cats. Y-axis begins at the 
lower limit of detection (≤10 copies/106). Mann-Whitney test.  
 
Appendix 3-3 Two-way ANOVA results of FIV PVL as determined by each set of 
primer and probea,b 
 
 Interaction Compartments Variants 
B14, B19, 
B28, B30 
31.07  
(p < 0.0001****) 
10.04  
(p = 0.0186*) 
2.56  
(p = 0.0494*) 
gag, GL8 V5 12.86 
(p = 0.3114) 
29.27 
(p = 0.0019**) 
1.776 
(p = 0.1121) 
 
aTwo-way ANOVA with Tukey’s multiple comparisons, average quantity of each variant of the 
four cats was analysed as column factor while individual compartment as row factor. 
bTable shows percentage of total variance, p value is shown in bracket. 
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Appendix 3-4 Comparisons of FIV PVL (copies/106 cells) between 22 tissue compartments as 
determined by GL8 V5 (pink), B14 (orange), B19 (drab), B28 (green) and B30 (blue) quantitative 
PCR (qPCR) of each individual cat A825 (A), A826 (B), A827 (C) and A828 (D). Quantification of 
PVL was performed in triplicate. Each bar represents the mean with standard deviation for the 
triplicates. The Y-axis is shown from the lower limit of detection (≤10 copies/106). Kruskal-Wallis 
test 
 
 
Appendix 3-5 Individual PCA plots of cats A825 (A and B), A826 (C and D), A827 
(E and F) and A828 (G and H). X-axis and Y-axis shows PC1 and PC2, 
respectively. The PC value, which indicates the percentage of the original 
variable that could be explained by that PC, was located at the lower left region 
of the figures. Loading plots, which demonstrate the relationship between each 
of the 22 compartments investigated in this study are shown on the left (Figure 
A, C, E and G). Score plots, which demonstrate the driver (PVL of each of the 
five Env V5 variants investigated in this study), of the relationship observed in 
loading plot are shown on the right (Figure B, D, F and H).  
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PCA loading (A) and score (B) plots of Cat A825. X-axis and Y-axis shows PC1 and PC2, which accounted for 74% and 21% of the variables, respectively. Together, 
these two PC explain 95% of all the variables. In the bi-plot (PC1 + PC2), tissue compartments were grouped together into five clusters (marked by red circle) according 
to the PVL of each of the five V5 variants determined. On PC1 (X-axis), most of tissue compartments  (three clusters on the left hand side, Figure A), including both 
lymphoid and visceral organs were grouped together by the PVL of GL8 V5 (Figure B). The rest of the compartments were grouped together by PVL of the other four V5 
variants (B14, B19, B28 and B30). There was evidence of separation between GL8 V5 and its V5 variants, in which B14, B19 and B30 are more close to each other 
compared to B28, on PC1 (X-axis). On PC2 (Y-axis), the grouping of submandibular LN, tonsil, mediastinal LN, thymus, small intestine and PBMC was driven by their B28 
PVL. The grouping of the remainder was driven by the PVL of GL8 V5 and its three V5 variants, B14, B19 and B30. Again, B28 appeared separate from the other V5 
variants investigated in this study, which strongly suggested that the selective pressure for B28 is different than for the other V5 variants. When both PC were analysed 
together, GL8 V5 PVL appeared to be the main driver of visceral organs while most of the lymphoid organs were grouped together by the combination of both B28 and 
GL8 V5 PVL in this cat. The rest of the tissues were influenced by the PVL of B14, B19 and B30.  
A B 
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PCA loading (C) and score (D) plots of Cat A826. X-axis and Y-axis shows PC1 and PC2, which accounted for 66% and 19% of the variables, respectively. Together, 
these two PC explain 85% of all the variables. In these two PCs (PC1 + PC2), tissue compartments grouped together into four clusters according to the PVL of each of 
the five V5 variants determined. In this cat, B14 appeared to be the least influential driver of the relationship, which in line with its low quantity, since it was only 
detected in the liver (Figure 3-7 and Appendix 3-5B). GL8 V5 PVL appears to be the main driver for most of the tissues on PC1 (X-axis) with additional influence from 
B14, B19 and B30 PVL on PC2 (Y-axis). Interestingly, B28 PVL appears to be the main driver for the cluster of thyroid and thymus, separating them from the rest of the 
tissue compartments on both PC1 and PC2.  
 
  
C D 
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PCA loading (E) and score (F) plots of Cat A827. X-axis and Y-axis shows PC1 and PC2, which accounted for 53% and 27% of the variables, respectively. Together, 
these two PC explain 80% of all the variables. In this cat, most of the tissues were grouped together (two major clusters on the right side of Figure E) by the PVL of 
both B28 and B30 (F), while bone marrow, popliteal LN, liver and PBMC were driven by GL8 V5 and B19 on PC1 (X-axis). Similar to A826, B14 showed the least influence 
as its PVL was very low and detectable only in PBMC (Figure 3-7 and Appendix 3-5C). On PC2 (Y-axis), tissue compartments were separated into three groups in which, 
similar to PC1, bone marrow, popliteal LN and liver were driven by GL8 V5 PVL (in the middle), a second group composed mainly of lymphoid organs, driven by B30 and 
partially by B19 (above zero on Y-axis) and a third group composed mainly of visceral organs including thymus were driven by B28 (below zero on Y-axis).  
 
E F 
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PCA loading (G) and score (H) plots of Cat A828. X-axis and Y-axis shows PC1 and PC2, which accounted for 58% and 26% of the variables, respectively. Together, 
these two PC explain 84% of all the variables. On both PC1 and PC2, most of the tissues were grouped together under the influence of B19 PVL. Stomach and intestine 
were driven by B30 PVL and were grouped together at the top of the plot whereas bone marrow and the remaining tissues were driven by GL8 V5 PVL. The dominance 
of B28 in the thyroid explains its separation from the rest of the tissues at the far left corner of the plot. Unlike the other three cats in which GL8 V5 and B28 appeared 
to be on the opposite direction of the plot, they were positioned close to each other. This might be related to the undetectable PVL in the thymus of this cat by any 
qPCR, since the influence of B28 PVL on the position of thymus was the only consistent pattern observed in the other three cats (Appendix 3-5)
G H 
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Appendix 3-6 FIV PVL in thymus and bone marrowa 
 
 GL8 V5 B14b,c B19 B28c B30 
bone 
marrow 
108,883 
(14,967 – 
218,000) 
- 9,675 
(2,090 – 
13,800) 
- 1,606  
(632 – 
5,553) 
thymus 71,200 
(5,727 – 
865,333) 
- 27,300 
(5,900 – 
37,150) 
217,000 
(167,333 – 
1,397,646) 
30,667 
(19,967 – 
61,700) 
 
a
median (copies/106 cells with range in brackets) was calculated from PVL of four cats.  
bB14 and B28 were undetectable in bone marrow of all cats. 
cB14 was only detectable in thymus of A825. 
 
Appendix 3-7 Level of CD134 and CXCR4 mRNA in nine tissues of four cats* 
 
 CD134 mRNA (range) CXCR4 mRNA (range) 
A825 1,190 (584 – 2,823) 3,306 (1,177 – 37,846) 
A826 2,494 (946 – 4,892) 13,787 (1,314 – 56,609) 
A827 1,715 (307 – 3,067) 3,544 (1,764 – 35,009) 
A828 1,897 (575 – 4,144) 6,838 (1,892 – 49,295) 
 
*median of nine tissues; thyroid gland, spleen, submandibular lymph node, retropharyngeal 
lymph node, prescapular lymph node, mesenteric lymph nodes, popliteal lymph node, bone 
marrow and thymus gland. 
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Appendix 3-8 Level of CD134 and CXCR4 mRNA in nine tissue compartments* 
 
 CD134 mRNA (range) CXCR4 mRNA (range) 
thyroid 1,187 (946 - 1,697) 4,827 (2,515 – 7,219) 
spleen 1,149 (575 - 2,669) 2,730 (1,773 – 5,167) 
submandibular LN 950 (747 - 2,851) 7,366 (1,764 – 16,528) 
retropharyngeal LN 1,774 (307 - 3,130) 11,845 (3,306 – 30,553) 
prescapular LN 2,505 (2,162 - 3,674) 32,224 (7,912 – 45,662) 
mesenteric LN 3,484 (1,714 - 4,892) 36,428 (24,402 – 56,609) 
popliteal LN 2,306 (1,037 - 3,067) 2,096 (1,177 – 3,293) 
bone marrow 1,619 (1,031 - 2,618) 2,285 (1,514 – 3,153) 
thymus 2,268 (1,190 - 2,534) 17,281 (6,817 – 49,295) 
 
*median of four cats; A825 – A828, plasmid copies number   
 
Appendix 3-9 CD134 mRNA:CXCR4 mRNA ratio of each tissue* 
 
 
 A825 A826 A827 A828 median 
thyroid 0.47 0.34 0.24 0.18 0.29 
spleen 0.33 0.52 0.51 0.27 0.42 
SMLN 0.09 0.17 0.42 0.42 0.30 
RPLN 0.50 0.16 0.09 0.06 0.12 
PSLN 0.27 0.07 0.09 0.08 0.08 
MSLN 0.07 0.09 0.05 0.17 0.08 
PLN 2.21 0.79 0.93 0.70 0.86 
BM 0.68 0.74 0.83 0.68 0.71 
thymus 0.17 0.18 0.10 0.05 0.14 
median 0.33 0.18 0.24 0.18 0.25** 
 
*mRNA quantifications were performed in triplicate, ratios calculated from the mean of 
triplicates  
**median of all tissues of four cats 
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Appendix 3-10 Comparisons of the level of CD134 and CXCR4 mRNA in three 
tissue compartments of the FIV negative and positive cats* 
 
 CD134 mRNA (range) CXCR4 (range) 
FIV negative FIV positive FIV negative FIV positive 
bone marrow 98  (68 - 368) 388 (286 - 582) 114 (86 - 441) 343 (164 - 486) 
spleen 37 (16 - 58) 248 (172 - 492) 13 (2 - 22) 145 (46 - 331) 
thymus 363 (94 - 645) 334 (181 - 602) 2,238 (32 – 3,145) 1,049 (434 – 3,101) 
 
*median of three cats; FIV negative A810 – A812, FIV positive  A825 – A827, plasmid copies 
number   
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Appendix 4-1 Type and number of tests requested between groups 
 
Test requested* FIV negative FIV positive 
detectable 
PVL 
undetectable 
PVL 
Feline gingivitis profile 
(FHV & FCV isolation, FeLV Ag, FIV Ab) 
27 4 2 
Feline neurological profile 
(FeLV Ag, FIV & FCoV Ab, Toxoplasma 
gondii Ab) 
4 1  
Feline pyrexic profile 
(FeLV Ag, FIV & FCoV Ab, haematology, 
ALP, ALT) 
2 1  
Feline uveitis 
(FeLV Ag, FIV & FCoV Ab, Toxoplasma 
gondii Ab) 
4 2 1 
FeRV profile (FeLV Ag + FIV IF) 52 15 1 
FeRV profile + FPV profile (FPV PCR & Ab)  1  
FeRV + FCoV (FCoV Ab) 3  1 
FeRV + FIP (FCoV Ab, α1-AGP, 
haematology/cytology) 
2   
FeLV Ag (ELISA) 14   
FIV + FCoV + FCV (FeLV Ag,  2   
FCoV + Chlamydia felis PCR 1   
FHV + Chlamydia felis PCR 1   
Chlamyia felis PCR 1   
FIV Western Blot   1 
FIV Ab (Immunofluorescence) 1 56 8 
total 114 80 14 
 
* Ag = antigens, Ab = antibodies, α1-AGP = alpha-1-acid glycoprotein, FCV = feline calicivirus, 
FCoV = feline coronavirus, FeLV = feline leukaemia virus, FeRV = Feline Retrovirus, FIV = feline 
immunodeficiency virus, FHV = feline herpesvirus, FPV = feline parvovirus 
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Appendix 4-2 Type and number of tests requested between groups 
 
Test requested* FIV negative FIV positive 
Healthy** sick Healthy sick 
Feline gingivitis profile 
(FHV & FCV isolation, FeLV Ag, FIV Ab) 
1 26  4 
Feline neurological profile 
(FeLV Ag, FIV & FCoV Ab, Toxoplasma 
gondii Ab) 
 2  1 
Feline pyrexic profile 
(FeLV Ag, FIV & FCoV Ab, haematology, 
ALP, ALT) 
 5  1 
Feline uveitis 
(FeLV Ag, FIV & FCoV Ab, Toxoplasma 
gondii Ab) 
1 3  2 
FeRV profile (FeLV Ag + FIV IF) 14 8 6 6 
FeRV profile + FPV profile (FPV PCR & Ab)    1 
FeRV + FCoV (FCoV Ab) 2 6   
FeRV + FIP (FCoV Ab, α1-AGP, 
haematology/cytology) 
 4   
FeLV Ag (ELISA) 1    
FIV + FCoV + FCV (FeLV Ag,   2   
FCoV + Chlamydia felis PCR  1   
Chlamydia felis PCR 1    
FIV Ab (Immunofluorescence)   11 14 
total 21 57 17 29 
 
* Ag = antigens, Ab = antibodies, α1-AGP = alpha-1-acid glycoprotein, FCV = feline calicivirus, 
FCoV = feline coronavirus, FeLV = feline leukaemia virus, FeRV = Feline Retrovirus, FIV = feline 
immunodeficiency virus, FHV = feline herpesvirus, FPV = feline parvovirus, ** one unknown 
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Appendix 4-3 Clinical History of FIV negative cats 
 
I.D. Age* Sex neuter Breed** sick/healthy single/multi 
364289 1Y 9M female neuter DSH healthy unk 
364296 1Y 9M male neuter ragamuffin unk unk 
364530 <1Y female unk DSH healthy unk 
364610 unk female unk DSH healthy unk 
364613 1Y 9M female unk maine coon healthy unk 
364614 1Y 11M female unk maine coon healthy unk 
364648 8Y 3M female neuter DSH sick unk 
364853 1Y female unk unk healthy unk 
364865 11Y 6M male neuter DSH unk multi 
364966 5M male neuter DSH unk unk 
365010 2Y 10M male unk DSH unk unk 
365013 12Y 8 M female neuter persian sick unk 
365043 12Y female neuter DSH sick unk 
365093 2Y 8M female neuter DLH sick unk 
365084 unknown unk unk DSH healthy unk 
365117 >1Y female neuter DMH sick unk 
365136 3Y 9M female neuter DSH sick unk 
366828 1Y 9M female neuter DSH sick unk 
366831 6W female unk DSH unk unk 
366832 unknown female unk DSH unk unk 
366836 6W male unk DSH unk unk 
366837 unknown male unk DLH unk unk 
366838 6W male unk DSH unk unk 
366864 6M female unk bengal healthy unk 
366865 1Y 3M female neuter DSH sick unk 
366866 7Y female neuter DLH healthy unk 
366884 unknown female unk DSH unk unk 
366889 1M female unk british blue 
cross 
sick unk 
366892 13Y female unk burmese sick unk 
366893 unknown female unk DSH unk unk 
366933 8M male neuter BSH sick unk 
366935 2M female unk BSH healthy unk 
366936 10Y male unk DLH unk unk 
366941 11Y 1M male unk DSH sick unk 
366953 12M male unk DSH sick unk 
366955 15M female unk DSH healthy unk 
366961 4Y 2W female unk DSH healthy unk 
206 
I.D. Age* Sex neuter Breed** sick/healthy single/multi 
366975 3Y male unk DSH unk multi 
366976 unk unk unk DSH unk multi 
366981 2Y 6M female neuter DSH sick unk 
366985 3Y male neuter ragdoll sick unk 
367015 1Y1M female neuter DSH sick unk 
367055 1Y 2M male neuter DSH healthy multi 
367064 14Y male unk DSH sick unk 
367069 3Y 6M female unk DSH sick unk 
367082 9M female neuter DSH sick unk 
367123 3Y male neuter DSH unk unk 
367124 17Y male neuter DSH unk unk 
367179 unknown female unk DSH unk unk 
367182 3Y male neuter DSH sick multi 
367231 16Y 10M male neuter DSH sick unk 
367237 11Y 9M female unk DLH sick multi 
367288 11Y male neuter DSH sick unk 
367289 unknown female unk DSH unk unk 
367290 5Y 2M female unk tortoise 
shell 
sick unk 
367291 3Y 11M female neuter ragdoll sick single 
367320 unk male neuter DSH sick unk 
367328 8Y female unk DSH sick unk 
367344 >1Y male entire DSH unk unk 
367345 1Y female unk bsh sick unk 
367353 7Y female neuter DSH unk unk 
367393 4Y female neuter DSH sick unk 
367404 11M female neuter cornish rex sick multi 
367420 2Y 2M male unk DSH sick unk 
367421 1Y 9M female neuter DSH sick unk 
367422 1Y 9M female neuter DSH sick multi 
367424 5Y 1M male neuter DSH sick unk 
367425 5Y 10M female neuter unk healthy unk 
367428 4M male entire burmese sick multi 
367443 2Y 6M female neuter DSH sick unk 
367448 8Y 11M male neuter siamese sick unk 
367468 unk female unk DSH sick unk 
367477 6M male entire DSH sick unk 
367479 4Y male neuter DSH sick unk 
372359 11Y 10M male neuter DSH unk unk 
372269 11Y 8M male neuter bengal healthy unk 
367523 2Y 11M female neuter DSH sick unk 
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I.D. Age* Sex neuter Breed** sick/healthy single/multi 
367535 1Y 1M female neuter DSH sick multi 
367551 unk female entire DSH unk unk 
367564 2Y male neuter DSH sick unk 
367565 2Y female neuter DSH sick unk 
367566 12Y 1M male neuter DLH sick unk 
372506 unk unk unk DLH unk unk 
367578 4M male entire DSH sick unk 
367580 4M male entire DSH sick unk 
367581 8Y female neuter siamese sick unk 
367582 4M female entire DSH sick unk 
367594 unk unk unk unk sick unk 
367595 5Y female neuter DSH sick unk 
367597 14Y 2M female neuter DSH sick unk 
367607 11M male entire DSH healthy multi 
367626 3Y male neuter DSH sick unk 
367644 15Y female neuter persian unk unk 
367645 4Y 3M famale neuter DSH healthy unk 
367646 7Y 1M male unk DLH healthy unk 
367652 6M female neuter DSH unk unk 
367654 unk male neuter DLH healthy unk 
367655 4Y female unk DLH unk unk 
367661 11M male unk DSH unk unk 
367662 9Y 2M male neuter DSH sick unk 
367663 11W female unk DSH unk unk 
367664 11M male entire DSH unk unk 
367665 9Y female neuter DSH sick unk 
367684 6Y 2M male neuter british blue unk unk 
367699 1Y 6M male unk DSH unk unk 
372770 3Y 6M female neuter DSH unk unk 
367704 10Y male neuter DSH unk unk 
367708 8Y male neuter DSH sick unk 
367743 2Y 6M female unk DSH healthy unk 
367744 7Y female unk DSH healthy unk 
367747 2Y female neuter bengal 
cross 
sick unk 
367748 3Y female unk DLH unk unk 
367749 5Y male unk DSH unk unk 
367728 4Y female unk DSH unk unk 
*Age: Y = year, M= month and W = week, unk = unknown 
**BSH = british short hair, DSH = domestic short hair, DMH, domestic medium hair and DLH = 
domestic long hair, All the cross and DSH, DMH and DLH were treated as being mixed breed.   
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Appendix 4-4 Lymphocyte subpopulations of FIV negative cats 
 
I.D. %CD4* %CD8* CD4:CD8 %CD4CD134** 
364289 28.95 13.61 2.13 6.25 
364296 18.58 8.50 2.19 10.35 
364530 28.68 8.95 3.20 20.84 
364610 27.12 5.92 4.58 9.48 
364613 17.61 5.58 3.16 12.64 
364614 22.02 6.26 3.52 10.02 
364648 23.76 4.04 5.88 19.89 
364853 29.05 8.05 3.61 23.09 
364865 40.60 21.52 1.89 13.31 
364966 10.87 7.61 1.43 16.52 
365010 17.56 25.88 0.68 15.00 
365013 15.52 13.16 1.18 26.20 
365043 8.84 6.86 1.29 42.87 
365093 36.99 22.92 1.61 28.36 
365084 19.46 7.36 2.64 71.31 
365117 20.93 11.40 1.84 66.27 
365136 10.61 8.38 1.27 59.09 
366828 6.75 2.40 2.81 3.87 
366831 9.44 2.13 4.43 10.92 
366832 6.06 2.73 2.22 10.86 
366836 0.51 0.48 1.06 15.62 
366837 5.12 1.48 3.46 20.00 
366838 0.93 0.32 2.91 8.49 
366864 39.58 8.78 4.51 7.97 
366865 20.86 12.33 1.69 2.58 
366866 30.78 15.29 2.01 1.40 
366884 26.85 9.34 2.87 8.68 
366889 31.79 21.08 1.51 8.47 
366892 33.56 15.36 2.18 23.81 
366893 47.31 8.02 5.90 3.04 
366933 26.78 14.94 1.79 1.82 
366935 30.14 4.66 6.47 14.78 
366936 5.91 7.70 0.77 13.75 
366941 15.00 24.87 0.60 19.02 
366953 22.99 19.79 1.16 6.58 
366955 22.77 6.58 3.46 8.10 
366961 46.01 11.38 4.04 8.39 
366975 26.63 19.89 1.34 5.44 
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I.D. %CD4* %CD8* CD4:CD8 %CD4CD134** 
366976 22.17 11.65 1.90 9.60 
366981 26.71 12.88 2.07 4.18 
366985 13.52 6.48 2.09 6.77 
367015 27.43 10.77 2.55 9.96 
367055 42.30 9.44 4.48 2.69 
367064 33.44 10.89 3.07 20.54 
367069 16.58 4.90 3.38 6.47 
367082 37.05 6.98 5.31 2.25 
367123 3.66 9.84 0.37 7.37 
367124 24.28 12.55 1.93 8.77 
367179 28.83 10.84 2.66 4.02 
367182 4.58 7.84 0.58 19.65 
367231 34.93 3.69 9.47 17.78 
367237 28.69 16.12 1.78 8.95 
367288 8.54 6.90 1.24 14.68 
367289 47.35 11.56 4.10 11.28 
367290 18.50 33.22 0.56 2.74 
367291 28.43 20.35 1.40 2.96 
367320 33.57 10.39 3.23 1.15 
367328 2.88 2.52 1.14 7.34 
367344 33.89 10.67 3.18 6.46 
367345 30.74 16.05 1.92 1.75 
367353 28.42 11.09 2.56 4.09 
367393 12.15 45.35 0.27 24.96 
367404 28.11 20.97 1.34 9.01 
367420 18.00 13.83 1.30 6.47 
367421 32.32 20.46 1.58 4.68 
367422 21.82 6.01 3.63 4.45 
367424 15.46 13.84 1.12 23.29 
367425 17.11 11.70 1.46 8.08 
367428 58.30 3.40 17.15 4.36 
367443 28.09 13.49 2.08 2.93 
367448 23.74 13.79 1.72 27.09 
367468 11.42 6.38 1.79 5.89 
367477 13.87 3.95 3.51 3.60 
367479 24.77 24.86 1.00 9.41 
372359 12.91 4.95 2.61 16.12 
372269 17.26 3.69 4.68 8.12 
367523 38.96 11.57 3.37 13.68 
367535 33.88 16.87 2.01 4.80 
367551 20.64 21.56 0.96 7.27 
210 
I.D. %CD4* %CD8* CD4:CD8 %CD4CD134** 
367564 26.04 10.57 2.46 16.87 
367565 36.41 20.15 1.81 15.18 
367566 17.23 14.10 1.22 15.71 
372506 15.29 4.84 3.16 25.79 
367578 33.83 12.12 2.79 14.04 
367580 15.37 5.85 2.63 15.61 
367581 34.42 24.36 1.41 6.36 
367582 28.05 11.80 2.38 19.03 
367594 21.99 5.31 4.14 9.06 
367595 28.39 15.45 1.84 8.53 
367597 25.19 17.39 1.45 18.44 
367607 23.04 12.59 1.83 11.75 
367626 23.19 15.33 1.51 11.11 
367644 22.19 21.11 1.05 29.80 
367645 11.76 4.60 2.56 23.35 
367646 15.95 15.77 1.01 32.27 
367652 22.22 13.64 1.63 22.98 
367654 26.12 16.45 1.59 22.58 
367655 16.44 11.93 1.38 26.67 
367661 40.82 28.29 1.44 15.25 
367662 28.13 16.52 1.70 20.18 
367663 11.58 1.82 6.36 10.85 
367664 41.17 10.92 3.77 14.88 
367665 19.35 10.22 1.89 14.52 
367684 17.28 6.75 2.56 23.31 
367699 32.45 10.06 3.23 22.43 
372770 24.25 18.43 1.32 38.02 
367704 18.77 18.01 1.04 30.75 
367708 9.66 15.97 0.60 14.13 
367743 31.06 18.45 1.68 7.81 
367744 25.70 21.83 1.18 32.05 
367747 44.87 16.12 2.78 12.40 
367748 34.10 11.33 3.01 9.39 
367749 28.42 33.70 0.84 24.47 
367728 21.86 25.73 0.85 32.86 
 
*%CD4 and %CD8 showed their percentage in lymphocyte population 
**%CD4CD134 showed its percentage in CD4+ population 
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Appendix 4-5 Clinical History of FIV positive cats 
 
I.D. Age* Sex neuter Breed** sick/healthy single/multi 
345921 4Y male neuter DSH unk unk 
345998 unk male entire DSH unk unk 
346096 12Y 7M male neuter DSH sick multi 
346171 3Y 10M male neuter DSH unk unk 
346173 unk female unk DSH unk unk 
346223 8Y male neuter DSH sick single 
346224 7Y female unk unk sick unk 
346225 2Y male unk DSH healthy unk 
346271 6Y 10M male unk DSH healthy multi 
346346 2Y 1M male neuter DSH unk unk 
346267 6Y male neuter DSH sick unk 
346301 9Y 1M male unk DSH sick unk 
346303 2Y 10M male entire DSH unk unk 
346363 >1Y male unk DSH healthy unk 
346302 >1Y female unk DSH healthy unk 
346466 >1Y male unk DSH healthy unk 
346537 unk male unk DSH healthy multi 
346512 14Y male entire DSH sick unk 
346540 >1Y male unk DSH healthy unk 
346541 8Y 5M male unk DSH sick unk 
346660 2Y male unk DSH sick unk 
346661 >1Y male neuter DSH healthy unk 
346681 >1Y male unk DSH healthy unk 
346795 >1Y male entire unk unk unk 
346805 >1Y male neuter persian 
cross 
sick unk 
346913 7Y male unk DSH sick multi 
346938 6Y male neuter DSH sick multi 
346940 3Y male neuter DSH healthy unk 
346970 5Y male entire DSH unk unk 
346998 10Y male neuter DSH sick unk 
347076 >1Y male unk DSH sick unk 
347024 >1Y male unk DSH healthy unk 
347075 2Y 9M female neuter DSH unk multi 
347138 12Y male unk DSH sick multi 
347175 11Y 2M female neuter DSH sick multi 
347178 >1Y male unk DSH healthy unk 
347202 6Y male neuter DSH sick unk 
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I.D. Age* Sex neuter Breed** sick/healthy single/multi 
347251 3Y male neuter DSH healthy multi 
364247 5Y male entire DLH unk unk 
364298 11Y 5M male entire DSH sick single 
364324 6Y male entire DSH unk unk 
364455 6Y male unk DSH sick unk 
364456 3Y male unk DSH unk unk 
364459 unk male neuter DSH unk unk 
364483 1Y 6M male neuter unk unk unk 
364457 unk female unk DSH sick single 
364480 2Y male neuter DSH unk unk 
364506 8Y male neuter DSH sick multi 
364611 unk male unk DSH unk multi 
364726 >1Y male unk unk unk unk 
364735 3Y male neuter DLH unk unk 
364791 2Y male neuter DSH healthy unk 
366922 2Y male neuter DSH unk unk 
364944 4Y male neuter DSH unk unk 
364983 2Y male entire DSH unk unk 
365045 10Y male unk DSH sick multi 
365078 unk male unk DSH healthy unk 
365085 7Y male unk DSH sick unk 
365092 >1Y male entire DSH unk unk 
365194 unk male entire DSH unk unk 
365292 3Y male entire DSH sick unk 
365294 4Y 6M male entire DSH unk unk 
365363 2Y female neuter DSH sick unk 
365434 >1Y male unk DSH unk unk 
366973 8Y 6M male neuter Maine Coon unk unk 
367097 unk male unk DSH unk unk 
367133 7Y 6M male neuter DSH sick unk 
367206 >1Y male unk DSH unk unk 
367396 3Y 6M male neuter DSH unk unk 
367418 2Y 5M male entire DSH healthy unk 
367423 3Y female entire DSH unk unk 
367516 5Y male unk DSH unk unk 
367517 7M female unk DSH sick unk 
367647 unk male neuter DSH unk unk 
368231 12Y 3M male unk DSH sick single/multi 
368352 2Y male neuter DSH healthy unk 
368353 >1Y male unk DSH unk unk 
368406 9Y male neuter DSH unk unk 
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I.D. Age* Sex neuter Breed** sick/healthy single/multi 
368407 7Y 5M male neuter DLH sick unk 
368508 8Y male entire DSH sick unk 
 
*Age: Y = year, M= month and W = week, unk = unknown 
** DSH = domestic short hair and DLH = domestic long hair, All the cross and DSH and DLH were 
treated as being mixed breed. 
 
Appendix 4-6 Lymphocyte subpopulations of FIV positive cats 
 
I.D. %CD4* %CD8* CD4:CD8 %CD4CD134** FIV proviral load*** 
345921 6.75 1.45 4.66 15.24 779 
345998 23.20 20.94 1.11 19.76 21 
346096 17.20 14.83 1.16 52.73 156 
346171 19.61 25.29 0.78 40.02 368 
346173 12.94 26.25 0.49 27.85 13,038 
346223 8.32 53.16 0.16 19.81 105,446 
346224 17.01 26.27 0.65 20.55 9,827 
346225 30.11 22.55 1.34 96.96 21,212 
346271 26.77 7.85 3.41 20.43 72 
346346 7.38 8.08 0.91 22.75 3,257 
346267 17.12 8.96 1.91 18.89 4,583 
346301 29.70 6.75 4.40 6.30 11 
346303 33.25 7.55 4.40 11.82 488 
346363 24.60 14.19 1.73 43.18 851 
346302 25.15 5.17 4.86 67.37 7,903 
346466 21.58 16.07 1.34 47.83 872 
346537 13.73 11.45 1.20 39.75 30 
346512 25.11 15.57 1.61 18.56 1,418 
346540 25.54 17.46 1.46 22.67 52 
346541 22.61 14.57 1.55 61.84 129,829 
346660 0.27 0.34 0.79 27.27 1,758,848 
346661 21.02 11.97 1.76 38.78 2,362 
346681 29.49 5.48 5.38 24.06 49 
346795 32.28 24.32 1.33 28.82 1,902 
346805 24.71 22.43 1.10 67.83 15,762 
346913 16.83 41.84 0.40 56.44 49 
346938 8.16 2.59 3.15 29.63 2,983 
346940 37.50 5.24 7.16 83.75 2,871 
346970 25.86 11.54 2.24 51.75 14 
346998 14.29 12.96 1.10 48.92 20 
347076 25.92 16.20 1.60 24.91 3,143 
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I.D. %CD4* %CD8* CD4:CD8 %CD4CD134** FIV proviral load*** 
347024 8.70 18.27 0.48 45.63 2,168 
347075 16.17 24.16 0.67 40.90 464 
347138 9.40 7.89 1.19 43.49 159 
347175 15.87 9.65 1.64 30.08 10,102 
347178 24.17 30.29 0.80 39.95 20 
347202 13.00 22.28 0.58 51.25 1,629 
347251 13.02 19.61 0.66 28.19 1,010 
364247 13.87 2.19 6.33 12.37 24 
364298 14.42 9.58 1.51 17.82 7,936 
364324 30.57 13.99 2.19 26.30 12,251 
364455 17.31 26.00 0.67 55.80 5,760 
364456 3.94 1.33 2.96 12.50 2,408 
364459 42.94 13.92 3.08 31.94 6,178 
364483 21.04 18.07 1.16 46.65 3,505 
364457 0.03 0.80 0.04 20.00 1,467,822 
364480 28.97 21.79 1.33 47.55 150,280 
364506 10.94 10.05 1.09 26.48 6,077 
364611 21.79 11.91 1.83 10.41 4,512 
364726 14.86 25.81 0.58 20.92 369 
364735 4.92 15.18 0.32 28.35 16,167 
364791 27.22 9.19 2.96 22.84 1,145 
366922 22.78 20.97 1.09 35.65 9,242 
364944 17.09 20.21 0.85 38.17 11,133 
364983 17.21 24.68 0.70 33.20 42,246 
365045 15.92 32.67 0.49 29.05 7,204 
365078 4.21 6.98 0.60 50.51 117,882 
365085 8.72 45.53 0.19 26.68 1,671 
365092 6.12 23.83 0.26 27.74 12,425 
365194 13.68 30.87 0.44 11.83 342 
365292 18.86 20.62 0.91 28.74 692 
365294 13.65 15.34 0.89 25.27 12,693 
365363 26.60 15.23 1.75 22.16 767 
365434 28.73 20.18 1.42 20.52 134 
366973 25.50 6.67 3.82 14.71 6,174 
367097 26.59 20.41 1.30 9.48 6,142 
367133 1.62 5.57 0.29 5.10 1,669 
367206 22.20 23.62 0.94 16.81 432 
367396 30.22 12.57 2.40 22.62 3,221 
367418 36.93 21.46 1.72 7.75 233 
367423 18.27 16.01 1.14 10.08 1,021 
367516 21.35 14.97 1.43 5.56 815 
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I.D. %CD4* %CD8* CD4:CD8 %CD4CD134** FIV proviral load*** 
367517 7.32 2.72 2.69 15.90 16,521 
367647 20.52 22.62 0.91 29.22 20,028 
368231 15.64 7.76 2.02 26.47 2,840 
368352 22.20 15.56 1.43 16.78 6,504 
368353 23.81 11.85 2.01 25.68 274 
368406 6.41 5.48 1.17 68.22 150,972 
368407 9.70 11.34 0.86 32.68 2,690 
368508 26.89 16.70 1.61 16.74 30,2401 
 
*%CD4 and %CD8 showed their percentage in lymphocyte population 
**%CD4CD134 showed its percentage in CD4+ population 
***FIV Proviral load was reported as copies/106 cells. 
 
Appendix 4-7 Clinical Histories of FIV positive with FIV PVL below limit of 
detection 
 
I.D. Age* Sex Neuter Breed** sick/healthy Single/Multi 
346098 5Y 6M male unk DSH healthy unk 
364351 13Y 8M male neuter DSH sick unk 
364423 1Y 6M male neuter DSH unk unk 
364462 6Y male neuter DSH sick unk 
364484 1Y female unk unk unk unk 
365042 2Y 7M male neuter DSH healthy single 
365119 6Y 4M male neuter DSH unk unk 
367007 unk unk unk unk unk unk 
368206 4y male unk DLH sick unk 
368324 >1Y male unk DSH unk unk 
368351 >1Y male neuter DSH sick multicat 
368362 7Y 9M male unk DSH sick unk 
368366 >1Y male unk DSH unk unk 
377855 16Y male neuter DLH sick unk 
 
*Age: Y = year, M= month and W = week, unk = unknown 
** DSH = domestic short hair and DLH = domestic long hair, All the cross and DSH and DLH were 
treated as being mixed breed. 
  
216 
Appendix 4-8 Lymphocyte subpopulations of FIV positive with PVL below limit of 
detection (10 copies/106 cells)  
 
I.D. %CD4* %CD8* CD4:CD8 %CD4CD134** 
346098 34.68% 15.11% 2.30 93.17% 
364351 10.03% 6.94% 1.45 24.05% 
364423 13.39% 3.71% 3.61 13.28% 
364462 29.99% 9.72% 3.09 20.33% 
364484 23.88% 24.96% 0.96 38.10% 
365042 14.93% 15.49% 0.96 42.02% 
365119 7.03% 4.32% 1.63 36.78% 
367007 15.26% 10.49% 1.45 16.48% 
368206 21.16% 8.22% 2.57 90.20% 
368324 17.96% 18.55% 0.97 39.44% 
368351 38.16% 18.45% 2.07 30.61% 
368362 16.03% 13.66% 1.17 28.78% 
368366 13.36% 13.30% 1.00 20.01% 
377855 27.00% 9.98% 2.71 64.54% 
 
*%CD4 and %CD8 shown as percentage of total lymphocyte population 
**%CD4CD134 shown as percentage of CD4+ population 
 
 
 
Appendix 4-9 Effect of FIV serostatus and clinical manifestation of gingivostomatitis in sick cats 
(A) and all cats (B), Fischer’s exact test and presented as relative risk and odd ratio. 95% CI: 95% 
confidential interval  
 
0 20 40 60
FIV positive
FIV negative
sick cats only
number
gingivostomatitis
others
p = 0.1126
relative risk = 0.5665 (95% CI: 0.2853 - 1.1250)
odd ratio = 0.4380 (95% CI: 0.1694 - 1.1330)
0 50 100 150
FIV positive
FIV negative
all cats
number
gingivostomatitis
others
*p = 0.0198
relative risk = 0.4218 (95% CI: 0.1979 - 0.8992)
odd ratio = 0.3680 (95% CI: 0.1562 - 0.8672)
A B
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Appendix 4-10 Correlation between percentage of CD4+CD134+ T lymphocytes (A) and CD4+ T 
lymphocytes (B) and FIV PVL in sick FIV positive cats with (orange squares) and without (pink 
circles) co-infections. X-axis shows percentage of cells and Y-axis shows FIV PVL (copies/106 
cells), Spearman r test 
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Appendix 4-11 CD134-usage (phenotype) of pseudotypes bearing Envs from 
healthy and sick FIV positive cats* 
 
    15/10/15 23/11/15 25/11/15 29/11/15 Phenotype 
healthy 
346271C10 88.18 111.51 70.11 79.61 intermediate 
346271C11  n.a. 363.90 291.02 134.31 early 
346302C2 34.76 273.60 139.12 212.43 early 
346302C18 19.11 299.14 98.59 88.56 intermediate 
346302C21 36.16 250.26 89.40 175.55 intermediate 
347178C10 27.78 309.07 396.48 367.00 early 
347178C11  n.a. 301.15 198.67 319.47 early 
347251C14 11.43 192.22 83.65 92.36 intermediate 
368352C20 86.41 535.14 7.60 7.00 late 
sick 
346938C5 434.58 343.56 298.07 266.78 early 
346938C24 62.98 272.52 12.12 11.92 late 
346938C43  n.a.  351.25 233.90 244.06 early 
347076C9 137.47 840.62 399.08 392.84 early 
347076C31 88.40 416.90 372.85 417.23 early 
347202C4 568.21 1064.96 529.52 820.43 early 
347202C5 18.33 117.68 86.30 89.93 intermediate 
365045C2 88.54 208.22 157.50 185.29 intermediate 
367133C5 6.77 19.91 21.20 28.53 late 
control 
GL8 195.49 1730.62 395.13 646.26 early 
KKS 25.64 63.66 35.70 40.14 intermediate 
B2542 4.69 10.55 9.05 8.60 late 
VR1012 0.97 2.89 4.50 3.50 negative 
 
*The values shown are the FFF/FFHH ratios for each HIV(FIV) pseudotype (row). The assay was 
repeated 4 times on 4 different dates (columns). The ratio of each pseudotype was compared 
with the ratio of three prototypic control pseudotypes; GL8 for early, KKS for intermediate and 
B2542 for late variants. Early variants are highlighted in blue, intermediate variants are 
highlighted in green and late variants are highlighted in yellow. The interpretations were made 
on the consensus readouts of the 4 repeats.  n.a. = not analysed. Note: only very low ratios were 
designated as late variants. 
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Appendix 4-13 Sample submission form for the diagnosis of feline infectious 
disease  
 
 
Lab use only Date received 
Feline Infectious Disease 
VETERINARY SURGEON’S NAME & ADDRESS   ANIMAL DETAILS   NB: please use separate forms for each cat 
VDS vet ref no:   Owner name:  
Submitting vet name:   Animal name:  
Vet practice name & address   Breed:  
   Sex:  
Postcode:   Age/DOB:  
Tel: Fax:  Previous ref:  
Results email:     
Date sampled:        Please send VTM:  
Samples sent (Please tick box) It is very important to specify which type of samples are sent, both on the sample tubes and on this form 
   Hep     EDTA Blood       Serum        Plasma       Ascites        Pleural Effusion            Faeces  Urine  
   Sick             Healthy  Indoor cat  Free-roaming  Pre-mating                 Single cat                     Multi-cat house  
      SWABS:                 VTM   Charcoal              Dry       Oropharynx  Nasal                     SWAB SITE:  Conjunctival 
Tests required (please tick box) To qualify for profile discounts, samples must be sent together  
Brief clinical history 
 Feline infectious peritonitis (FIP) profile 
For FIP diagnosis in sick cats 
(FCoV antibodies, haematology/cytology, A:G ratio, α1-AGP) 
 Dry FIP: 2 x 1ml heparin blood, 1ml EDTA blood 
Wet FIP: 1ml heparin blood & 2 samples of 1-2ml effusion in 
plain & EDTA tubes. Please send effusion if possible 
 Feline coronavirus (FCoV) antibodies and α1-AGP  1ml heparin blood or serum 
 FCoV RT-PCR (real-time PCR)  For FCoV shedding: 5g faeces (NO cat litter) 
For wet FIP confirmation: 1ml effusion in EDTA or plain tube 
 Feline leukaemia virus (FeLV) antigen (p27 ELISA) 
To detect FeLV antigen: screening test only 
 1ml heparin blood AND 1ml EDTA blood 
 Feline leukaemia virus (FeLV) virus isolation 
To detect FeLV viraemia (& confirm in-clinic test positive) 
 1ml heparin blood AND 1ml EDTA blood 
 Feline immunodeficiency virus (FIV) antibodies (IF)  1ml heparin blood or serum 
 Feline retrovirus profile (FeLV antigen, FIV antibodies)  1ml heparin blood AND 1ml EDTA blood 
 FeLV, FIV and FCoV (FeLV antigen, FIV and FCoV antibodies)  1ml heparin blood AND 1ml EDTA blood 
 Virus isolation (Feline calicivirus, Feline herpesvirus)  Oropharyngeal swab in our virus transport medium (VTM)* 
 Feline herpesvirus (real-time PCR)  Oropharyngeal or conjunctival swab in VTM* or dry  
Do not send samples containing fluorescein 
 Chlamydophila felis (PCR)  Conjunctival swab in VTM* or dry 
 Bordetella bronchiseptica (culture & sensitivity)  Nasal swab in bacterial transport medium* or tracheal wash. All 
bacteria isolated will be reported. 
RESPIRATORY DISEASE        *Free on request 
 Feline coronavirus (FCoV) antibodies (immunofluorescence, IF)  1ml heparin blood or serum 
 *New* Feline leukaemia virus (FeLV) qPCR  
To detect FeLV proviral DNA (& confirm in-clinic test positive) 
 1ml heparin blood AND 1ml EDTA blood 
Veterinary Diagnostic Services, School of Veterinary Medicine, 
College of Medical, Veterinary and Life Sciences, University of Glasgow, 
Bearsden Road, Glasgow G61 1QH, United Kingdom 
Tel: +44 (0) 141 330 5777 Fax: +44 (0) 141 330 5748 
email: vet-sch-vds@glasgow.ac.uk     Website: www.glasgow.ac.uk/vds 
University of Glasgow, charity number SC004401 
Please include drugs at time of sampling Please enclose printed clinical notes if appropriate 
F    /    E 
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 Feline conjunctivitis profile 
(FHV PCR, Chlamydophila felis PCR, Mycoplasma felis culture & PCR) 
 Conjunctival swab (dry OR VTM*) 
AND conjunctival swab in bacterial transport medium* 
 Gingivitis profile 
(Virus isolation, FeLV, FIV) 
 Oropharyngeal swab in VTM*, 1ml heparin blood 
AND 1ml EDTA blood 
 Diarrhoea profile 
(Bacteriology, parasitology NOT Cryptosporidium) 
 > 10g faeces 
 Diarrhoea profile PLUS 
(Bacteriology, parasitology INC.Cryptosporidium, FCoV PCR & T. foetus PCR) 
 > 15g faeces- NO cat litter 
 Pyrexic cat profile 
(FeLV, FIV, FCoV, FIA, haematology, ALP, ALT) 
 2 x 1ml heparin blood,  2 x 1ml EDTA blood  
and 2 air-dried smears 
 Old thin cat profile 
(FIV, T4, urea, creatinine, ALP, ALT) 
 2 x 1ml heparin blood or serum 
 Uveitis profile 
(FeLV, FIV, FCoV, Toxoplasma) 
 1ml heparin blood, 1ml serum and 1ml EDTA blood 
 Feline parvovirus (FPV, feline panleucopaenia) profile 
FPV DNA (PCR) and FPV antibody tire (HAI) 
 Faeces (NO cat litter) or gut contents and 
1ml heparin blood or serum 
 Feline neutralising antibodies immune status (neutralising titre) 
 
 1ml heparin blood or serum 
 Feline parvovirus antibodies (HAI) 
 
 1ml heparin blood or serum 
 Feline parvovirus DNA (PCR) 
 
 Faeces or gut contents– NO cat litter 
 Feline pox (Cowpox virus) 
 
 Lesion material or crust in a sterile container or VTM* 
 Feline blood groups 
 
 1ml EDTA blood 
 Feline calicivirus plaque typing 
(To distinguish vaccine FCV from field FCV) 
 Oropharyngeal swab in VTM* 
plus vial of vaccine batch 
BACTERIOLOGY AND MYCOLOGY  PLACE SWABS FOR BACTERIOLOGY IN BACTERIAL TRANSPORT MEDIUM* 
  
 Full culture and sensitivity   
 Aerobic culture and sensitivity (urine, ears)   
 Enrichment culture (blood, joint fluid)   
 Fungal culture including Dermatophytes  Plucked hair sample or toothbrush 
 Mycoplasma felis culture and real-time PCR  Swab in bacterial transport medium* 
and BAL samples in plain sterile tube 
PARASITOLOGY   
 Toxoplasma gondii antibodies (latex agglutination test)  1ml SERUM ONLY (not plasma) 
 Protozoa screen (Giardia, Isopora etc)  Faecal sample (at least 5g) 
 Cryptosporidium spp (ZN staining)  Faecal sample (at least 5g) 
 Aelurostrongylus abstrusus (modified Baermann technique)  BAL preferred/sputum/faeces (>10g) 
 Nematode and cestode egg screen (McMaster technique)  Faecal sample (at least 10g) 
 Ectoparasite screen  Skin scrape on a slide (no sellotape or KOH) 
Any other testing (please specify): 
For more information or to download submission forms please visit our website at www.glasgow.ac.uk/vds  
Residual samples may be used for approved research, test development or teaching. 
If the client indicates that they would prefer that residual samples are not used in this way, please check this box  
August 2012 
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Appendix 5-1 Representative gating strategy and contour plots to identify lymphocyte 
subpopulations of mitogen-stimulated PBMC. Lymphocytes (P4) were identified by size (forward 
scatter area, FSC-A, X-axis) and granularity (size scatter area, SSC-A, y-axis) (top left). Single 
CD4 and CD8 positive T lymphocytes was identified by plotting CD4-FITC against CD8-PE (bottom 
left). Level of CXCR4 and CD134 expression on CD4+ (top) and CD8+ (bottom) T lymphocytes was 
determined by plotting either CD4-FITC or CD8-PE against CXCR4 (middle) and CD134 (right), 
respectively. 
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Appendix 5-2 Representative plots for the determination of viability (A), proliferation (B) and 
lymphocyte subpopulations (C) of PBMC cultures expanded from cat 310304, 7 days after 
isolation. Cell viability was determined by 7-aminoactinomycin D (7-AAD) staining, with 7-AAD 
positivity denoting dead cells (A). Cell proliferation was determined by carboxyfluorescein 
succinimidyl ester (CFSE) staining, in which CFSE positive cells were non-proliferative (B). PBMC 
with no stimulant was used to set the cut-off (black line). Each individual stimulant was defined 
using a different colour; PHA with IL-2 (blue), ConA with IL-2 (red) and anti-feline CD3 with IL-2 
(yellow) (A, B).  
 
 
 
Appendix 5-3 Map of Plasmid pLKO-fCD134-IP 
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Appendix 5-4 CD134 expression (as a percentage) of the inducible CD134 CLL 
cell line at different concentrations of doxycycline. 
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